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Abstract 
Haneen Adel Daoud Basheer 
Title: Pharmacological characterization of chemokine receptor 7 (CCR7) as a 
potential therapeutic target in cancer 
Keywords: Cancer, Chemokine, CCR7, pharmacology 
The expression of CCR7 was evaluated in different cancer cell lines by using 
flow cytometry, western blot, Immunofluorescence and immunohistochemistry. 
We showed for the selected cell lines that the expression is maintained in cells 
grown as spheroids, and xenoplanted in mice. Furthermore, we showed the 
expression of CCR7 correlates with stage of the disease in patient derived head 
and neck cancer tissue. We also showed that expression of CCR7 in cancer cell 
lines correlates with migratory aptitude towards CCL21 in a scratch assay, 
Boyden chamber assay and spheroid invasion assay.  
We then showed that the expression of CCR7 is elevated under serum 
starvation and under hypoxia in cancer cell lines grown as monolayers and as 
spheroids; and that there is a correlation between hypoxia and CCR7 
expression in spheroids, xenografted cells and clinical cancer tissue. However, 
we found that in cell line OSC-19, the increase in the expression of CCR7 did 
not correlate to increased migration. Our investigations following this 
observation showed that whilst hypoxia increases the expression of CCR7, it 
concurrently causes a decrease in reactive oxygen species (ROS) which 
strongly abrogates migratory aptitude in OSC-19, resulting in an overall loss of 
migration in OSC-19 cells.  
In addition, we characterised OSC-19 as a suitable model to evaluate small 
molecule CCR7 antagonists using a number of different assays. In particular, 
we showed that ICT13069 antagonised response of this cell line across a 
number of drivers of malignancy such as migration, invasion in 2D and 3D 
models. 
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 2 
 
1.1 Cancer & Metastasis 
Cancer accounted for 8.8 million deaths worldwide in 2015 (WHO, 2017) . Recent 
figures indicate that 14.1 million new cancer cases were diagnosed and 32.6 
million people are still living with cancer within 5 years of diagnosis in 2012 
worldwide (WHO, 2014 ). In the UK, approximately 163,444 cancer related deaths 
occurred in 2014 (Cancer Research UK, 2014). 
Cancer results from an abnormal growth of cells. Over the past four decades much 
is discovered about the molecular mechanisms underlying this disease. In both 
animal and in human studies, it has been observed that cancer is triggered by 
multiple successive genetic and epigenetic changes in cells, leading to their 
transformation into a population with an imbalance between proliferation and 
death; eventually developing into cells that can invade adjacent tissues and 
metastasise to distant organs (Hanahan and Weinberg, 2000). Within this broad 
definition, the disease can be subclassified and in fact, there are over 100 different 
types of cancer and multiple subtypes within each cancer that have been 
described. However, despite such variety, Hanahan and Weinberg, have proposed 
common traits shared by nearly all cancer types that they described as Cancer 
Hallmarks Figure 1. 
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Figure 1: The First six established hallmarks of cancer. 
These characteristics are shared by most cancer cells (Hanahan and Weinberg, 2000). 
 
These traits or common characteristics include: (1) Self-sufficiency in growth 
signals, (2) Unresponsiveness to anti-growth signals, (3) Evasion of apoptosis, (4) 
Uncontrolled replicative potential (5) Angiogenesis, (6) Tissue invasion and 
metastasis.  
These hallmarks can be acquired at different time points via different mechanisms 
in different cancer types, but they can ultimately lead cancer cells to proliferate, 
survive, invade and colonise other tissues. Since the initial publication of these 
  
   
 
 4 
 
hallmarks, researchers have proposed other traits and hallmarks, which are also 
important for the progression and development of cancer, to be added to the initial 
list. They include “enabling” hallmarks (Hanahan and Weinberg, 2011) which are 
necessary to allow the acquisition of all the earlier mentioned characteristics and 
result from the genomic instability and the pro-inflammatory state of cancer cells. 
These hallmarks include the escape from the immune system and reprogramming 
of the metabolic processes to provide energy to support the endless growth and 
survival of cells Figure 2. There are many molecular factors that can contribute for 
acquiring of tumour cells’ hallmarks, among which are the chemokines and their 
cognate receptors that will impact most of hallmarks by acting on cancer cells and 
the surrounding microenvironment (Balkwill, 2012). For instance, CCR7 can 
influence the tumour cell proliferation, invasion and migration of cancer cells to the 
lymph node as well as recruiting certain immune cells, involved in resolving the 
immune reaction, towards the tumour site in order to evade the destruction by 
effector immune cells  
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Figure 2: Cancer hallmarks (Hanahan and Weinberg, 2011). 
Researchers have proposed additional hallmarks that are important to support the 
progression and development of cancer. Here drug treatment options are suggested next to 
each hallmark. 
 
The development of cancer leads to significant morbidity and, if untreated, the 
death of the patient (Ruddon, 2007). However, the majority of the deaths, by some 
estimates 90% of human cancer deaths, are reported to be caused not by the 
growth of primary tumour, but by metastasis (Mehlen and Puisieux, 2006). 
Metastasis is the process by which the cancerous cells from a primary site spread 
to other parts of the body (Mehlen and Puisieux, 2006) and this process is one of 
the specific hallmarks that differentiate a benign from a malignant neoplasm 
(Chambers et al., 2002). A 5-year survival is considered good for patients with 
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(a) 
(b) 
localized disease in most cancers, but this rate decreases dramatically once the 
patient is diagnosed with metastatic cancer, according to the US National Cancer 
Institute Surveillance Figure 3 (Steeg, 2016). Importantly, for most types of primary 
(localised) cancer, survival rates have improved from 2005 to 2015, however, for 
metastasised cancers, survival rates have hardly changed.  
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(c) 
 
Figure 3: US National Cancer Institute surveillance for cancer patients(Steeg, 2016). 
(a) The 5-years survival rate is considered good for most cancer types for patients diagnosed 
with localized disease. (b) Those with lymph node spread known as regional disease at 
diagnosis have lower overall survival compared with patients with localized disease, with the 
exception of bladder or prostate cancer patients. (c) The survival rate of patient with distant 
metastasis is decreased dramatically in all cancer types compared with localized disease 
(Steeg, 2016).  
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 Challenges in Developing Treatments for Metastasis 1.1.1
Despite the significant role of metastasis on patient prognosis, there are limited 
therapeutic options available in the clinic to prevent or treat metastasis. There are 
a number of reasons for that. Metastasis is a complex and multistep process which 
involves invasion, intravasation, extravasation and colonization at the metastatic 
site Figure 4 (Nguyen et al., 2009, Schroeder et al., 2012). Whilst this implies 
multiple opportunities for intervention in the metastatic process, it also puts 
significant limitation to validity and reliability of preclinical models, which by nature 
focus on single aspects of the process, and clinical data, which need to be strictly 
quantifiable.  
The majority of the available cancer therapeutic strategies are focused on 
eradicating the primary tumour rather than targeting the metastatic process, but 
even so, these drugs are tested on patients diagnosed with metastatic disease 
(Mueller and Zlotnik, 2009, Stock et al., 2013, Steeg, 2016). The end points of 
these clinical trials are the shrinkage of tumour size which is easily quantifiable, as 
well as an increase in overall survival, or progression free survival which can be 
multifactorial. However, for an anti-metastatic drug to be considered effective, it 
should prevent the formation of metastases which is not easily quantifiable. 
Furthermore, the vast majority of drugs currently available clinically were not tested 
in preclinical anti-metastatic models in their developmental stage. Indeed, the 
majority of the information about anti-metastatic behaviour of these drugs is often 
gained from adjuvant trials, using overall survival, progression free survival and 
cancer recurrence as the end points or from available clinical data from studies 
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initially directed towards combination or chemotherapy resistant therapies. This is 
because of the hurdles in initiating clinical trials by using an anti-metastatic agent 
on its own in non-terminal patients. To make the situation more difficult to interpret, 
conflicting data was gathered for these drugs in metastasis-focused pre-clinical 
experiments. For instance, some FDA approved drugs such as paclitaxel, cisplatin, 
and anti-androgens have stimulated metastasis in preclinical models (Steeg, 
2016). 
Furthermore, preclinical data suggesting anti-metastatic potential for a drug, do not 
necessarily translate to clinical studies. For example, αvβ3 and αvβ5 integrin 
inhibitor, cilengitide had been shown to be a good candidate for preventing 
metastasis in mice preclinical models, however failed in clinical studies (Scaringi et 
al., 2012). Integrins can regulate the development and progression of tumours as 
they are involved in increasing the adhesion of tumour cells to the extracellular 
matrix (ECM) and they affect angiogenesis, survival, invasion and metastasis 
(Ganguly et al., 2013, Desgrosellier and Cheresh, 2010). Cilengitide has been 
shown to prevent metastasis and increase apoptosis as monotherapy or in 
combination with other agents such as temozolomide in glioblastoma, non-small 
cell lung cancer, head and neck and melanoma in preclinical models (Wichmann et 
al., 2017, Scaringi et al., 2012). The preclinical data was encouraging to progress 
cilengitide into clinical trials. However, Phase III trials in glioma were negative for 
an overall survival end point. Phase II trials were conducted in patients with bone 
metastatic prostate cancer, metastatic melanoma and advanced non-small-cell 
lung cancer, showing very little clinical activity. These failures at the clinical stage 
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could be attributed to the pharmacokinetic profile of cilengitide, or in choosing the 
wrong cancer type; for instance, glioma was chosen to test for anti-metastatic 
activity whereas glioma does not really involve distant metastasis as part of its 
progression (Scaringi et al., 2012).  
On the other hand, the relative success of Denosumab proves that metastasis can 
be targeted successfully to increase patient survival and quality of life. Bone 
metastasis is one of the most common sites of metastasis in advanced cancer. 
Skeletal metastases are most common among prostate, lung, breast, kidney, 
myeloma, and thyroid cancers. Bone metastases can be either osteolytic (bone 
destructing) or osteoblastic (bone forming) or a mixture of both (Weidle et al., 2016, 
So et al., 2012). Bone metastasis is considered to be facilitated by the fenestrated 
capillaries of the bone marrow, high blood flow, and the presence of adhesive 
molecules on cancer cells that can bind to osteoblasts and osteoclasts, as well as 
the bone matrix (Weidle et al., 2016). These types of cell play an important role in 
bone re-modelling and its niche structure The osteolytic metastases require the 
activation of osteoclasts by binding of activator NF-κB ligand (RANKL) Gul et al., 
2016), which is produced by osteoblasts, to the RANK receptor on the osteoclasts’ 
surface. RANKL can also trigger angiogenesis, migration and invasion by inducing 
the production of proteins involved in these processes, such as matrix 
metalloproteinases (MMPs; Gul et al., 2016). Bone metastases will eventually lead 
to skeletal related complications (SREs; Weidle et al., 2016). SREs are associated 
with pathologic fractures, the need for bone surgery, radiation to bone or surgery, 
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spinal cord compression and hypercalcemia. SRE leads to compromised quality of 
life, loss of mobility and reduced survival rates 
Tumour cells trigger RANKL expression by osteoblasts through the secretion of 
cytokines and hormones, in some cases, cancer cells can express RANKL to 
directly activate the osteoclasts. Denosumab is a fully humanized monoclonal 
antibody that binds to RANKL, thereby inhibiting the activation of RANK and the 
destruction of bone. Denosumab has already been approved by the FDA for the 
prevention of SRE in breast, prostate and myeloma cancers with bone metastases. 
Denosumab was superior to zoledronic acid, which is a bisphoshonate that induces 
the death of osteoclasts and is the current standard of care to delay or prevent 
SRE in bone metastatic cancer patients (Rolfo et al., 2014). In addition, no 
difference was observed in overall survival (OS) between patients treated with 
denosumab or zoledronic acid in breast and prostate cancer studies. However, in a 
Phase III clinical trial in non-small cell lung cancer, denosumab has been reported 
to increase the overall survival compared with zoledronic acid in patients with 
metastatic lung cancer (Scagliotti et al., 2012).  
Furthermore, Smith et al., have shown in a Phase III clinical trial study in 
castration-resistant prostate cancer patients that denosumab causes a delay in the 
development of bone metastasis, compared with placebo (Smith et al., 2012).  
The success of denosumab is a result of coherent understanding of the molecular 
mechanism in the metastatic process, preclinical studies focusing on the metastatic 
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process, rather than primary tumours and that adequate clinical trials design with 
relevant endpoints is a key factor in this context.  
 
 
Figure 4: The metastatic process steps.  
Cancer cells escape the primary tumour intravasate, extravasate and colonise a favored 
secondary site (Schroeder et al., 2012). Reduction in adhesion to neighbouring cells (a) 
facilities the cells movement to invade through the basement membrane and stromal cells (b). 
Hence cells are free to intravasate (c) the blood or lymph. Once cancer cell are in the blood or 
lymph vessels, the distribution of the cancer cells is determined by the flow and interactions 
between cancer cells and the secondary organs that they colonise. In the blood stream 
tumour cells can express receptors that bind to metastasis-supporting sites (d) or to platelets 
(e), which protect the cancer cells from the immune system. After reaching the secondary site, 
tumour cells can reside at the capillary beds of the secondary site and can exit the 
bloodstream (f) by inducing endothelial cell retraction or death. To colonise in the secondary 
site (g), cancer cells start to release pro-inflammatory molecules and proteinases that induce 
their neighbours to release growth factors. From (Schroeder et al., 2012).
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Table 1: Typical sites of metastasis for solid tumours (Robins, 2006, Ahmad 
et al., 2011, Aranovich et al., 2013, Kowalski, 2001, Agalianos et al., 2016)  
Tumour type Principle site for distal 
metastasis 
Principle site for regional 
lymph node metastasis 
Breast bone, lungs, liver and brain axillary and internal mammary 
lymph nodes 
Lung adenocarcinoma brain, bone, adrenal glands and liver cervical lymph nodes 
 
Skin melanoma 
 
lungs, brain, skin and liver 
site dependent, for  example: head 
and neck melanoma; the most 
common site  is cervical lymph 
nodes 
Colorectal cancer liver and lungs mesenteric lymph node 
Pancreatic carcinoma liver and lungs para- aortic lymph node 
Prostate cancer bone para- aortic lymph node 
inguinal lymph node 
Head and neck lungs cervical lymph node 
Uveal melanoma  liver internal iliac, external iliac, or 
obturator lymph nodes 
 
 A new approach to anti-metastatic drugs  1.1.2
Clearly, developing anti-metastatic drugs remains an unmet clinical need as it 
would notably reduce tumour recurrence and improve patient survival. Therefore, 
as a better understanding of the complex metastatic process emerges, there is an 
opportunity to exploit these new findings to develop new targeted approaches for 
metastasis. For example, an interesting observation in metastasis is that primary 
tumours of certain organs usually metastasise to other specific organs (Murphy, 
2001, Muller et al., 2001), e.g. breast cancer normally migrates to the bone, lungs, 
brain, while colorectal cancer usually metastasises to the liver (Table 1). Although 
studies on the metastatic process have revealed many molecular factors that 
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contribute to invasion and metastasis, e.g. adhesion molecules and proteases, the 
exact mechanism of this directional migration was unclear until the role of the 
chemokine system has shown to be one of the key players in the metastatic 
process and particularly in organ specific metastasis. (Dowsland et al., 2003). 
Whilst the role of chemokine system in the metastasis to different organs have 
been demonstrated we are going to focus on metastasis to the lymph nodes which 
as discussed in the introduction to this chapter, is a major negative prognostic 
factor.  
 Lymph node metastasis  1.1.3
Metastasis of tumour cells to the lymph nodes is an early event and therefore, is 
considered as a key indicator of tumour stage and therapeutic options (Das et al., 
2013). Metastasis of tumour cells to the regional lymph nodes is associated with 
poor prognosis and local tumour recurrence after the resection of surgically 
removable malignancies (Achen and Stacker, 2008). Furthermore, the lymphatic 
spread is not only involved in local disease recurrence, but also leads to lethal 
distinct metastases (Sperveslage et al., 2012, Guo et al., 2013, Kawada and 
Taketo, 2011). It has been shown that distant metastasis is often observed along 
with induced lymph node metastasis (Hirakawa et al., 2007). 
Despite, the high prognostic importance of the lymphatic spread in cancer 
progression, the underlying mechanisms by which tumour cells migrate to lymph 
nodes remain unclear. It has been proposed that molecular pathways, mediated by 
proteins such as VEGF-C, can induce lymphangiogensis, and de-novo generation 
of new lymph vessels, and are critical for lymphatic metastasis in melanoma 
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(Hirakawa et al., 2007), breast (Ran et al., 2010) and prostate (Mumprecht and 
Detmar, 2009). In contrast, the migration of human pancreatic ductal 
adenocarcinoma (PDAC) to the lymph node does not require lymphangiogenesis 
(Sipos et al., 2005). This suggests that other mechanisms facilitate lymph node 
metastasis in PDAC. In this way, the molecular pathways that are involved in the 
lymphatic spread might be dependent on tumour type.  
The involvement of chemokines and their cognate receptors in the lymphatic 
metastasis has been reported in different types of cancer (Xiao et al., 2014, Achen 
and Stacker, 2008). More interestingly, the most commonly expressed chemokine 
receptors on tumours that lead to the lymphatic spread are CXCR4 and CCR7 
(Xiao et al., 2014, Cunningham et al., 2010, Guo et al., 2013, Irino et al., 2014). 
In the following sections, a brief introduction to chemokines and their role in 
cancer, focusing on the role of CCR7 in normal and cancer cells, and the 
therapeutic potential of targeting CCR7 as an anti-metastatic target will be 
discussed.  
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 Chemokines and their Receptors 1.1.4
 Definition and Nomenclature of Chemokines and their Receptors 1.1.4.1
Chemokines are a family of chemo-attractant cytokines that exert their effects 
through binding to cell surface chemokine receptors which belong to the seven 
trans-membrane (7TM) helical G-protein coupled receptor (GPCR) family (Figure 
5; Bennett et al., 2011). The N terminus and three extracellular loops are directed 
towards the outside of the cell, whereas the C terminus and three intracellular 
loops are exposed to the cytoplasm (Allen et al., 2007). The chemokine system is 
comprised of 49 chemokine ligands divided into four subfamilies (CXCL1–18, 
CCL1-CCL28, XCL1-2, and CX3CL1) which bind and activate 18 chemokine cell 
surface receptors (CXCR1-6, CCR1-10, XCR1 and CX3CR1), and also bind 6 
atypical receptors (ACKR1-6), see table 2 (Viola and Luster, 2008, Hauser and 
Legler, 2016). This classification of chemokines is based on structure rather than 
function and is according to the number and the spacing of the first two cysteine 
residues (C) in the amino-terminal part of the protein (Slettenaar and Wilson, 
2006). 
Although there are chemokine ligands and receptors which are uniquely paired 
within each subfamily, there is apparent promiscuity in the chemokine system. This 
means that some chemokines can bind and activate more than one chemokine 
receptor or the same receptor could be activated by different chemokines (Allen et 
al., 2007). For example, chemokine receptor CXCR4, which is one of the most 
studied chemokine receptors, is selectively activated by chemokine CXCL12, 
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whereas chemokine receptor CCR7 is activated by two chemokines, CCL19 and 
CCL21. 
The nomenclature of chemokines starts with their subclass, followed by “L” for 
“ligand” and a number for the corresponding gene nomenclature (Dowsland et al., 
2003). The nomenclature system of chemokine receptors also starts with the 
subclass, followed by “R” for “receptor” and the corresponding gene number. 
 
 
Figure 5: A proposed structure for the chemokine receptor.  
The G-protein coupled receptor consists of 7 TMs, N terminus and three extracellular loops, 
and C terminus and three intracellular loops. Figure courtesy of Dr. Victoria Vinader. 
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Table 2: Chemokine receptors and their known ligands (Bonecchi and 
Graham, 2016, Viola and Luster, 2008).  
Chemokine 
receptors 
Ligands 
CCR1 CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3 CCL5, CCL7, CCL8, CCL11 ,CCL13, CCL15, CCL16, CCL24, CCL26, CCL28 
CCR4 CCL17, CCL22 
CCR5 CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
CXCR1 CXCL6, CXCL7, CXCL8 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR3 CXCL4, CXCL9, CXCL10, CXCL11 
CXCR4 CXCL12 
CXCR5 CXCL13 
CXCR6 CXCL16 
XCR1 XCL1, XCL2 
CX3CR1 CX3CL1 
ACKR1 >20 inflammatory chemokines belonging to the CC and CXC families 
ACKR2 Agonists for CCR1 and CCR5  
ACKR3 CXCL12, CXCL11 
ACKR4 CCL19, CCL21, CCL25, CXCL13 
ACKR5 C5a 
ACKR6 chemerin 
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Chemokines are also classified according to their pattern of expression and related 
function as homeostatic or inflammatory chemokines (Fernandez and Lolis, 2002). 
The homeostatic chemokines are constitutively produced and perform various 
functions, such as trafficking of lymphocytes to lymphoid tissues, immune 
surveillance, and localization of T or B cells in the lymphatic system and the 
architecture of secondary immune organs. The inflammatory chemokines are only 
produced during an inflammatory stimulus or infection. The secretion of the 
inflammatory chemokines causes the migration of leukocytes to the injured or 
infected area. However, depending on the biological context, some chemokines 
may be considered both homeostatic and inflammatory.  
 Glycosaminoglycans Binding 1.1.4.2
Chemokines other than CXCL16 and CX3CL1, exist as soluble chemokines that 
can bind to the negatively charged glycosaminoglycans (GAGs), e.g. heparin 
sulphate, via their basic N terminus (Scholten et al., 2012). It has been reported 
that chemokines such as CCL2, CCL3, CCL5, CXCL8, CCL21 and CCL19 have a 
GAG binding domain (Vinader and Afarinkia, 2012, Vives et al., 2004, Stringer et 
al., 2002, Koopmann and Krangel, 1997). GAGs are bound to proteins on the cell 
surface and/or on the ECM and act as traps for chemokines. The binding of GAGs 
to chemokines has multiple effects (Vinader and Afarinkia, 2012). Firstly, it creates 
a chemotactic gradient which facilitates cell migration towards the source of 
chemokine production. Secondly, it induces chemokine conformational changes 
that facilitate its binding to the corresponding receptor. Thirdly, the binding of 
GAGs to chemokines could have importance in terms of selectivity in chemokine-
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chemokine receptor pairing. Finally, the binding of GAG is an essential requirement 
for chemokine receptor functionality in vivo, even though it is not required for 
receptor activation (Hamel et al., 2009). 
Binding of chemokines to their receptors results in activation of a number of 
intracellular signal transduction pathways. Therefore, chemokines can significantly 
influence the biology of the cell in different contexts. One major outcome of 
chemokine activation is cell migration towards the source of chemokine production, 
following the chemotactic gradient (Slettenaar and Wilson, 2006). This process is 
known as chemotaxis. 
Once the chemokine receptor is activated, the bound guanosine diphosphate 
(GDP) is exchanged to guanosine triphosphate (GTP) in the α G protein subunit 
(Figure 6; Allen et al., 2007). This leads to Gα and Gβ dissociation and departure 
from the receptor complex, entering the next stage of signal transduction. The Gα 
subunit interacts with adenyl cyclase which converts adenosine triphosphate (ATP) 
to cyclic adenosine monophosphate (cAMP). The Gβ subunit phosphorylates 
phosphatidylinositol-3-kinase (PI3K) which activates mitogen-activated protein 
kinases (MAPK) pathway. Gβ also phosphorylates phospholipase C (PLC) which 
accumulates inositol triphosphate and diacylglycerol in the cytoplasm (Kruizinga et 
al., 2009). These in turn, among other downstream effectors, induce Ca2+ 
mobilization, which is involved in cell shape and motility (Kruizinga et al., 2009).  
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Figure 6: Chemokine receptor activation. 
Chemokines bind to the chemokine receptor, activate it and triggers a cascade of signalling. 
The bound GDP is exchanged by GTP in the α subunit of G protein. This leads to Gα and Gβ 
dissociation and departing from the receptor. The Gα subunit interacts with adenyl cyclase. 
P: 
guanosine diphosphate; GTP: guanosine triphosphate; G: guanosine; PI3K: phosphorylates 
phosphatidylinositol-3-kinase; PLC: phospholipase C. 
 
The consequent cascade of downstream effectors activation eventually results in 
several biological functions (Figure 7). It has been observed that the Gi subclass 
are the primary Gα subunit associated with chemokine receptor’s induced 
chemotaxis and it’s well known that this subclass inhibits adenylate cyclase 
therefore it is the release of free β subunit from Gi that is responsible of 
chemotaxis as shown by (Neptune and Bourne, 1997). Nonetheless, depending on 
the cell-type and chemokine receptors expressed on these cells, G proteins other 
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than Gα-i could be activated which could results in different signalling pathway and 
function (Mellado et al., 2001). 
The biochemical pathway of chemokine receptors is not only dependent on G 
protein activation (Mellado et al., 2001). It has been shown that chemokine 
receptors activation can result in transactivation of other signalling pathways, e.g. 
binding of CXCL12 to CXCR4 results in EGF receptor activation (Mellado et al., 
2001, Porcile et al., 2005). Another significant property of chemokine receptors is 
their ability to homo or hetero-dimerize with other chemokines, GPCR and other 
cell surface proteins. It has been speculated that chemokine receptor dimerization 
is responsible for their biological functions (Mellado et al., 2001). 
Activation of the chemokine receptor and the consequent signal transduction to 
downstream effectors leads to the directional sensing and cell polarization that 
contributes to cell migration (Raman et al., 2011). Accumulation of small GTPase, 
RAC, cell division control protein 42 (CDC42) and PI3K at the front edge of the 
cells results in actin polymerization and F-actin formation, whereas accumulation of 
phosphatase and tensin (PTEN) tyrosine/ phosphatidylinositol 3-phosphate (PI3P) 
phosphatase and Rho GTPase at the trailing end causes actomyosin contraction 
and tail retraction. 
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Figure 7: Chemokine receptor signaling in migration and survival/proliferation. 
 Different signaling pathways can be activated by chemokine-chemokine receptor interaction. 
Chemokine receptors are GPCR, as such; they are involved in activating G proteins, primarily 
Gi. However, it has been shown chemokine receptors can also signal through other G proteins 
or even non- G proteins signaling pathways. These signaling pathways can also vary 
depending on certain pairing between a chemokine and a chemokine receptor and the cell 
type. This accounts for the different physiological roles that chemokine receptor activation 
can induce. Solid lines indicate direct effect, dashed lines indicate indirect effect. (O'Hayre et 
al., 2008).  
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In addition to the conventional chemokine receptors that signal through G proteins, 
there are 6 atypical chemokine receptors which signal in a G-protein-independent 
manner and do not result in cell migration. These 6 receptors include, ACKR1, 
previously called Duffy antigen receptor for chemokines (DARC); ACKR2, known 
as (D6 or CCBP2); ACKR3, also called CXC-chemokine receptor 7 (CXCR7) or 
RDC1; ACKR4, previously known as (CC chemokine receptor-like 1 (CCRL1) and 
also known as CCX-CKR; ACKR5 known as (CCRL2) and ACKR6 known as 
PITPNM3 (Hauser and Legler, 2016, Ulvmar et al., 2011, Bonecchi and Graham, 
2016). The function of the atypical chemokine receptors is to regulate the 
chemokine expression by scavenging, transporting, or storing them to help with 
resolution of inflammatory response at the inflammation site (Bonecchi and 
Graham, 2016). 
 Chemokine receptors in cancer 1.1.5
The aberrant chemokine receptor expression in cancer cells is associated with 
oncogenic mutations, hypoxia, epigenetic modulation and other changes in the 
tumour microenvironment (Zlotnik et al., 2011). For example, it has been observed 
that the angiogenesis-promoting molecule VEGF induces the overexpression of 
CXCR4 (Zlotnik et al., 2011). However, the expression of chemokine receptors 
such as CCR10 in melanoma may only mirror the already high expression of 
CCR10 on the normal counterpart cells (Rossi and Zlotnik, 2000). 
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Table 3: The expression profile of chemokine receptor on different type of 
tumours (Balkwill, 2012). 
Cancer type Chemokine receptors expressed by tumour cells 
 
Breast  
 
CXCR4, CXCR7, CCR4, CCR5, CX3CR1 
High grade serous ovarian  CXCR4 
Prostate cancer  CXCR4, CXC3R1 
Melanoma  CXCR4, CCR10, CCR7, CCR9, CXCR1,CXCR2, CXCR3 
Oesophageal cancer  CXCR4 
Non-small cell lung cancer  CXCR4, CCR7 
Head and neck cancer  CXCR4, CCR7, CXCR5 
Bladder cancer  CXCR4 
Colorectal cancer CXCR4, CCR6, CCR7, CXCR5 
Osteosarcoma CXCR4 
Neuroblastoma  CXCR4 
Pancreatic cancer  CXCR4, CX3CR1 
Acute lymphoblastic leukaemia  CXCR4, CXCR3 
Chronic lymphocytic leukaemia  CXCR4, CCR7, CXCR3 
Stomach cancer  CXCR4, CCR7, CCR4 
Non-Hodgkin’s lymphoma  CCR7 
T cell leukaemia  CCR7 
Cutaneous lymphoma  CCR3, CCR4, CCR10 
Hodgkin’s lymphoma  CCR5 
Multiple myeloma CCR1 
Glioma  CXCR4, CXCR7, CX3CR1 
 
Studies on chemokine receptors on cancers have shown that tumours overexpress 
certain chemokine receptors to match the chemokines produced by organs to 
which these cells normally metastasise Table 3 (Balkwill, 2012). The most 
commonly expressed chemokine receptor on tumours is CXCR4, followed by 
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CCR7, although other chemokine receptors are also expressed, as indicated in 
table 3 (Balkwill, 2012). 
Once the chemokine receptors are activated, the cancer cells can adopt normal 
cellular pathways to migrate towards the source of chemokine production resulting 
in metastasis (Zlotnik et al., 2011). In addition, cancer cells can express chemokine 
ligands for the same chemokine receptors that they are expressing (Balkwill, 
2012). It has been speculated that this autocrine loop is involved in the increased 
cell survival and resistance to chemotherapy of the primary and metastatic tumours 
(Balkwill, 2012). However, when cancer cells are ready to metastasise following a 
concentration gradient of chemokines, they shut down this autocrine loop by 
repressing chemokine production, while maintaining the receptor expression, e.g. 
in breast cancer cells, CXCL12 gene has been found to be epigenetically silenced 
without affecting the expression of CXCR4 (Wendt et al., 2008). 
 Role of CCR7 in normal physiology 1.1.6
The chemokine receptor 7 (CCR7) was first identified in 1993 (Birkenbach et al., 
1993). It is a homeostatic chemokine receptor which has a crucial role in immune 
responses and its aberrant expression, like other chemokine receptors such as 
CXCR4, has been associated with the development of autoimmune diseases 
(Comerford et al., 2013).  
Normally, CCR7 is expressed on naive and memory and regulatory T cells, B cells, 
and mature dendritic cells (DCs) (Förster et al., 2008). Two ligands, CCL19 and 
CCL21, have been identified to activate CCR7 (Comerford et al., 2013). CCL21 is 
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expressed in lymph nodes, Peyer’s patches and their endothelial venules, the T-
cell zones of the spleen and the lymphatic endothelium of multiple organs. CCL19 
is expressed mainly by stromal cells in the T-cell zone of the spleen, lymph nodes 
and Peyer’s patches (Mashino et al., 2002). Although, both ligands bind to CCR7, 
they may play different roles. CCL19 and CCL21 share only 32% amino acid 
sequence similarity and only the latter has a GAGs binding domain (Steen et al., 
2014). 
The lack of sequence similarity in CCL19 and CCL21 can explain differences in 
their functional roles by which CCL19 and CCL21 can activate CCR7 to trigger 
different signalling pathways (Comerford et al., 2013). It has been shown that 
CCL19 can induce internalization and desensitisation of the receptor, whereas 
CCL21 cannot (Steen et al., 2014). In regards to migration, some in vitro studies 
have shown that DCs migrate more efficiently towards CCL21, controversially, 
others have shown that DCs migrate more efficiently towards CCL19 (Nandagopal 
et al., 2011, Ricart et al., 2011). Furthermore, Ricart et al. have shown that murine 
DCs present biased migratory movement, which depends on the ligand 
concentration (Steen et al., 2014). Thus, CCL21 induces migration at higher levels 
when its concentration is significantly high. On the other hand, CCL19 causes this 
increase in migration at relatively low concentrations. Of note, despite the above 
findings, in vivo experiments have shown that CCL21 plays the dominant role in 
migration (Comerford et al., 2013).  
Despite that different signalling and functions result from binding of CCL21 or 
CCL19 to CCR7, a similar chemokine receptor activation model has been 
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proposed by both CCL21 and CCL19 (Scholten et al., 2012). Chemokines bind to 
the outside N terminus and the extracellular loops of the chemokine receptor. This 
binding is mainly due to the ionic interaction between the negatively charged 
residues of chemokines and the positively charged amino acids at the N terminus 
and the extracellular loops of the receptor. This changes the chemokine to the 
conformation needed to interact with a second binding site consisting of 
extracellular loops and/or TM domains leading to receptor activation Figure 8. It 
has been shown in Ott et al., study that CCR7 has four important second binding 
sites including, Lys3.33 (137), Gln5.42 (227), Lys3.26 (130) and Asn7.32 (305) (Ott et al., 2004). 
This study fits with the proposed model of 2 step model of binding decribed above 
because these four resides in CCR7 were demonstrated to be involved in receptor 
activation without affecting CCL21 or CCL19 affinty binding. 
 
Figure 8: The proposed two step model for chemokine receptor activation.  
(a) Chemokine binds at the recognition site, the N terminus and extracellular loops. (b) 
Change in the chemokine conformation to position its binding at the external loops and 
transmembrane domains, which activates the receptor (Scholten et al., 2012).  
(b) (a) 
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After activation by CCL21 or CCL19, CCR7 expressing immune cells are then 
recruited to lymph nodes to initiate an immune response and in establishing central 
and peripheral tolerance to differentiate between self and non-self-antigen, 
preventing the development of autoimmune diseases (Förster et al., 2008, 
Comerford et al., 2013, Worbs and Förster, 2007). 
 Role of CCR7 in cancer  1.1.7
The CCR7 axis plays a dual, and at first sight conflicting role in cancer. As 
discussed above, CCR7 and its ligands are highly involved in immune responses 
and therefore, may have an anti-tumour role by recruiting leukocytes that are 
capable of initiating an immune response to cancer. However, tumour cells can 
readily circumvent this process by: (1) secretion of CCL21 to recruit immune cells 
(T regulatory cells) that are involved in tolerogenic responses, producing 
immunologic tolerance (Shields et al., 2010); (2) secreting oxysterols (oxygenated 
derivatives of cholesterol) that act as ligands of the liver X receptor (LXR) which 
results in inhibiting CCR7 expression in maturing DCs (Zlotnik et al., 2011, 
Villablanca et al., 2010). Consequently, the DCs lose the ability to migrate and 
initiate an anti-tumour response see Figure 9. Furthermore, cancer cells can 
upregulate CCR7 expression and hijack its signalling pathways to enable cells to 
migrate and colonise the lymph nodes (see below). In fact, there is now mounting 
evidence that CCR7 is a promotor of cancer progression and metastasis which we 
will discuss below.  
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Figure 9: Inhibition of CCR7 expression on immune cells. 
Tumour cells inhibit DC CCR7 expression to prevent antitumor responses by secreting 
oxysterol to interact with LXR expressed on DC resulting in halting the migration of DC to the 
tumour site (Zlotnik et al., 2011).  
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 CCR7 expression in cancer and lymphatic metastasis 1.1.8
The expression of chemokine receptors can be downregulated, upregulated or 
show no significant difference in cancer cells in comparison to normal cells (Wang 
et al., 2004, Muller et al., 2001). However, all the studies carried out so far have 
shown that CCR7 expression is always upregulated in cancer tissues and cell 
lines, compared with their normal counterparts, with no discrepancy between gene 
and protein level (Takanami, 2003, Muller et al., 2001, Xia et al., 2014, Ueda et al., 
2010) 
The association between CCR7 expression and lymphatic metastasis has been 
investigated in human tissues by immunohistochemical and clinicopathologic 
correlation studies. It has been shown that CCR7 expression correlates with lymph 
node metastasis and poor prognosis in a number of malignancies, e.g. in breast 
(Liu et al., 2010), pancreatic ductal adenocarcinoma (Sperveslage et al., 2012, 
Guo et al., 2013), esophageal squamous cell carcinoma (Irino et al., 2014), tongue 
carcinoma (Xia et al., 2014), breast cancer(Li et al., 2014), gastric carcinoma 
(Mashino, 2002, Zhou et al., 2013), head and neck cancer (Li et al., 2011), non-
small cell lung cancer (Takanami, 2003), cervical cancer (Shang et al., 2009), 
tonsillar cancer (Pitkin et al., 2007), prostate cancer (Heresi et al., 2005), colorectal 
cancer and pancreatic cancer (Zhao et al., 2011). Recent studies have suggested 
a potential role for the chemotactic effect of CCR7 in the migration of leukemic 
cells to the central nervous system; (Buonamici, 2009).  
In addition, cells in which CCR7 expression is upregulated are shown to have 
enhanced metastatic potential and vice versa, ones in which the expression is 
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downregulated have diminished metastatic potential. In a study conducted by 
Henry et al., the induced expression of CCR7 in B16 murine melanoma increased 
the migration of cells to lymph nodes (Wiley et al., 2001). However, B16-CCR7-
transfected and control cells show no preference for lung metastasis or increased 
proliferation. Similarly, enhanced migration to the lymph node along with 
proliferation has been observed in CCR7-transfected PT45P1, which is a PDAC 
cell line, compared with the control cells (Sperveslage et al., 2012). In addition, 
Cunningham et al, have reported that the induced expression of CCR7 in mouse 
breast cancer cells alters the metastatic destination from the lung to the lymph 
nodes (Cunningham et al., 2010). In their model, injecting 10 mice with CCR7– 
breast cancer cells has led to lung metastasis (10/10 mice), however in the 
corresponding experiment with the CCR7+ cells, mainly lymph node metastasis 
(6/10 mice) and a reduced rate of metastasis to the lungs (4/10 mice) was 
observed. 
Whilst a correlation between CCR7 expression and lymphatic metastasis can be 
inferred from these studies, the underlying mechanisms by which CCR7+ tumour 
cells migrate to the lymph node is yet to be fully elucidated. It has been suggested 
that the CCR7/CCL21 interaction plays an important role in this process (Legler et 
al., 2014). Importantly, knocking down of CCR7 in different cancer types also 
confirmed the importance of CCR7 for lymphatic selectivity (Xia et al., 2014, 
Maekawa et al., 2008). To the best of our knowledge few studies have addressed 
the correlation between CCL19 and lymphatic metastasis. Where experiments 
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have been performed, no association was observed between CCL19 expression 
and lymphatic metastasis in PDAC (Sperveslage et al., 2012).  
In addition, utilizing Enzyme-Linked Immunosorbent Assay (ELISA), presence of 
CCL21 and CCL19 is detected in cell culture supernatant produced by PDAC cell 
lines, BxPc3, Capan1, Colo357, HPAF2, Panc89, T3M-4 and PT45P1. This 
suggests that not only do these ligands originate in lymph vessels and nodes but 
also in the tumour microenvironment and that CCL21/CCL19 may participate in the 
metastatic process by autocrine stimulation of CCR7 leading to intravasation 
(Sperveslage et al., 2012).  
Different in vitro experiments have shown a decrease in motility, invasion and 
adhesion of tumour cells where CCR7 was knocked down (Xia et al., 2014). 
Furthermore, in lung adenocarcinoma, blocking CCR7 using antibodies showed a 
significant suppression of cell migration (Maekawa et al., 2008). The number of 
metastases to lymph nodes was significantly reduced in vivo after knocking down 
CCR7 (Maekawa et al., 2008). Muller et al. have reported that breast cancer cells 
co-express CCR7 and CXCR4 and blocking of CXCR4 using antibodies resulted in 
suppressing lymph node metastasis (Muller et al., 2001). However, in a different 
study loss of other chemokine receptors expression such as, CCR6, was 
suggested as important as the presence of expression of CCR7 for migration of 
squamous cell carcinoma of the head and neck to the lymph node (Wang et al., 
2004).  
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Although the lymphatic metastasis is highly correlated with the CCR7/CCL21 axis, 
it is not determined yet if this single chemokine interaction is the only responsible 
interaction for lymphatic selectivity. Some studies have demonstrated that 
CCR7/CCL21 might be the ultimate important interaction for lymph node selectivity. 
Wiley et al. have shown that the induced expression of CCR7 cells but not CXCR5, 
in melanoma, correlated with lymph node metastasis (Wiley et al., 2001). Keeping 
in mind that the CXCR5 ligand CXCL13 is expressed in the lymph nodes as well, 
that could confirm that the lymphatic metastasis is dependent on CCR7 
expression. Also, despite that in a non-small cell lung carcinoma study, CCR7 
rather than CXCR4 expression, was correlated with lymph node metastasis 
(Takanami, 2003). However, in submucosal esophageal cancer expression of 
CXCR4 was correlated with lymph node metastasis (Sasaki et al., 2008).  
While CCR7 expression and subsequent activation might be one of the most 
critical steps for lymphatic selectivity, loss of expression of other chemokine 
receptors such as CCR6 loss of expression in head and neck cancer, may also 
play a role (Wang et al., 2004). This, however, needs further investigation to 
determine whether single or multiple chemokine interactions are involved in guiding 
the metastatic destination to the lymph node either by loss or gain of expression.  
 Other metastasis-supporting roles for the CCR7 axis 1.1.9
In addition to chemotaxis, CCR7 activation has been shown to have multiple roles 
which support tumour progression and metastasis. The PI3K/Akt pathway triggered 
by the activation of CCR7 in head and neck cancer and T cell lymphoma has been 
shown to be involved in survival and growth in both primary and metastatic 
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tumours (Wang et al., 2005, Zhao et al., 2011). Activation of CCR7 by CCL21 is 
associated with blood and lymph node vessels formation in breast, pancreatic 
cancer and melanoma. (Tutunea-Fatan et al., 2015, Zhao et al., 2011, Takekoshi 
et al., 2012). Although the mechanism underlying the induction of angiogenesis 
and lymphangiogenesis is currently unclear, there is strong evidence that 
CCR7/CCL21 axis is involved in the process of metastasis (Zhao et al., 2011). In 
B-cell chronic lymphocytic leukaemia and colon cancer, activation of CCR7 by 
CCL21 has also been shown to promote MMP-9 production, which has a major 
role in degrading the ECM, hence promoting invasion and metastasis (Li et al., 
2011). In breast cancer cells, CCR7 activation by its ligand CCL21 was recently 
found to inhibit detachment induced apoptosis (anoikis) by upregulating anti-
apoptotic proteins and downregulating apoptotic proteins through PI3K and c-Jun 
N-terminal kinase (JNK) pathways (Kochetkova et al., 2009), consequently 
increasing the cell survival and the number of metastatic cells. Of note, this CCL21 
induced survival was only observed by loss of attachment and not by serum 
deprivation or treatment with cytotoxic drugs. Conversely, CCR7 activation by 
CCL21 in non-small cell lung cancer (NSCLC) was found to increase cell 
proliferation and survival via the extracellular-signal-regulated kinase (ERK) 
pathway but not AKT, p38, or JNK. (Xu et al., 2012). A recent study has shown that 
the other ligand for CCR7, CCL19, is associated with increased proliferation, 
invasion and anoikis inhibition through ERK and Akt pathways in breast cancer (Su 
et al., 2014). Interestingly, this study showed that CCL21, which is proved by 
published work to have more significant importance on the downstream effects 
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upon CCR7 activation, did not increase the expression level of either ERK or Akt. 
Accordingly, these inconsistent findings on the signalling pathways of CCR7 
activation could be related to the use of different cell types and/or different 
experimental conditions in the studies. 
In summary, activation of the CCR7 receptor by its ligands in cancer cells triggers 
several signaling pathways leading to, depending on cancer type, cell migration, 
survival, proliferation and metastasis particularly to the lymph nodes. Furthermore, 
conventional treatments have proved to be inefficient when it comes to cancer 
metastasis that is responsible for cancer relapse and most of patient’s deaths. 
Accordingly, targeting CCR7 using small molecule antagonists can reduce or 
inhibit progress of metastasis providing better opportunities for patient’s survival. 
As discussed earlier, a key requirement for developing anti-metastatic therapeutics 
is the availability of reliable in vitro models to predict anti-metastatic potential of 
drug agents. In the following section, we review the advantages and disadvantages 
of available techniques to assess metastatic potential in cancer cells when treated 
with drug agents. 
 In vitro invasion and migration assays 1.1.10
As described earlier the major challenge in developing anti-metastatic inhibitors is 
the testing of these inhibitors in suitable preclinical models. Here we are going to 
focus on the in vitro assays that inform on migratory and invasiveness. In drug 
discovery, in vitro assays are favoured because of their ease in handling, 
increased reducibility and most importantly they are high throughput drug testing 
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and are less expensive compared with the in vivo assays. Furthermore, the use of 
animal in drug studies is controversial ethically and therefore proceeding with more 
promising confident compounds from in vitro to in vivo studies would reduce the 
conflict. In the following subsection definitions of migration and invasion and the 
most common 2D and 3D assay are briefly described (Kramer et al., 2013, Eccles 
et al., 2005, Decaestecker et al., 2007). 
 Definition of migration and invasion 1.1.10.1
Cancer cells mimic the movement of normal cells, as observed during embryonic 
morphogenesis, would healing and immune-cell trafficking (Kramer et al., 2013, 
Eccles et al., 2005). That movement in cancer cells is crudely classified into 
migration and invasion although there is no clear cut differentiation between the 
two. Migration is usually used in non-pathological description of cell movement in 
the body. On the other hand, invasion is often used to describe a pathological 
disorder of cancer cell movement. Malignant carcinomas are defined by the ability 
of tumour cells to invade and penetrate through tissues and basement membranes 
and infiltrate into the underlying interstitial tissues. For example intestinal cancers 
are considered invasive, when the tumour mass penetrates through the basal 
membrane and enters the submucosal muscle layer. Obviously, although 
assessing migration is useful in determining metastatic potential, assessment of 
invasion is more relevant. 
The distinction between migration and invasion become clearer when we refer to in 
vitro cell movement. Any cell movement on a 2D surface (basal membranes, ECM 
fibers or plastic plates) or 3D tissue without any obstructive network, such as 
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collagen, that does not require any destruction or proteolysis of matrices is defined 
as migration. On the other hand, invasion occurs when cells move through a 3D 
matrix, and requires modulation of adhesion, modification or proteolysis of 
extracellular-matrix components. Therefore, invading cells must modify their shape 
and interact with and are involved in remodeling of the ECM.  
 2D and 3D migration and invasion assays.  1.1.10.2
1.1.10.2.1 2D Migration assays 
1.1.10.2.1.1 Microcarrier bead assay 
Cells are grown to reach confluency on microcarrier beads. Thereafter, cell-coated 
beads are placed in 24-well plates and left for a certain period of time. Later the 
beads are removed and the migrated cells that are now attached to the plastic 
surface are fixed and stained with crystal violet. The migrated cells are then 
quantified. (Kramer et al., 2013, Eccles et al., 2005, Decaestecker et al., 2007)  
1.1.10.2.1.2 Wound healing  
Cells are grown to reach confluency on a cell culture treated plastic surface 
Attached cells are then wounded manually by hand using a pipette tip or 
automatically by using electric signals. Cells that migrate into the wounded area 
can then be monitored by time-lapse microscope or manually taking imaging at 
certain time points. Cell migration can be calculated by measuring the free surface 
area before and after migration. This assay is very popular because it is easy to 
set-up, analyze and inexpensive, however, this assay is not suitable for cells that 
need more than 24 h to close the wounded area because it cannot distinguish 
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between proliferation and migration, unless performed under very low serum 
conditions. Furthermore, the gap closure rate is not uniform and is speeded up as 
the gap narrows. Also, the free surface area after migration has to be normalized to 
the free surface area before, for each scratch, to circumvent the differences in 
widths of scratches if performed manually. (Kramer et al., 2013, Eccles et al., 2005, 
Decaestecker et al., 2007).  
1.1.10.2.1.3 Ring assay 
Cells are seeded to the circular inner region of a Teflon or glass ring in 6 well 
culture plates. The ring is removed after several hours and the attached cells are 
left to migrate for several hours. The cells are then washed fixed and stained. The 
cell migration is calculated by the net increase of total area covered by the cells or 
as the average of the linear distances covered by from the point of origin. (Kramer 
et al., 2013, Eccles et al., 2005, Decaestecker et al., 2007) . 
 
1.1.10.2.1.4 Single cell tracking assays 
Colloidal gold migration assay is used to track single cell locomotion of cultured 
cells on a glass coverslip that is covered with gold particles. The cells are left to 
migrate and are fixed before adding the coverslip onto microscope slides. In 
assessing the cell migration, computer-aided analysis can monitor the images of 
the tracks made by the cells and to measure the areas of the tracks. Under the 
microscope, the colloidal gold particles form a homogenous layer of small dark 
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dots and the migrating single cells phagocytose the gold particles leaving white 
tracks that can be evaluated by computer-assisted image analysis. 
Single cells migration can also be tracked by using microscopes equipped with a 
time lapse video system. Manual or automated tracking can be achieved with 
computer aided software. Cell division, proliferation and path crossing can also be 
taking into account if recorded for sufficient time. 
Another single migration assay is the Dunn assay. Briefly, a microscope slide that 
has 2 chambers connected via a bridge horizontally. Media containing cells are 
added to one chamber and media containing chemoattractants are added to the 
other chamber. Cells sense the gradient of the chemoattractant and start to move 
towards it. Cells can be counted at the surface of the connecting bridge under the 
microscope. This assay is valuable when it comes to test expensive compounds, 
because of the small volumes needed. (Kramer et al., 2013, Eccles et al., 2005, 
Decaestecker et al., 2007) . 
1.1.10.2.1.5 Under agarose spot assay 
This assay permits the tracking of cell migration in response to multiple 
chemokines. Chemokines at specific concentrations are diluted in agarose and 
applied as a drop on the glass bottom petri dish as a spot. Then, media 
containing cells is added to the petri dish and cells are left to migrate. 
Chemokine will start to diffuse and therefore cells will migrate under the agarose 
spot towards the source of the chemokine if they only express the cognate 
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receptor for the corresponding chemokine. Later, cells migrated under the 
agarose spot are quantified for each individual chemokine (Ahmed et al., 2017) 
1.1.10.2.2 3D migration/invasion assays  
1.1.10.2.2.1 Transwell assay  
The transwell assay known also as Boyden chamber assay consists of two 
chambers; the upper one has a porous membrane. The pore size (5–12 µm) is 
smaller than the cell size to prevent active cell movement. Briefly, cells suspended 
into media are added to the upper chamber and can migrate vertically through the 
porous membrane towards the lower chamber, which contains the medium with the 
appropriate chemoattractant. The horizontal migration/invasion of cells until 
reaching the pores is an important element in this assay. Migrated cells on the 
reverse side of the porous membrane are fixed, stained and counted. The transwell 
assay can be modified for invasion, if the inserts are coated with a matrix (e.g. 
collagen, fibronectin) prior to seeding the cells. Hence the cells are moving towards 
the lower chamber, the transwell assay can be used to investigate chemotaxis 
(Kramer et al., 2013, Eccles et al., 2005, Decaestecker et al., 2007) . 
1.1.10.2.2.2 Gel invasion assay 
Cells are seeded onto the surface of collagen gel and left to migrate into the gel to 
monitor the depth of the invasion using a phase-contrast microscope. (Kramer et 
al., 2013, Eccles et al., 2005, Decaestecker et al., 2007) . 
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1.1.10.2.2.3 Spheroid/single cell suspension invasion assay 
Spheroids which are 3D clusters of tumour cells are confronted with normal cells 
(see section 1.1.10.4 for methods used for growing spheroids), initially on semi-
solid agar to allow cells attachment, and later in media for few days. This type of 
study is useful to study immune cells infiltration into tumours in vitro. In addition 
normal cells can be grown into spheroids and a cell suspension of tumour cells is 
added to it, to study cancer invasion into normal tissue. The cell count is not an 
easy task and needs either deep confocal imaging or good sample preparation if 
analyzed with flow cytometry to differentiate between truly invaded cells and cells 
attached to the spheroid surface. (Kramer et al., 2013, Eccles et al., 2005, 
Decaestecker et al., 2007) . 
1.1.10.2.2.4 Spheroid invasion assay 
Tumour spheroids are embedded into a 3D matrix such as collagen I or matrigel 
and topped up with media containing a chemoattractant, if the spheroid is derived 
from non-invasive cancer cell lines it will stay compact, with no signs of invasion, if 
the spheroid is derived from an invasive cancer cell line such as the breast cancer 
line MDA-MB-231, it will invade into the matrix. Invasion can be recorded through 
live imaging or by taking images at different time points and the invasive area over 
time is analysed. (Kramer et al., 2013, Eccles et al., 2005, Decaestecker et al., 
2007) .  
Despite the fact that the 3D spheroid assays requires relatively more experimental 
effort compared with other assays, it is highly important to use it for in vitro analysis 
before proceeding for in vivo work. Therefore, the importance of spheroids in 
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evaluating compounds and the different method used to generate them are 
discussed in the following section. 
 Importance of spheroids in drug screening  1.1.10.3
Culturing cells on 2D cell culture plates has been used to study cancer cell biology 
as well as drug screening, although this assumes that cells grown as monolayers 
on plastics can mimic the physiology and environment of real tissues. While the 2D 
cultured cells can provide valuable information about cell migration, they do not 
account for the complex conditions found in in vivo (Lin and Chang, 2008). It has 
been demonstrated that PC-3 prostate cancer cell line cultured as 3D spheroids 
have a significant reduction of β1-integrin expression compared with cells cultured 
as 2D monolayers (Sameni et al., 2008). Therefore, growing cells as spheroids has 
been suggested to provide a model closer to the in vivo conditions, namely, the 
cell-to-cell and cell-to-matrix, as well as availability of nutrients, oxygen level and 
growth factors gradients (Hirschhaeuser et al., 2010). These features allow for a 
better understanding of the physiological process in vivo and can provide a more 
successful selection of compounds during tests.  
Improving our in vitro experimental set up to better mimic the in vivo situation can 
be very beneficial for the use of animals in research as this raises many ethical 
concerns and in this way, the use of animals can be reduced to the most promising 
candidates.  
In this context, is very important to observe the difference between spheroids and 
cell aggregates. The latter are sometimes mistakenly in the literature considered as 
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spheroids, since they are not true spheroids, they will not provide the perquisites 
for their use as spheroids in drug testing (Friedrich et al., 2009). Cell aggregates 
lack cell-cell and cell-matrix interactions and the spherical geometry. In addition, as 
they are loose aggregates, they can detach easily and are difficult to transfer them 
for drug testing (Hirschhaeuser et al., 2010). Most importantly, these aggregates 
cannot develop the pathophysiological characteristics of a true spheroid Figure 10. 
Spheroid with diameters larger than 200 μm will develop a gradient of oxygen, 
glucose, lactate and ATP that is highest at the outer layers and lowest at the most 
inner areas (Mehta et al., 2012, Lin and Chang, 2008). Hence the spheroid can 
mirror the in vivo situation, with cells at the rim are closer to oxygen and nutrients, 
likewise tumour cells that are close to blood vessels. The inner cells are far from 
the nutrients and oxygen supply and therefore become quiescent and eventually 
die.  
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Figure 10: Spheroid characteristics.  
Images of different analytical methods; autoradiography, the tunnel assay, bioluminescence 
imaging, and probing with oxygen microelectrodes showing the different gradient of oxygen, 
lactate, apoptosis, glucose, proliferation, apoptosis and necrosis through spheroid section. 
(Hirschhaeuser et al., 2010).  
 
The responses of potential anti-tumour drug candidate molecules on 3D models 
can be influenced by multiple factors including diffusion barrier, different 
expression of the particular target, modulation of DNA damage and repair 
mechanisms, cell cycle distribution and cell-cell and cell-matrix interactions, 
therefore growing spheroids of a particular size can provide a valuable insight into 
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drug screening studies (Mehta et al., 2012, Hirschhaeuser et al., 2010, Friedrich et 
al., 2009). 
In spite of, the valuable physiologically relevant information that can be gained 
from spheroids model, they can sometimes give negative results in compounds 
screening due to the complexity of the system and therefore falsely mistaken active 
compounds into inactive ones. However, this might not be related to 
compound/target interaction of a hit molecule, but for physiological parameters 
such as permeability and diffusion of compounds which cannot be assessed in hit 
selection of compounds and of course can be improved by SAR studies performed 
by medicinal chemists. Hence, both 2D and 3D studies have to be considered, 
especially in therapeutic screening in drug discovery.   
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 Methods for growing spheroids 1.1.10.4
The formation of spheroids comprises of 3 important steps Figure 11 (Cui et al., 
2017). (1) Cells in suspension that are close to each other can form loose 
aggregates, resulting from ECM fibers binding to the integrin on the cells. These 
aggregates that have high cell-cell interaction results in cadherin expression 
increase. (2) Further cadherin upregulation is followed at the membrane surface 
with more compacted aggregates (3) Tight spheroids are formed from the solid 
aggregates due to homophilic cadherin –cadherin binding. 
 
 
Figure 11: Spheroids formation steps. Cells that are in close proximity due to integrin-ECM 
interaction, results in loose cell aggregates, later cadherin is upregulated and tighter 
aggregates are formed. Finally cadherin-cadherin interaction results in spheroid compaction. 
From (Cui et al., 2017)..   
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To date, many methods have been developed to grow spheroids. These are:- (1) 
The conventional method of forced floating by preventing attachment of cells to cell 
cultures surfaces, hanging drop and spinner flask, (2) The matrix and scaffold 
methods, (3) The microfluidic devices Figure 12. A brief description on the different 
spheroids formation techniques is summarised in Figure 12. 
 
Figure 12: Methods for developing 3D spheroids. 
(a) Forced floating method (b) Hanging drop method (c) Spinner flask method (d) Matrices and 
scaffolds (e) Microfluidic system. Adapted from (Cui et al., 2017, Breslin and O'Driscoll, 2013).  
  
   
 
 49 
 
Table 4: Description of spheroid formation methods (Breslin and O'Driscoll, 
2013, Hirschhaeuser et al., 2010, Foty, 2011, Patra et al., 2013, Cui et al., 
2017). 
 
 
 
  
Method Hanging 
drop 
Spinner flask Forced floating Scaffolds and 
matrices 
Microfluidic 
cell culture 
platforms 
Spheroids 
size 
small small and large 
spheroids can 
be produced 
small and large 
spheroids can be 
produced 
small and large 
spheroids can 
be produced 
small and 
large 
spheroids 
can be 
produced 
      
Ease of 
technique 
easy easy easy easy easy 
      
Cost inexpensive inexpensive inexpensive expensive expensive 
      
High scale 
production 
incompetent competent competent competent  incompetent 
      
Variation in 
size 
uniform variant variant variant uniform 
      
Labour 
intensive 
yes yes no no no 
      
Mimic Cell-
matrix 
interaction 
no no no yes yes 
 
Drawbacks 
 
media 
exchange is 
difficult due 
to small 
volume of 
the drop 
 
damage by 
shear force 
and 
no control over 
spheroids size 
and shape 
 
no control over 
spheroids size 
 
difficulty to 
retrieve 
spheroids after 
culturing 
 
difficulty for 
further 
analysis 
due to small 
volume 
produced 
by plate 
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In summary (table 5), there are a number of different migration and invasion 
assays available and the importance to include a 3D model in the drug screening is 
highlighted. Therefore, in next chapters we have used some of these assays 
including wound healing, transwell and 3D spheroid invasion assays to assess the 
effect of CCL21 or CCL19 on cell migration/invasion in CCR7 expressing cells and 
evaluate the effectiveness of our in house developed CCR7 antagonists in blocking 
cell migration and invasion.  
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Table 5: Comparison of common in vitro migration and invasion assays. 
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1.2 Aims and objectives 
Currently, many aspects of the role of CCR7 in cancer remain unclear. For 
example, whilst it is known that CCR7 is upregulated in tumours, there is little 
known about the factors that regulate the expression of CCR7 and how these 
affect tumour cell’s functions response to CCL21 or CCL19.  
Antagonism of CCR7 receptor could not only provide valuable information on the 
role of the receptor in cancer, it may also lead to the discovery of novel therapeutic 
agents with promising potential, in preventing lymph node metastasis. Therefore 
the aims of this research project are:- 
 To study the protein expression of CCR7 in different cell lines, xenografts 
and clinical tissue and assess how wide spread is the CCR7 expression, 
and assess the functional response of cell lines in order to choose a model 
for screening of CCR7 antagonist compounds in vitro and later in vivo. 
(Chapter 2). 
 To investigate the regulation of CCR7 expression by stress induced 
conditions; hypoxia, serum deprivation, mechanical stress and 3D geometry, 
to mimic the settings that tumours encounter in vivo and to investigate if an 
increase in the expression of CCR7 correlates with an increase in drivers of 
malignancy (e.g. migration, proliferation, survival) (Chapter 2). 
 To carry out siRNA CCR7 knockdown studies on OSC-19 cells in vitro in 
order to better understand the CCR7/CCL21 functional roles in cancer and 
to gain confidence in the hypothesis that CCR7 antagonism is a good 
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strategy to stop the migration and invasion of cancer cells and thus improve 
the survival of cancer patients (Chapter 3).  
 To evaluate the effect of CCR7 antagonism on receptor activation, 
migration, invasion in different in vitro pharmacological assays that include; 
scratch, transwell, and spheroid invasion assays in order to characterise 
and identify small molecules, to understand their structure activity 
relationship and develop potent compounds that can potentially increase the 
quality of life and the survival of patients (Chapter 4).  
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2                                           Chapter 2: 
Expression of CCR7 in cancer cell 
lines and impact of cellular stress 
on its expression 
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2.1 Introduction 
A number of studies have previously shown that CCR7 is present in different types 
of solid tumours (chapter 1) (Tutunea-Fatan et al., 2015, Zhang et al., 2016, Lu et 
al., 2016, Shuyi et al., 2008, Xia et al., 2014, Oliveira-Neto et al., 2013, Tutunea-
Fatan et al., 2015, Peng et al., 2015) and that its expression contributes to the 
expansion of cancers. However, factors and mechanisms that regulate the 
expression of CCR7 remain largely unknown.  
During the progression and development of cancer, tumour cells encounter cellular 
stress through a multitude of factors such as hypoxia, nutrient deprivation, 
uncontrolled growth in confined space, and unresolved inflammation. Cellular 
stress is known to have a significant impact on cancer progression (see below). In 
view of the significance of CCR7 to the growth, invasion and metastasis of head 
and neck cancers, it would therefore be reasonable to hypothesise that one or 
more these factors can exert that impact through regulation of CCR7 axis. 
However, so far, little is known about how these stress factors can affect the 
expression of CCR7 in the tumour. Therefore, we set out to explore how the 
expression of CCR7 may be regulated in cancer cell lines by some of these factors 
and then extend that investigation to clinical tissue. 
In this chapter, we first provide a brief overview from literature of how stress factors 
can impact on cancer expansion. We will then report on changes in the expression 
of CCR7 and its functional response in cancer cell lines under stress conditions, 
focusing specifically on the role of hypoxic stress.  
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 Chronic Inflammation of cancer 2.1.1
The idea of cancer as an inflamed tissue was postulated many years ago by 
(Dvorak et al., 1984). In his paper, Dvorak et al proposed that stroma cells within 
tumours share many traits with those in wound-healing skin, and suggesting that 
tumour cells enhance the stroma formation by activating wound healing processes, 
resulting in increased cell proliferation, and inadvertently to invasion and 
metastasis. The role of inflammation in promotion of tumours by an experiment in 
which, injecting Rous sarcoma virus into chickens, results in tumour development 
not only directly at the injection site, but also at other sites where injuries were 
sustained by the animals (Schafer and Werner, 2008). This suggests that 
inflammatory response in those sites of injury can promote tumour formation. In 
addition, the injection of pro-inflammatory growth factors is also shown to initiate 
tumour development, which can then be prevented by anti-inflammatory treatment, 
indicating that inflammation was responsible for the development of wound-
triggered tumour (Schafer and Werner, 2008).  
It is noteworthy that chemokine axes, and CCR7 axis in particular, play a critical 
role in the inflammatory response which is associated with tumours. For example, it 
has been demonstrated that chemokines and chemokine receptors are not only 
expressed on stroma cells, where they contribute to wound healing, but also on the 
tumour cells themselves (Coussens and Werb, 2002). This has led to the 
hypothesis that autocrine activation of chemokine receptors may be involved in the 
growth and metastasis of pancreatic, head and neck, and non-small-cell lung 
cancers (Coussens and Werb, 2002, Wang et al., 2008). Furthermore, the 
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presence of inflammatory cells within the tumour and surrounding areas, has been 
shown in different types of cancer and their role in supporting cancer progression is 
well established (Coussens and Werb, 2002). It has been shown that the 
expression of chemokines in tumours help in the recruitment of immune cells to 
support tumour progression and immune escape (Yaguchi et al., 2011, Kitamura et 
al., 2015). For instance, the expression of CCL22 and CCL28 in ovarian cancer 
has shown to attract CCR4 or CCR10 expressing regulatory T cells that can 
suppress the anti-tumour responses caused by other subset of immune cells such 
as leukocytes that are involved in the kill of tumour cells. 
Many studies have shown the involvement of CCL21 during chronic inflammation 
and wound healing process. For instance, it is likely that CCL21 accelerated the 
wound repair when injected into skin wounded mice by recruiting innate lymphoid 
cells and other innate immune cells cell that can differentiate into different types of 
skin cells (Li et al., 2016). Furthermore, the expression of CCL21 in melanoma 
tumors was shown to recruit the regulatory T cells to tumour site which are 
associated with an immunotolerant response (Shields et al., 2010). 
 Hypoxia in cancer 2.1.2
Oxygen is a key energy substrate for ATP generation and any disruption of its level 
risks damage to nucleic acids, lipids, and proteins. Consequently, many 
pathophysiological diseases such as cardiovascular, cerebrovascular, lung and 
cancer can develop as result of this disruption (Brown and Wilson, 2004). In the 
body, oxygen is maintained at a steady level, ranging from 16% in the pulmonary 
alveoli to less than 6% in the other organs (Semenza, 2001, Semenza, 2012). 
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However, the level of oxygen within the tumour can be as low as 0.1% in tumours 
(Evans et al., 2007). See table 6. 
Hypoxia activates a number of signalling pathways that lead eventually to 
migration, proliferation, apoptosis, angiogenesis and metabolic reprogramming 
Figure 13 (Majmundar et al., 2010), through a family of hypoxia inducible factors 
HIF-1, HIF-2 and HIF-3 (Kietzmann et al., 2016). Hypoxia inducible factors are 
composed of a HIF-α and a HIF-β subunit (Semenza, 2001, Majmundar et al., 
2010, Muz et al., 2015). The cellular levels of the alpha subunits are tightly 
regulated through changes in oxygen level, in contrast to the beta unit, which is 
constitutively expressed. The regulation of HIF’s involves continuous production of 
the HIF-α unit which is then degraded under normoxia in oxygenated cells after 
hydroxylation by oxygen sensors, prolyl-4-hydroxylase domain (PHD) and factor 
inhibiting HIF-1(FIH-1). However, the HIF-α is stabilized and activated under 
hypoxia. It should be noted that further regulation of HIF-α level is also achieved 
through other pathways such as Extracellular Receptor Kinase (ERK) and nuclear 
factor κB (NFκB), receptor tyrosine kinases (RTK), GPCR, toll-like receptors (TLR), 
and alarmins receptors activation (Kietzmann et al., 2016). Moreover, nitric oxide 
(NO) and reactive oxygen species (ROS) have been shown to decrease or 
increase HIF-α levels (Panieri and Santoro, 2016, Muz et al., 2015, Kietzmann et 
al., 2016).  
During hypoxia, the stabilized HIF-1α combines with HIF-1β enabling the combined 
complex to translocate to the nucleus and thus, regulate various genes such as 
those involved in angiogenesis or transport of oxygen. The stabilization of HIF1-α 
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is a hallmark of hypoxia, therefore detecting HIF-1α is used to screen for hypoxia. 
However, as the HIF-1α is one of the hardest proteins to detect in cells cultured 
under hypoxia, other downstream proteins that are increased through stabilisation 
of HIF-1α are routinely screened for as indirect evidence of HIF-1α stabilisation. 
For example, as one of the target genes of HIF-1 is enzyme lactate dehydrogenase 
A (LDH-A), its detection can be used as evidence of HIF-1α stabilisation (Elkashef 
et al., 2016, Semenza, 2013). 
The induction of HIF-1α is usually performed by two simple methods:- (Wu and 
Yotnda, 2011) (1) The Incubator Chamber that is attached to hypoxia tank that has 
certain level of O2 and (2) Cobalt Chloride (CoCl2) which is a chemical inducer HIF-
1α. The CoCl2 method has the advantage to be fast, inexpensive and the ability to 
handle flasks freely without affecting the hypoxia level. However, CoCl2 can also 
regulate other genes apart from HIF-1α and therefore checking what other effects 
CoCl2 have on particular cells is highly recommended (Wu and Yotnda, 2011). 
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Figure 13: HIF-α regulation. HIF-α is regulated under hypoxic and normoxic conditions. Under 
normoxia where oxygen is present, HIF-α is degraded after hydroxylation by oxygen sensors 
PHD and FIH-1. In the contrary, under hypoxia the activity of PHD and FIH-1 is dropped and 
HIF is stabilised. In addition, HIFα is regulated through PI3K/AKT/mTOR, MAPK and NFκB 
pathways by cytokines, lipopolysaccharides, and growth factors. From (Muz et al., 2015) 
 
 The role of hypoxia in cancer progression  2.1.2.1
Solid tumours larger than 1 mm3 contain regions of low oxygen levels or “hypoxia” 
Table 6. The diffusion of oxygen through tissue is limited to 200 µm, therefore cells 
that are closer to blood vessels are well oxygenated and cells located further from 
blood vessels are poorly oxygenated. As the tumour grows in size, hypoxic regions 
develop and become larger. Cancer cells respond to the low oxygen level by a 
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number of routes and in particular by generating new blood vessels in a process 
known as angiogenesis.  
Indeed, hypoxia transcription factors, mainly HIF-1 and HIF-2 have been reported 
to be involved in all steps of blood vessel formation (Krock et al., 2011), for 
instance: (1) Endothelial progenitor cells are recruited from bone marrow by 
hypoxia transcription factors and are later differentiated into endothelial cells by 
VEGF that is also regulated by hypoxia, specifically HIF-α; (2) induction of MMPs in 
order to split pre-existing blood vessels; (3) complete maturation of the new blood 
vessels by recruiting smooth muscle cells and pericytes. 
These newly developed blood vessels are profoundly abnormal, dysfunctional and 
provide insufficient supply of nutrients and oxygen. Furthermore, the new 
vasculature do not provide the tumour cells with nutrients and oxygen that meet the 
demand of the growing tumour, leading to even more hypoxia (Dachs and Tozer, 
2000) and eventually to formation of necrotic foci. Thus, larger tumours become 
highly hypoxic with abnormal vasculature which eventually contributes to 
metastasis and evasion of the immune system making them resistant to therapy.  
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Table 6: Oxygenation level in different tissues and corresponding tumours. 
Adapted from (Muz et al., 2015, Evans et al., 2007) 
Tissue % of O2 
 Normal Cancer 
Brain 4.6 1.7 
Breast 8.5 1.5 
Cervix 5.5 1.2 
Head and neck 10 2.5-0.1 
Kidney cortex 9.5 1.3 
Liver 4-7.3 0.8 
Lung 5.6 2.2 
Pancreas 7.5 0.3 
Rectal mucosa 3.9 1.8 
 
The permeable and heterogeneous vasculature of newly developed blood vessels 
facilitates all the pre-metastatic steps; extravasation, circulation, and the 
establishment of tumour cells to new tissues to escape from the hypoxic 
environment in the primary tumour (Tsai and Wu, 2012, Muz et al., 2015). In 
addition, hypoxic cells themselves have a better ability to metastasize. For 
example, multiple myeloma cancer cells cultured in vitro under hypoxia and then 
injected into mice were able to metastasize to the new bone marrow faster than the 
normoxic cells (Azab et al., 2012). It also has been reported that mouse models 
that bear cervical or sarcoma cancer cells, have increased number of lymph node 
and lung metastases respectively after exposing the models to cycles of hypoxia 
(Cairns and Hill, 2004, Muz et al., 2015). It has been shown that hypoxia affects 
the migratory behaviour of cancer cells via an epithelial-mesenchymal transition 
(EMT) (Guo et al., 2013, Azab et al., 2012). EMT is a biological process that allows 
a trans-differentiation of epithelial cells to mesenchymal cell phenotype. This 
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phenotype is responsible for increased migratory capacity, invasiveness, and 
resistance to apoptosis. Hypoxia induces EMT by reducing the expression of 
epithelial-associated genes, such as E-cadherin, β-catenin and increasing the 
expression mesenchymal-like genes, such as N-cadherin, vimentin, smooth 
muscle actin, and CXCR4 (Azab et al., 2012, Hu et al., 2014). Therefore, tumour 
oxygenation is a key driving factor for cancer progression and aggressiveness of 
the majority of human cancers and their metastases that correlates with poor 
prognosis and overall survival.  
 Drugs targeting Hypoxia 2.1.2.2
One of the biggest challenges in cancer therapy is resistance to chemotherapy and 
radiation (Tsai and Wu, 2012). The resistant cells are the major cause of patient 
relapse and metastasis. Cancer cells develop hypoxia (see the previous section), 
and in particular, hypoxic cells are resistant to chemotherapy and radiation (Muz et 
al., 2015). 
The subpopulation of hypoxic cancer cells become resistant to chemotherapy 
treatment by different processes such as:- (1) induced quiescence - a state of cell 
cycle arrest, (2) inhibiting apoptosis and senescence of cells, (3) controlling 
autophagy, p53, and mitochondrial redox, (4) reduced drug delivery and cellular 
uptake of chemotherapeutic agents (Hockel and Vaupel, 2001, Muz et al., 2015). 
In regard to radio-therapy resistance, one of the most important factors for 
successful radiation treatment is the oxygenation level within the tumour (Brown 
and Wilson, 2004). Under normoxia where oxygen is abundant, the radiation 
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induces radical formation which are able to react with DNA leading to irreversible 
DNA damage. Under hypoxic conditions cells are resistant to DNA damage. In 
addition, radio-sensitivity is determined by the cell cycle phase of the tumour cells. 
Irradiated cells are more prone to cell death in the G2/M phase, where the repair 
mechanisms are less effective. Many chemotherapeutics agents and radio-therapy 
target the highly proliferating tumour cells rather than the low proliferating cells 
sparing the dormant cells that can cause tumour regrowth and relapse (Wilson and 
Hay, 2011).  
Currently, the evaluation of tumour oxygenation and HIF expression can be used to 
determine the effectiveness of chemo and radio-therapy. For instance, high 
expression of HIF-1α and HIF-2α in head-and-neck cancer samples is correlated to 
resistance of the chemotherapeutic agent carboplatin, when compared to samples 
expressing low level of HIF-1α or HIF-2α (Koukourakis et al., 2002). In addition, 
oropharyngeal cancer biopsies with high expression of HIF-1α correlated 
negatively with disease free survival after irradiation. In addition, HIF-1α expression 
can serve as a strong predictive and prognostic marker in individuals treated with 
radio-therapy (Muz et al., 2015, Dachs and Tozer, 2000). Moreover, inhibition of 
HIF-1α in an in vivo model of gastric cancer, increased sensitivity to carboplatin, 
when compared to wild type (Rohwer et al., 2010). Likewise, inhibition of HIF-2α 
increased the sensitivity of renal cancer cells to doxorubicin, by restoring the 
expression of the tumour suppressor gene p53 (Roberts et al., 2009). 
One of the earliest approaches to treat cancer was proposed by Folkman by using 
anti-angiogenic agents (Wilson and Hay, 2011). Bevacizumab is a monoclonal 
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antibody against VEGF (vascular endothelial growth factor), it was successfully 
approved for treatment of metastatic colorectal and lung cancers (Wilson and Hay, 
2011, Rohwer et al., 2010, Hockel and Vaupel, 2001). Later, it was also approved 
by the FDA for treating metastatic breast cancer along with paclitaxel as first line 
treatment (Montero et al., 2012). However, the long term use of such agents is 
linked to an increase in the ability of cancer cells to metastasize, while decreasing 
the primary tumour size (Wilson and Hay, 2011).  
HIF-1α is an interesting target for treatment, (Wang et al., 2011, Tsai and Wu, 
2012). It has been reported that 90% of the invading cells of gastric cancer 
biopsies expressed HIF-1α, while normal tissues showed no HIF-1α expression 
(Muz et al., 2015). HIF-1α deficient gastric cells by siRNA grown in vitro showed 
less migratory behaviour (Rohwer et al., 2009). It was also observed that less 
metastases developed after the inhibition of HIF-1α in vivo by using antisense 
oligonucleotide (EZN-2968) to inhibit its activity and no toxicity was observed in a 
Phase I clinical trial in solid tumours (Guise et al., 2014, Lalani et al., 2007, 
Albertella et al., 2008), however the trial was stopped due to suspended 
development of EZN-2968. Currently a new phase I trial has been initiated in 
hepatocellular carcinoma patients to establish a proof of concept (Wigerup et al., 
2016). 
Another way of targeting the metastatic process is to target molecules downstream 
of HIF-α signalling. For example, carbonic anhydrase IX (CAIX) promotes survival 
and invasion of breast tumour in vivo and its inhibition by CAIX inhibitors has 
shown to reduce tumour growth and less lung metastases (Gieling et al., 2012). 
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Another example is lysyl oxidase (LOX) that is secreted by cancer cells under 
hypoxia to recruit cells from the bone marrow that serve as a pre-metastatic niche 
for metastasis and its inhibition by irreversible inhibitor of LOX in a breast tumour 
model in vivo, reduced the metastasis of the cancer cells to lungs (Erler et al., 
2006).  
Chemokines are also upregulated by hypoxia (Wilson et al., 2006, Tsai and Wu, 
2012). For instance, the chemokine receptor CXCR4 has shown to be upregulated 
under hypoxia primarily through HIF-1α in melanoma, breast, gastric, pancreatic, 
lung, ovarian and renal cancers (Sun et al., 2015, Schioppa et al., 2003, Pore and 
Maity, 2006, Oh et al., 2012, Liu et al., 2006). Oh et al, have demonstrated that the 
up-regulation of CXCR4 expression in gastric cell lines was HIF-1α dependent and 
associated with increased invasion and migration (Oh et al., 2012). Of course, 
blocking CXCR4 signalling with antibodies, low molecular weight antagonists and 
synthetic peptide antagonists decreased the formation of metastases in different 
types of cancer and can hence counter this hypoxia driven invasion and migration 
of cancer (Chatterjee et al., 2014). 
 CCR7 and hypoxia in cancer 2.1.2.3
In contrast to CXCR4, CCR7 expression under hypoxia is far less studied. The 
expression of CCR7 under hypoxia was evaluated in lung, ovarian, prostate and 
breast cancers (Li et al., 2009, Li et al., 2008, Wilson et al., 2006, Cheng et al., 
2014, Huang et al., 2013). It was demonstrated that CCR7 expression in breast 
and lung cell lines is induced under hypoxia via HIF-1α. Furthermore, the 
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expression of CCR7 in lung clinical tissues is correlated positively with HIF-1α and 
HIF-2α and clinical stage and lymph node metastasis (Li et al., 2009). Currently, 
there are no studies on the relationship between CCR7 and hypoxia in head and 
neck cancers.  
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 Nutrient deprivation in cancer  2.1.3
The reduction of blood flow does not only result in hypoxia, but also in nutrient 
deprivation (Wek and Staschke, 2010). For instance, the protein kinase GCN2 and 
its downstream target, the transcription activator ATF4 are involved in the stress 
pathway. When cells are glucose deprived, GCN2 phosphorylates the α subunit of 
the translation initiation factor, eIF2, to compensate for nutrient deprivation by 
upregulating ATF4 which in turn increase amino acid synthesis and transport 
pathways by upregulating genes such as asparagine synthetase (ASNS) which is 
involved in alleviation of nutrient deprivation (Wek and Staschke, 2010). 
Tumour cells which are nutrient starved in vitro, upregulate the expression of 
different chemokine receptors. The expression of CXCR3 in colon cancer cells was 
upregulated in serum starved cells at the membrane bound level, but not in terms 
of total cellular level (Kawada et al., 2007). The expression of CCR7 was 
upregulated in thyroid carcinoma after serum starvation (Sancho et al., 2006). 
Furthermore, CCR7 activation was reported to protect from cell death in serum 
starved cell in pancreatic cancer (Zhang et al., 2016). Currently, there are no 
studies on the relationship between CCR7 and nutrient deprivation in head and 
neck cancers. 
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 Aims and objectives 2.1.4
Studies on the regulatory factors that control the expression of CCR7 receptor are 
scarce particularly in head and neck cancer. Therefore, we set out to determine 
how stress factors such as hypoxia and serum deprivation affect receptor 
expression and its functional response to CCL21 or CCL19.  
 The main aims and objectives of this Chapter are:- 
 
- To study the expression of CCR7 in different cell lines evaluate the 
usefulness of these cells as in vitro models.  
- To evaluate the functional role of CCR7 i.e responses to CCL21 and CCL19 
in different pharmacological assays under normoxic and hypoxic conditions. 
- To study the impact of stress factors by mimicking in vivo stress related 
conditions in 2D and 3D in vitro models on the protein expression of CCR7 
in different head and neck cell lines and study the underlying mechanisms 
that regulate its expression. 
- To study the correlation between the expression of CCR7 and hypoxia in in 
vivo system of head and neck xenografts as well as clinical tissues  
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2.2 Materials and methods 
 Materials 2.2.1
Tissue culture materials and reagents were all obtained from (Sigma-Aldrich) 
unless otherwise specified. 
 Cell lines 2.2.2
All cell lines (PANC-1, U-87 MG, DU-145, PC-3, MDA-MB-231, MCF-7, DLD-1, 
HT-29, SW-480, COLO-205, FaDu, SCC-4, A-253, Detroit 562) were obtained from 
European Collection of Cell Cultures (ECACC) UK, American Type Culture 
Collection (ATCC) USA or NCI Developmental Therapeutics Programme. OSC-19 
was a generous gift from Prof Faye M. Johnson (M.D., Anderson Cancer Center, 
Houston, Texas, USA). See table 7 for more background information about the 
used cell lines. These cell lines were chosen to understand how spread is the 
CCR7 expression among different types of cancer. OSC-19 cell line was chosen 
later after confirmed expression of CCR7 as a model to investigate the role of 
CCR7 in cancer and the potentiality to inhibit its effects by small molecule 
antagonists because it was shown by Kawashiri et al that OSC-19 cell line is a 
representative model of lymph node metastasis when implanted into the tongue of 
nude mice (Kawashiri et al., 1995). 
Cells were grown in complete appropriate media at 37°C, 5% CO2 atmosphere and 
100% humidity (see appendix I for medium used for each cell line). All cells were 
passaged when the cells were ~70% confluent, according to the standard 
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operating procedure for cell culture in the Institute of Cancer Therapeutics (ICT; 
see section  2.2.5). 
Table 7: Cell lines information. (ATCC, 2017 and Cellosaurus, 2017) 
 (1)
nt = not tested 
(2)
+ = authenticated 
Cell line Tissue of 
origin 
Drived from Disease DNA finger 
print 
PANC-1 
 
pancreas pancreas/duct adenocarcinoma    nt
(1)
 
U-87 MG  
 
brain brain glioblastoma nt 
DU-145 
 
prostate metastatic site brain carcinoma nt 
PC-3 
 
prostate metastatic site bone carcinoma nt 
MDA-MB-231 
 
breast metastatic site pleural 
effusion 
adenocarcinoma  +
(2)
 
MCF-7 breast metastatic site invasive ductal 
carcinoma 
 
adenocarcinoma + 
DLD-1 
 
colon colorectal adenocarcinoma + 
HT-29 
 
colon colorectal adenocarcinoma nt 
SW-480 
 
colon colorectal adenocarcinoma nt 
COLO-205 
 
colon metastatic site ascites adenocarcinoma nt 
OSC-19 tongue metastatic cervical lymph 
node 
squamous cell 
carcinoma 
 
nt 
SCC-4 tongue tongue squamous cell 
carcinoma 
 
+ 
FaDu pharynx pharynx pharyngeal 
squamous cell 
carcinoma 
 
+ 
Detroit 562 pharynx metastatic site pleural 
effusion 
pharyngeal 
squamous cell 
carcinoma 
 
+ 
A-253 submaxillary 
salivary gland 
submaxillary salivary gland epidermoid 
carcinoma 
+ 
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 Xenografts  2.2.3
Paraffin embedded xenografts were prepared by the staff at ICT. Briefly, cell lines 
were injected subcutaneously into Balb-c nude mice aged 6 to 12 weeks (Harlan, 
UK). Mice were sacrificed when the tumour size reached 150 mm3, afterwards, 
tumours were excised and immersed in 10% formalin for 24 h and processed for 
paraffin embedding. 
 Patients samples 2.2.4
 Head and neck tissue microarrays 2.2.4.1
Head and neck tissue microarrays slides (consecutive slides from block HN803c) 
were purchased from Insight Biotechnology Limited (P O Box 520, HA9 7YN, UK). 
The microarrays were prepared by the Biomax Company (https://www.biomax.us/). 
For patients clinical characteristics see appendix VII. 
 TNM classification 2.2.4.2
The samples were classified according to TNM system of head and neck cancer 
(Medscape, 2016). The extent of the primary tumor (T) Table 8, presence and 
extent of regional lymph node metastasis (N) Table 9, and presence or absence of 
distant metastasis (M) Table 10. The clinical characteristics of the patients are 
listed in appendix VII.   
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Table 8: Primary tumour extent (T) 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension 
T2 Tumour > 2 cm but not more than 4 cm in greatest dimension 
T3 Tumour > 4 cm in greatest dimension 
 
Table 9: Regional lymph nodes (N) 
Nx Regional nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node 3 cm or less in greatest 
dimension 
N2 Metastasis in a single ipsilateral lymph node > 3 cm but not more than 6 cm 
in greatest dimension; or in multiple ipsilateral lymph nodes, none > 6 cm in 
greatest dimension; or in bilateral or contralateral lymph nodes, none > 6 cm 
in greatest dimension 
N2a Metastasis in a single ipsilateral lymph node > 3 cm but not more than 6 cm 
in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest 
dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest 
dimension 
N3 Metastasis in a lymph node > 6 cm in greatest dimension 
 
Table 10: Distant metastasis 
Mx  Distant metastasis can’t be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 Passaging of cells  2.2.5
All cell lines were cultured and maintained at 5% CO2 and 100% humidity at 37°C. 
Cells were cultured in appropriate medium recommended by supplier and prepared 
according to the manufacturer instruction (for media composition for each cell line, 
refer to appendix I. For instance, to prepare Complete RPMI1640, 500 ml 
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incomplete RPMI was mixed with 50 ml of FBS, 5 ml sodium pyruvate solution (100 
mM), 5 ml L-glutamine solution (200 mM) and stored at 4°C. Thus, complete RPMI 
solution contains 1mM pyruvate, 2mM glutamine and 10% FBS. When cells 
reached ~70% confluency, they were washed twice using 10 ml of phosphate 
buffer saline (Severn Biotech ltd.) before adding 2 ml of 0.25% trypsin/EDTA for 5 
min in 37°C incubator to detach the cells from the flask. Trypsin was inactivated by 
addition of 10 ml of complete medium. The cell suspension was transferred to a 20 
ml universal tube and centrifuged for 5 min at 1000 rpm. Afterwards, media was 
carefully discarded and the retained cell pellet was then resuspended in 10 ml of 
fresh medium. Finally, cells were counted and the appropriate amount of the cell 
suspension was added to another 10 ml of complete medium in a new 75 cm2 cell 
culture flask and kept in the incubator. 
 Counting cells using hemocytometer and growth curve of OSC-19 2.2.6
The cell density was determined using a haemocytometer. 10 μl of cell suspension 
was added to each chamber of the haemocytometer. Cells were counted manually 
under the light microscope at 100x magnification power. In each chamber, cells in 
1 central and 4 corner squares were counted as shown in Figure 14. The cell 
density was then calculated according to the following equation: 
 
𝐶𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦  
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ∗ 104 
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Figure 14 : Haemocytometer chamber. Cells were counted in each square labelled (X). 
 Immunofluorescence detection for CCR7 staining  2.2.7
Immunofluorescence (IF) technique uses fluorescent antibodies to detect the 
protein of interest. It is useful and easy method for detection of proteins and their 
localization in cells. Here, IF was used to qualitatively detect the expression of 
CCR7 in a panel of cell lines. Cells at a density of 3 x 105 cells/ml (PANC-1, U-87 
MG, DU-145, PC-3 MDA-MB-231, MCF-7, DLD-1, HT-29, SW-480, COLO-205, 
OSC-19, FaDu, SCC-4, A-253, Detroit 562) were seeded on coverslips placed 
inside wells of a 6 well plate. The following day, cells were washed with PBS twice 
and fixed with 4% paraformaldehyde (PFA) for 15 minutes (min) at room 
temperature (R.T.) and left to air dry. These coverslips were used immediately or 
kept at -20°C in the dark until ready for analysis. On the day of the experiment, 
coverslips were taken out from the -20°C freezer and allowed to warm up to R.T 
and rehydrated by immersion in PBS for 5 min. Afterwards, cells were 
permeabilised using 0.1% Triton X-100 for 15 min at R.T. Subsequently, cells were 
blocked for non-specific binding for 1 h with 5% Bovine serum Albumin (BSA). After 
blocking, cells were either stained for CCR7 (Anti-CCR7 antibody, Abcam; 1:100 
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dilution with PBS) or Ki-67 (Anti-Ki-67 antibody, Abcam) (2:100 dilution with PBS) 
overnight at 4°C. The following day, cells were washed with PBS 3 times for 2 min 
each before adding the secondary antibody (Alexa Fluor® 546 Donkey Anti-Rabbit 
IgG, life technologies) for 1 h in the dark. After washing for 3 times/2 min each, one 
drop of mounting media containing DAPI (Vectashield, Vector laboratories) was 
added to microscope slides for nucleus staining, the coverslips were added on top 
of the DAPI-mounting medium and left to dry for 1 h at 4°C. Images were taken 
using a Leica DM 2000 fluorescence microscope using Tritc (red) channel. 
 Flow cytometry for quantification of CCR7 and CXCR4 expression 2.2.8
We used the direct staining procedure to investigate the expression of cell surface 
proteins (CCR7 and CXCR4). In the direct staining method the primary antibody is 
conjugated to a fluorochrome. For this method, cells (OSC-19, FaDu, PANC-1, 
MDA-MB-231, MCF-7, PC-3, DU-145, U-87MG, HT-29, DLD-1) were used at 60-70 
% confluency, washed twice with PBS, trypsinised and centrifuged. Afterwards, 
half million cells were transferred to an eppendorf tube, re-suspended in 100 μl of 
4% PFA for 10 min at R.T, and centrifuged. Supernatant was removed and cells 
were washed twice with 1% BSA. Cells were incubated either with anti-CCR7 
(2:100 dilution with PBS), (Alexa Fluor® 488 anti-human CCR7 antibody, 
BioLegend), anti-CXCR4 (5: 100) (Human CXCR4 Alexa Fluor® 488-conjugated 
Antibody, R&D systems), the isotype matched control for CCR7 (2:100) (Alexa 
Fluor® 488 Mouse IgG2a, κ Isotype Control Antibody, BioLegend) or the isotype 
matched control for CXCR4 (5:100) for 30 min at R.T in the dark. Finally, cells were 
harvested, washed three times for 2 min with 1% BSA solution and resuspended in 
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500 μl of 1%BSA solution, ready to be analysed on FACS Calibur Cytometer at 
Ex/Em: ~492–495/517–527 nm using the FL1H (green) channel. The fold change 
in fluorescence intensity mean was calculated by normalizing the mean 
fluorescence intensity of CCR7 or CXCR4 stained cells relative to the isotype 
control in each cell line. All reported results are averages from 3 independent 
experiments. 
 Western blot for CCR7 detection 2.2.9
 Protein extraction 2.2.9.1
To compare cell surface expression of CCR7 with whole cell lysate expression, the 
western blot technique was used. All cell lines were cultured as previously 
described in section  2.2.2. Pellets were washed twice with PBS and any remaining 
supernatant was removed after centrifugation and stored at -80ºC. On the 
extraction day, any remaining supernatant was removed and cells were 
resuspended in 300 μl complete RIPA lysis buffer (see appendix VIII for western 
blot preparation of buffers and solutions), mixed well by pipetting up and down and 
kept on ice for 20 min with mixing from time to time to ensure complete 
resuspension in lysis buffer. Subsequently, while kept on ice, cells were sonicated 
for 10 seconds (s) each time for 3 cycles. In between each sonication cycle cells 
were kept on ice for 30 s. Next, samples were centrifuged at 13,200 rcf for 15 min 
at 4ºC. Supernatants were taken to new microcentrifuge tubes to get rid of any un-
lysed cell pellet or any residual debris. Samples were stored at -80ºC until used. 
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 Determination of total protein concertation 2.2.9.2
The protein concentration was determined using the Bradford assay. BSA was 
used as a protein standard ranging from 0 mg/ml to 2 mg/ml. BSA was dissolved in 
distilled water (2 mg/ml), followed by serial dilution and 950 μl of Braford reagent 
was added to the standard samples and mixed well. Unknown samples were 
diluted 20x with distilled water and 800 μl of Bradford reagent was added to the 
unknown samples and mixed well. Finally 200 μl of standards and unknown 
samples were added to flat 96 well plate (Corning) in triplicates and the 
absorbance was measured using a Multiskan Spectrum spectrophotometer 
(thermoscientific) at 595 nm using SkanIt Software 2.4.4 RE. The standard 
calibration graph was generated by plotting the average absorbance 595 nm for 
each standard concentration on the y-axis and the corresponding BSA 
concentration on the x-axis on excel as shown below and the protein concentration 
of the unknown samples was calculated using the equation shown below in Figure 
15. 
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Figure 15: BSA standard curve. 
  Polyacrylamide gel preparation 2.2.9.3
The space integrated glass plates (Bio-Rad) were cleaned with water and 70% 
ethanol and then assembled according the manufacturer’s instructions. Resolving 
gel 12% or 10 % (see appendix VIII for components of resolving gel) was prepared 
and pipetted between the connected plates in the casting stand. Next, 1 ml 
isopropanol was added above the resolving gel which was left to set at room 
temperature for 30 min. Isopropanol was removed and the gel was washed several 
times with distilled water. The excess water was removed and the stacking gel was 
prepared and added on top of the resolving gel (see appendix VIII for components 
of stacking gel). The gel comb was inserted quickly but carefully and the gel was 
left to set at R.T for at least 30 min. Next, the comb was removed and the glass 
plate apparatus which contain the gel was then kept in a humid environment at 4°C 
until used. 
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 Gel electrophoresis 2.2.9.4
Samples 25 μg (CCR7 expression), 30 μg (LDH-A) or 50 μg for (HIF-1α) were 
taken out from -80°C and kept on ice to thaw and mixed with loading buffer (see 
appendix VIII for component of loading buffer), vortex and incubated at 95°C for 5 
min. Membranes were probed with LDH-A, it’s a well known HIF-1α target gene 
that is upregulated under hypoxia to increase lactate generation, as an indirect 
indicator of HIF-1α induction that has been used by many including ourselves 
(Elkashef et al., 2016). Next, the comb was removed from the glass plates 
apparatus was fitted in the clamping frame and electrode assembly and transferred 
to an electrophoresis buffer tank (Bio-Rad) filled with 1x running buffer (see 
appendix VIII for components of running buffer). The denatured samples 20 μl 
each were loaded to the wells of the gel as well as 5 μl of pre-stained protein 
ladder (Fermentas PageRuler™ Plus, Thermo Scientific). The gel was run at 70 
volts for 10 min, followed by 120 volts until the dye front reached the bottom of the 
plate, approximately for 90 min.  
 Protein transfer to nitrocellulose membrane  2.2.9.5
After gel electrophoresis, nitrocellulose membrane (Amersham Hybond ECL, GE 
health care Life Sciences) was soaked in distilled water for 1 min, followed by 
soaking the membrane, blotting paper and sponges in 1x transfer buffer for 15 min 
(see appendix VIII for components of transfer buffer). The transfer sandwich 
(membrane, blotting paper and sponges) was assembled and transferred to the 
transfer buffer tank (surrounded with ice) which contains 1x transfer buffer and run 
at 100 volts for 1 h. 
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 Post transfer and immunodetection of proteins  2.2.9.6
Nitrocellulose membrane was placed in an incubation box containing 5% w/v 
skimmed milk for blocking (appendix VIII) and shaked for 1 h. The blocking solution 
was removed and replaced with 10 ml of 5% milk solution containing the 
unconjugated primary antibody CCR7 (Abcam; 1:5000 in blocking solution). The 
membrane was incubated with the primary antibody overnight at 4ºC on a shaker. 
Then the membrane was washed with PBS TWEEN 20 (PBST) 3 times; 5 min 
each. Subsequently the membrane was incubated with 10 ml of 5% blocking 
solution containing (1:3500 in blocking solution) horseradish peroxidase (HRP) 
based secondary antibody or (1:500 in blocking solution) western dot 625 
fluorescence based secondary antibody (Life technologies) for 1 h on a shaker. 
Finally, the membrane was washed with PBST 3 times; 5 min each for detection 
method. 
 Detection method 2.2.9.7
The membrane was developed using the enhanced chemiluminescent system 
(Roche) or the transiluminator system depending on the secondary antibody type. 
For the chemiluminescent system, the solution was prepared according to the 
manufacturer’s instructions by mixing 10 μl of component B (NaBO3 solution) with 
990 μl of component A (Luminol substrate solution). Initially, the excess PBST was 
removed and the detection solution was pipetted on the protein side surface of the 
membrane. After incubation at R.T. for 1 min, the detection reagent was discarded 
and the membrane was placed on X-ray film Amersham hyperfilmTM ECL (GE 
Healthcare) in a X-ray cassette before being developed in Ilford developer for 2 
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min and Ilford fixer solution for another 2 min in the dark (for developer and fixer 
preparation see appendix VIII). The same membrane was washed with PBST (3 × 
5 min) and re-probed with primary and secondary antibodies to detect actin protein. 
For transiluminator system, the membrane was placed in the transiluminator in 
which the proteins side of the membrane faces the UV light for image uptake. The 
same membrane was washed with PBST (3 × 5 min) and re-probed with primary 
and secondary antibodies to detect actin protein. 
  Immunohistochemistry detection of CCR7 in xenografts and OSC-19 2.2.10
spheroids  
 Coating slides 2.2.10.1
Slides were immersed in acetone for 2 minutes, drained and incubated in 2% 3-
aminopropyltriethoxysilane (APES) solution for 2 min. APES solution was prepared 
by dissolving APES in acetone. Slides were left to dry and were washed twice in 
running water for several mins. The slides were then left to dry at R.T. overnight. 
 Immunohistochemistry and staining evaluation of CCR7 in 2.2.10.2
xenografts: 
Immunohistochemical studies were performed for comparison with the results from 
the protein expression analysis obtained by flow cytometry and western blot and to 
identify a good xenograft model. The paraffin-embedded tissues were sectioned 
using a Leica RM 2135 microtome (5 μm thick) and allowed to dry on hot plate at 
37°C for at least 2 h. Then, sections were subjected to immunostaining for CCR7. 
The mounted sections on positively charged coated slides were deparaffinised and 
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dehydrated by immersing them in the following mixtures: xylene (10 min x 2), 50% 
xylene/ethanol (5 min), 100% ethanol (10 min x 2), 90% ethanol (2 min), 70% 
ethanol (2 min), and distilled water (5 min). Endogenous peroxidase was blocked 
with 3% aqueous H2O2 for 30 min. Antigen retrieval was completed in the 
microwave to boil the sections in 10 mM citrate buffer (pH 6.0) for 20 min at 
intermediate power, allowed to cool down for 30 min and washed in PBS for 10 
min. Subsequent to the nonspecific binding being blocked with goat normal serum 
(15:1000 dilution with PBS; vectastain® ABC kit) for 20 min. Next, excess goat 
serum was removed and the sections were covered with CCR7 primary antibody 
(rabbit monoclonal IgG; Abcam,) and incubated at R.T for 1 h at (1:1000 dilution 
with PBS).  
The primary antibody was washed off with distilled water and the slides were left in 
PBS for 10 min. The slides were then dried around sections and covered with 
biotinylated secondary antibody (50:10000 dilution with PBS; IgG anti rabbit, 
vectastain® ABC kit). Meanwhile ABC reagent ( vectastain® ABC kit) was prepared 
by mixing one drop of A (Avidin) in 5 ml of PBS, adding 1 drop of B (biotinylated 
peroxidase) and mixing to give a mixture called (C). Secondary antibody was 
washed off by distilled water and slides were washed again in PBS for 10 min. 
Afterwards, sections were dried and incubated with ABC reagent for 30 min. The 
slides were rinsed with PBS for 10 min and colour was developed using DAB 
detection kit (Vector laboratories). The DAB solution was prepared by mixing 2.5 
ml of distilled water, 1 drop of buffer stock solution 2 drops of 3,3'-
diaminobenzidine (DAB ) and 1 drop of H2O2. DAB was disposed of into bleach; 
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following its incubation with the sections for 2 min. Sections were counterstained in 
Harris’ haematoxylin for 20 s, washed well in tap water and blued in Scott’s tap 
water for 2 min. Finally, sections were dehydrated and cleaned in 70% ethanol, 
followed by 90% ethanol, absolute ethanol 2 times, 50% xylene/ ethanol and 
xylene II, each for 2 min. Finally, slides were immersed in clean xylene for 5 min 
and mounted using DPX (a mixture of distyrene, tricresyl phosphate and xylene) to 
preserve stains. For Harris’ haematoxylin and Eosin staining of xenografts see 
appendix V. 
 Detection of CCL21 in head and neck mouse xenografts of head and 2.2.11
neck cancers 
We have discussed in chapter 1 and the current chapter, the significance of CCL21 
expression on tumours cells in modulating the immune response and enhancing 
tumour growth by autocrine activation (Shields et al., 2010, Wang et al., 2008). 
Therefore we sought to look for CCL21 expression in head and neck tissues 
because they have shown as described later in the result section to express high 
level of CCR7 compared to other cancer cell lines. Xenografts sections of (OSC-
19, FaDu, Detroit 235 and A-253) were stained following the staining described in 
section 2.2.10. The CCL21 antibody was diluted with PBS (1:40) before applied to 
sections, incubated overnight at 4°C and followed the rest of IHC staining that is 
described earlier. 
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 Effect of CCL21 or CCL19 on proliferation  2.2.12
 Growth curves of OSC-19 and FaDu  2.2.12.1
Performing a growth curve for OSC-19 and FaDu cells is important; in order to 
define their growth characteristics and to determine the best time for evaluation of 
the effect of CCL21 on cell proliferation and the effects of CCR7 antagonists. 
Growth curves of OSC-19 and FaDu cells were obtained using manual counting 
and MTT proliferation assay, for the preparation of MTT solution (see appendix II). 
For manual counting, 100 μl of cell suspension was mixed with another 100 μl of 
trypan blue solution; trypan blue has the ability to penetrate only the dead cells’ 
membrane, therefore highlighting the viable/dead cells. Next, 10 μl of the cell 
suspension/ trypan blue mix was loaded to each channel in the haemocytometer 
and viable cells (white) were counted. Note that dead cells appear blue. The cell 
density was calculated according to the following equation:- 
 
*The dilution factor = 2 (100 μl of cell suspension: 100 μl of trypan blue solution).  
The MTT assay was performed to create growth curves with different starting cell 
concentrations. 3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) 
is used to determine the number of viable cells. In viable cells, the yellow MTT 
enters the cells and passes to the mitochondria where it is reduced to insoluble 
dark purple formazan Figure 16. Then, the formazan is solubilised with an organic 
𝐶𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦  
𝑐𝑒𝑙𝑙𝑠
𝑚𝑙
 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗  104 
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solvent, e.g., Dimethyl Sulfoxide (DMSO). The purple colour of the solubilised 
formazan is then measured using colorimetric plate reader at 540 nm (Thermo 
Scientific multiskan). Reduction of MTT can only take place in metabolically viable 
cells; therefore the intensity of the colour indicates the population of viable cells. 
We first determined the appropriate condition where cells would be in log growth 
phase. Cells were passaged and counted as previously described and the desired 
cell concentrations were prepared: 5x102, 1x103, 5 x103, 1 x104, 5 x104, 1 x105 
cells/ml. Cells were seeded in 96 well plates by loading 200 μl of each cell 
concertation to the specified wells. On day 0 (seeding day) and day 2, 3, 4, 5, 7 
(after seeding), on the specified day one plate was taken out from the incubator 
and 20 μl of 5 mg/ ml MTT stock solution was added and the plate was incubated 
for 4 h, the medium was removed and 150 μl of DMSO was added to each well to 
dissolve the puple-blue formazan crystals. Absorbance was then recorded at 540 
nm using the colorimetric plate reader. The mean absorbance was calculated from 
three independent experiments. The blank mean value (media with no cells) was 
subtracted from the absorbance mean values. Results were plotted as absorbance 
on y-axis against time on x-axis. 
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Figure 16: MTT metabolism in viable cells.  
MTT (yellow) is converted by mitochondrial reductase to formazan crystals (purple). 
 
 Proliferation rate after CCL21 or CCL19 addition using MTT  2.2.12.2
The effect of CCL21 or CCL19 on the proliferation rate of OSC-19 and FaDu cells 
was determined using MTT assay. OSC-19 or FaDu cells were seeded in a 96-well 
plate at a density of 1 x 104 cells/ ml and incubated for 24 h. Then, 20 μl of CCL21 
or CCL19 was added to each well containing 180 μl of media to achieve a final 
concentration of 1, 10 or 100 nM. After 72 h, the MTT assay was performed as 
described in section 2.2.12.1. Proliferation was calculated using this equation:- 
 
Where A is the absorbance of treated cells with CCL21 or CCL19, B is the 
absorbance of blank and C is the absorbance of untreated cells. 
𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 % =
𝐴 −  𝐵
𝐶 − 𝐵
∗ 100 
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 Effect of CCL21 or CCL19 on cell migration 2.2.13
 Wound healing assay: 2.2.13.1
OSC-19, FaDu, SCC-4, PC-3, DU-145, DLD-1 and SW-480 cells were seeded at a 
density of (8.5 x 105 cells/ml) in 24 well plates (350 µl/ well) and left overnight to 
reach confluency. On the following day, the supernatant was removed and the 
wells washed with PBS. A wound was scratched using a p200 pipette tip. The cells 
were then washed twice with PBS and treated with 2% FBS media containing 
CCL21 at (10 and 100 nM), CCL19 at (10 and 100 nM) or 2% FBS media alone as 
control. We used 2% FBS rather than 10% FBS to exclude the role of proliferation 
in our analysis. Images were taken using a lumascope 488 microscope at 0 h (after 
making scratch) and at 18, 24, 18, 14, 14, 42 and 21 h (after cell migration) for 
OSC-19, FaDu, SCC-4, PC-3, DU-145, DLD-1 and SW-480, respectively. Image J 
software was used to measure the free surface area of the wound at 0 h (Figure 
17-a) and at specific time points after migration (for example 18 h for OSC-19) 
Figure 17-b (Schneider et al., 2012). The % of the free surface area was calculated 
according to the following equation: 
% 𝑜𝑓 𝑓𝑟𝑒𝑒 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑎𝑓𝑡𝑒𝑟 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 = 100 −  
𝐴 − 𝐵
𝐴
 ∗ 100 
Where A= Free surface area at 0 h and B = free surface area after migration at 
specific time point for each cell line. 
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Figure 17: Wound healing assay.  
Photos were captured at 0 h (A) and 18 h (B). 
 
 IF staining for Ki-67 in wound healing assay 2.2.13.2
Our results from the wound healing assay showed positive results, with CCL21 
enhancing the migration of OSC-19, SCC-4, PC-3 and DU-145. Accordingly, we 
choose one of these cell lines as a model for our investigation on the role of CCR7 
in cancer progression and to test and evaluate CCR7 antagonists in preventing cell 
migration. OSC-19 was chosen and to confirm that the results seen in the 
migration assay relate to migration, rather than proliferation, we stained with Ki-67, 
a marker for proliferation. OSC-19 cells were seeded at 8.5 x 105 cells/ml on 
coverslips in 6 well plates were seeded on coverslips in 6 well plates. The following 
day, cells were washed with PBS twice and the wound healing assay was 
performed as described in section 2.2.13.1. Immediately after scratch half of the 
coverslips were fixed with PFA for 15 min at room R.T. and left to air dry and kept 
at -20°C until ready to use. The other half of cells on the coverslips were left to 
migrate for 18 h with or without CCL21 and fixed in the same way as previously 
described. On the day of the experiment, immunofluorescence staining (IF) was 
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performed as described in  2.2.7. The cells were incubated with Ki-67 antibody 
(2:100 dilution with PBS) (Abcam) for 0 h and 18 h or with CCR7 (1:100 dilution 
with PBS) overnight at 4°C. On the following day, cells were washed with PBS 3 
times for 2 min each before adding the secondary antibody (Alexa Fluor® 546 
Donkey Anti-Rabbit IgG, life technologies) for 1 h. After washing with PBS (2 min, x 
3), one drop of mounting media containing DAPI was added to microscope slides 
for nucleus staining. The coverslips were added on top of the DAPI-mounting 
medium and left to dry for 1 h at 4°C. Images were taken using a Leica DM 2000 
fluorescence microscope using Tritc (red) channel for CCR7 and Ki-67 and blue for 
DAPI.  
 Expression of CCR7 using flow cytometry after serum deprivation 2.2.14
Cells were cultured at 37oC, 5% CO2 and 100% humidity, when reached 60-70% 
confluency, the media was removed and cells were washed twice with PBS. Next, 
0% FBS or 10% FBS media was added to the cells for 24 h before analysing them 
for CCR7 expression using flow cytometry as described earlier in section  2.2.8. 
 Effect of CCL21 or CCL19 on CCR7 receptor activation using (Ca2+) 2.2.15
flux assay 
Binding of ligands to GPCRs can induce an intracellular increase in calcium 
concentration that can be measured using a Ca2+ sensitive fluorescence dye; this 
method can be used for high throughput screening as an indication of receptor 
activation. We used this assay to look for CCR7 functionality through binding to its 
ligands. Cells cultured in 10% FBS were seeded in 96-well black plate at 1x105 
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cells/well cell density and left to attach overnight in the incubator. The following 
day, media was removed and cells were washed with 100 μl of the assay buffer 
twice. Quickly but carefully 100 μl of the loading dye (Molecular ProbesTM Fluo-4 
NW, Invitrogen) was added to each well and incubated for 1 h at 37°C. 
Fluorescence intensity was measured in response to 20 μl addition of CCL21 or 
CCL19 (100 nM in well concentration), added using Thermo Scientific Flouroskan 
Ascent FL at excitation wavelength 485 nm and emission wavelength 538 nm at 
37°C.  
 CCL21 detection using enzyme-linked immunosorbent assay  2.2.16
Enzyme-linked immunosorbent assay (ELISA) is a technique used for detecting 
and quantifying substances based on antigen-antibody interaction. Antigen binds to 
the bottom of the pre-prepared plates that allow protein binding, later antibodies 
are added to bind to the attached antigen. The binding can be detected by directly 
labelled primary antibodies, labelled secondary antibodies that bind to the primary 
antibody or by the sandwich method, where the antigen is bound between two 
antibodies. Here, human CCL21 ELISA kit was purchased from (Thermo-scientific) 
for detecting CCL21 produced from OSC-19 cultured cells. In, 1 ml of 8.5 x105 
cells/ml OSC-19 cells was added to each well of a 6 well plate and left to form 
confluent monolayer. After 24 h, cells were washed twice with PBS and multiple 
scratches of total 8 were made using 200 pipette tips. Next, 2% FBS media was 
added to all wells and the supernatant was collected after 18 and 24 h and stored 
at -80ºC until ready to analyse. On the day of the experiment, lyophilized 
recombinant human CCL21 standard was centrifuged and 400 μl of 1X assay 
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diluent B was added. After mixing, 50 ng/ml of CCL21 standard was used to 
prepare serial dilutions (8,000, 3200, 1280, 204.8, 81.92, 32.76 pg/ml). 
Supernatant and/or standard (100 μl) was added to pre-coated 96 wells strip plate 
in Triplicate, covered and incubated overnight at 4ºC with gentle shaking. The 
solution was discarded and washed 4 times with 300µL of 1X wash buffer. At each 
washing step complete removal of liquid was assured for good performance. After 
the last wash, the plate was inverted and blotted against clean paper towels to 
remove any remaining wash buffer. Next, 100 μl of 1X biotinylated antibody was 
added to each well and incubated for 1 h at R.T. with gentle shaking. The solution 
was discarded and the washing step was repeated as described earlier. Next, 100 
μl of streptavidin-HRP solution was added to each well and incubated for 45 
minutes at R.T. with gentle shaking. The solution was discarded and the washing 
step was repeated as described earlier and 100 μl of 3,3′,5,5′-
Tetramethylbenzidine (TMB) substrate to each well. After, 30 min of incubation at 
R.T. in the dark with gentle shaking, 50 μl of stop solution was added to each well. 
The plate was evaluated within 30 min of stopping the reaction by measuring the 
absorbance on a colorimetric plate reader (Thermo-electron Corporation, Multiskan 
Ex) at 450 nm. The standard curve was generated by plotting the average 
absorbance (450 nm) for each standard concentration on the y-axis and the 
corresponding CCL21 concentration on x-axis as below using excel Figure 18. The 
equation generated from the standard curve was then used to calculate the amount 
of CCL21 present at each time.  
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Figure 18: CCL21 standard calibration curve.  
 Role of Hypoxia in CCR7 expression 2.2.17
 Incubation of cells under hypoxia 2.2.17.1
The head and neck cell lines were seeded in 75 cm2 flasks and incubated under 
normoxic conditions (37ºC, 5% CO2 and 100% humidity). Later, when cells 
reached 60%-70%, cells were either kept at normoxic conditions (control) or 
transferred to a hypoxia chamber (Whitley H35 hypoxystation) (0.1% O2, 95% N2, 
5% CO2 and 100% humidity) for 24 h prior to cell harvesting for flow cytometry and 
western blot analysis. The cells inside the hypoxia chamber were washed once 
with PBS that was placed in the hypoxia chamber 24 h earlier. Then, pre-hypoxic 
media was added to cells and left for the appropriate incubation period.  
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 CCR7 protein expression in head and neck cell line after hypoxia  2.2.17.2
After 24 h of culturing cells under hypoxia, cells were washed twice with PBS, 
trypsinised and spinned down. For CCR7 expression, half million cells were 
transferred to an eppendorf tube, re-suspended in 100 μl of 4% PFA for 10 min at 
R.T. and centrifuged. All these operations take place in the hypoxic chamber. After 
fixation, cells were moved out of the hypoxic chamber and the CCR7 staining was 
performed as described earlier in section  2.2.8. Cells cultured under normoxia 
were also examined for CCR7 expression for comparison. All hypoxic and 
normoxic samples were analysed using flow cytometry as before in section  2.2.8. 
 Detection HIF-1α or LDH-A 2.2.17.3
To confirm the existence of a hypoxic environment in the hypoxia chamber, cells 
were washed twice with PBS and trypsinised in the hypoxia chamber. After 
centrifugation, the supernatant was removed in the chamber and cell pellets were 
moved to the -80ºC until used. Normoxic cells were also included for comparison 
and cultured in parallel to the hypoxic cells. Subsequently, hypoxic and normoxic 
cells were taken out from -80ºC storage and kept on ice for protein extraction using 
RIPA buffer see section  2.2.9.1, followed by the western blot steps described in 
section  2.2.9. After sample loading into the gel, membranes were incubated for 
(1:1000 dilution with PBS) HIF-1α (BD transduction laboratories) or (1:500 dilution 
with PBS) LDH-A (Abcam). The membrane was incubated with the primary 
antibody overnight at 4ºC on a shaker, followed by secondary antibody incubation 
and developing for HIF-1α or LDH-A as described in  2.2.9. 
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 Induction of HIF-1α using cobalt chloride (CoCl2)  2.2.17.4
In addition to the hypoxia chamber, the chemical Cobalt chloride (CoCl2) was used 
to stabilise HIF-1α under normoxia (Wu and Yotnda, 2011) in order to examine 
whether expression of CCR7 was increased by HIF-1α. To determine the non-toxic 
concentration of CoCl2 for HIF-1α induction in OSC-19 cells, an MTT assay was 
carried out. Cells were seeded into 96 well plates by adding 180 μl of cell 
suspension containing 1 x 104 cells/ml to each well and incubated at 37ºC, 5% CO2 
and 100% humidity for 24 h. Next, cells were treated with CoCl2 serial dilutions 
ranging from 10 μM to 500 μM (in well concentrations) for 24 h, the media was 
removed and exchanged with fresh media and the cells were incubated for further 
48 h. After 96 h from seeding the cytotoxicity was evaluated using MTT solution as 
described earlier in section 2.2.12. 
To induce HIF-1α expression, OSC-19 cells were seeded into 75 cm2 flasks and 
incubated at 37ºC, 5% CO2 and 100% humidity. According to the MTT assay 
results, OSC-19 cells were treated with (200 and 100 μM CoCl2) for 24 h before 
being trypsinised for protein extraction. Western blot for HIF-1α detection was 
performed as previously described in section  2.2.17.2. 
 Cells migration under hypoxia  2.2.18
OSC-19 cells were seeded at a density of (8.5 x 105 cells/well) in 24 well plates 
and left overnight to reach confluency, the supernatant was removed and the wells 
washed with PBS. Later, a wound was scratched using a p200 pipette tip and 0 h 
photos were taken. Cells were either kept at normoxia or transferred to the hypoxia 
chamber. Afterwards, the cells were washed twice with PBS and treated with 2% 
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FBS media containing CCL21 at (10 and 100 nM in well concentrations), CCL19 at 
(10 and 100 nM in well concentrations) or 2% FBS media alone as control. Finally, 
at 18 h, photos were taken and analysed as before  2.2.13.1.  
Another experimental setting was also performed, in which OSC-19 cells were 
seeded at (1.6 x 104 cells/well) at normoxic conditions for 48 h and then transferred 
to hypoxia or kept in normoxia. After 24 h of transferring cells to the hypoxia 
chamber, scratches were produced inside the chamber, cells were washed with 
PBS and the plate was taken out of the chamber for not more than 10 min for 
capturing photos at 0 h and immediately returned back to hypoxia and treated with 
2% FBS media containing CCL21 at (10 and 100 nM in well final concentration), 
CCL19 at (10 and 100 nM in well, final concentrations) or 2% FBS media alone as 
control. After 18 h after migration photos were captured and analysed as 
before  2.2.13.1. 
 Proliferation under hypoxia 2.2.19
In order to evaluate the proliferation rate after adding CCL21 under hypoxia, 180 μ 
l of OSC-19 cell suspension were added to each well of a 96 well plate at a density 
of 1 x104 cells/ml. After 24 h, 20 μl of CCL21 solution was added to each well to 
achieve a final concentration in the well of 1, 10 or 100 nM. After 72 h, the MTT 
assay was performed as described in section earlier in section 2.2.12.2. Cells 
under normoxia (control) also received the same treatment. Proliferation rate under 
hypoxia was calculated by comparing results to normoxic cells, in both cases, 
control is considered when no CCL21 is added. 
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 Reactive oxygen species (ROS) detection and its effect on CCR7 2.2.20
expression 
It has been demonstrated the ROS facilities cancer progression by affecting the 
cell migration, as well as induction of chemokine receptors expression such as 
CXCR4 (Chetram and Hinton, 2013). Therefore, we evaluated the relationship 
between ROS and CCR7 expression by flow cytometry.  
In addition, we also carried out evaluation of ROS to understand their effect on cell 
migration and compare with what we had seen in our experiments in the hypoxia 
chamber and CoCl2 treatment.  
The cells were seeded in phenol red free RPMI medium (Gibco) into 25 cm2 flasks 
at a concentration of 4 x 104 cells/ml and incubated at 37˚C and 5% CO2 until 
reached 70% confluency. The following day, cells were moved to the hypoxia 
chamber treated with CoCl2 (200 μM and 100 μM) or with H2O2 200 μM (positive 
control for ROS induction) for another 24 h. Cells cultured under normoxia in 
phenol red free medium with no additional treatment were used as control. After 72 
h from seeding, the cells were trypsinised, washed and treated with 6-carboxy-
2',7'-dichlorodihydrofluorescein diacetate carboxy-H2DCFDA (Fisher scientific) 
before analysing the samples using flow cytometry. In addition, OSC-19 cells that 
were been treated with or without H2O2 (200 μM) were also analysed with flow 
cytometry for CCR7 expression.  
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 Relation between hypoxia and CCR7 in spheroids 2.2.21
 Spheroids formation and growth curve  2.2.21.1
OSC-19 cell suspension was prepared and diluted to the desired cell concertation 
as usual and seeded at 10000 cells/ well or 2000 cells/well in round 96 bottom well 
plates that were coated previously with 1.5% agarose solution to avoid cell 
adhesion. SCC-4 cells seeded at 2000 cells/well (for agarose preparation and plate 
coating see appendix VI). On the seeding day, the plate was centrifuged for 
spheroid initiation. The media was changed every other day for 7 days. The 
diameter of OSC-19 spheroids was measured from day 1 (after seeding day and 
every other day during the culture period using a calibrated graticule fixed to the 
eye piece of a light microscope using a 10x objective lens. Results were plotted as 
a graph with the mean of the diameters of at least 20 spheroids on the y-axis and 
time on the x-axis. Photos were taken at 100x magnification power on Lumascope 
488 microscope. 
 Pimonidazole treatment 2.2.21.2
To confirm the presence of a hypoxic core within OSC-19 500 µm spheroids, we 
used Hypoxyprobe™-1 Green kit (HPI) for hypoxia detection. 2000 cells spheroids 
on day 7 and 10000 cells spheroids on day 5 were treated with pimonidazole which 
is the active compound of Hypoxyprobe, it interacts with proteins in the hypoxic 
core and forms stable adducts. Briefly, the spheroids were transferred to 1.5 ml 
microcentrifuge, washed twice with PBS and then treated with pimonidazole at 
(100 μM) for 2 h at 37°C. During incubation the tubes were inverted every 30 min 
for homogenous penetration of pimonidazole. Next, the spheroids were washed 
  
   
 
 99 
 
with PBS and fixed with Bouin’s solution as described earlier. -ve control samples 
(no pimonidazole treatment) were also included. 
 Fixation and paraffin embedding of OSC-19 spheroids 2.2.21.3
Spheroids on day 1 and day 7 were transferred to a 20 ml universal tube and 
allowed to sediment down. Media was removed with care and spheroids were 
washed with PBS. Then 3 ml of Bouin’s solution was added for 75 min. Bouin’s 
solution was drained off and spheroids were washed with 70% ethanol several 
times to remove as much as possible of the Bouin’s solution. Finally, spheroids 
were left in in 70% ethanol for 1 h. The spheroids were then immersed in 90% 
ethanol for another h. Subsequently, the spheroids were covered with absolute 
ethanol for another hour and replaced with xylene for an h. Afterwards, spheroids 
were transferred to embedding moulds with minimum amount of xylene, covered 
with paraffin and left in the oven at 68°C for 30 min. The paraffin/ xylene mixture 
was removed after 30 min and replaced with paraffin twice after 30 minutes each 
time and left for 1 h in the oven. Finally, spheroids were centred in the middle of 
the mould, covered with fresh paraffin and left for 5 min in the oven to allow 
spheroids to settle at the bottom. Moulds were transferred to a cold plate overnight 
and then kept in the freezer at -20°C until ready to use. 
  Immunofluorescence staining 2.2.21.4
Spheroids were sectioned at 5 μm thickness on APES coated slides as described 
earlier in section  2.2.10.1. The slides were kept at 4°C until used. On staining day, 
the slides were baked at 45°C for 20 min and the mounted sections on positively 
coated slides were deparaffinised and dehydrated by the following procedure: 
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xylene (10 min x 2), 50% xylene/ethanol (5 min), 100% ethanol (2 min x 2), 90% 
ethanol (2 min), 70% ethanol (2 min), and distilled water (5 min). Antigen retrieval 
was completed in the microwave to boil the sections in 10 mM citrate buffer (pH 
6.0) for 20 min, allowed to cool down for 30 min and washed in PBS for 10 min. 
Sectioned were circled with zimed pen, treated with 0.1% triton X-100 for 10 min 
and washed 3 times with PBS ( 5min, x 3). Sections were blocked in 5% BSA at 
R.T for 1 h. Afterwards, the formed pimonidazole adducts were detected with FITC 
conjugated MAb1 (1: 150 diluted with PBS monoclonal mouse antibody, 
Hypoxyprobe™-1 Green kit), for 2 h at 37°C. Sections were washed with PBS (3 
min x 3) followed by nucleus staining with DAPI. For CCR7, Ki-67 detection, 
sections were incubated with CCR7 (1:100 dilution with blocking solution) or Ki-67 
(1:50 dilution with blocking solution) antibodies overnight at 4°C. After the PBS 
washing (3 min × 3), sections were incubated with the secondary anti rabbit 
antibody (1:200 dilution with PBS) for 1 h. Again, sections were washed with PBS 
before staining the nucleus with DAPI. The DAPI-mounting medium slides were left 
to dry for 1 h at 4° C. Images were taken using a Leica DM 2000 fluorescence 
microscope using Fitc (green), Tritc (red) and DAPI (blue) fluorescent channels.  
 Evaluation of CCR7, HIF-1α and Ki-67 in mouse xenografts of head and 2.2.22
neck cell lines 
The paraffin-embedded head and neck cell lines OSC-19, FaDu, Detroit, A-253 
mouse xenografts were sectioned using a Leica RM 2135 microtome (5 μm thick) 
on APES coated slides and allowed to dry on hot plate at 37°C for at least 2 h. 
Sequential sections were stained for CCR7, HIF-1α and Ki-67 as described earlier 
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in section 2.2.10.2 The incubation time for the primary antibodies CCR7 (1:1000 
dilution) HIF-1α (1:100 dilution) and Ki-67 (1:100 dilution) was overnight at 4°C. 
 Evaluation of CCR7 and HIF-1α in head and neck clinical samples 2.2.23
 Microarray slides staining  2.2.23.1
The microarray slides were processed according to the manufacturer instructions 
(Biomax). Initially, slides were de-paraffinized by immersing them into xylene for 
(10 min, x 2), 100% ethanol (5 min), 95% (5 min), 70% (5 min) and then distilled 
water (5 min). Next, slides were washed with PBS (5 min, x 2), treated with 3% 
H2O2 in distilled water for 5 min and washed again in PBS (5 min). Antigen retrieval 
was completed in the microwave to boil the sections in 10 mM citrate buffer (pH 
6.0) for 15 min at low power, allowed to cool down for 30 min and washed in PBS 
for 10 min. After antigen retrieval, IHC staining was followed as in section  2.2.10 
for CCR7 (1:1000 dilution) for 1 h at R.T and HIF-1α (1:100 dilution) for overnight 
at 4°C.  
 Evaluation of CCR7 and HIF-1α staining in microarrays 2.2.23.2
For the evaluation of the staining level of CCR7 and HIF-1α, H-score was used in 
this study. Briefly, tumour cells were only scored according to pre agreed staining 
level intensity (Figure 19) by two head and neck pathologist; Professor Keith D 
Hunter and Dr Lisette Martin, and the H-score was subsequently generated by 
adding the percentage of strongly stained cell (3×), the percentage of moderately 
stained cell (2×), and the percentage of weakly stained cell (1×), giving a possible 
range of 0–300. The score was independently obtained by the two pathologists and 
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the correlation between the two pathologists’ scores was above 0.9. The mean of 
the two values was obtained.  
 
Figure 19: Microarrays scoring intensity. Photos were taken by light microscope at 4x 
objective lens. 
 
  Statistical analysis  2.2.24
The significance of the results was assessed through a comparison of means using 
two-tailed student t-test in excel. Results were expressed as the mean ± standard 
deviation. P values were calculated to determine statistical significance of the 
results. *P < 0.05 and **P < 0.01 were deemed significant. 
Statistical analyses for clinical samples between H-scores of CCR7 and HIF-1α for 
each clinical stage (1, 2, 3 and 4) and lymph node metastasis were performed 
using Pearson correlation test and the significance of the results is represented by 
P value. Statistical differences between the H-score for CCR7 or HIF-1α 
expression between tumour cells and normal cells were evaluated using Mann-
Whitney U test. Association between high expression and clinical characteristics 
0 (None) 0 (Weak) 0 (Moderate) 3 (Strong)
Intensity 
score 
Intensity score
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was evaluated using Fisher exact test. High expression levels were assigned for H-
score ≥ 150. *P < 0.05 and **P < 0.01 were deemed significant. Clinical 
statistical tests were performed using Python 2.7 SciPy 0.19.The analysis was 
done by the bioinformatician Mr. Edvinas Pakanavicius from UCL University.   
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2.3 Results 
 Expression of CCR7 on cancer cell lines and xenografts 2.3.1
 CCR7 expression and its localization using qualitative 2.3.1.1
immunofluorescence staining method. 
The subcellular location of the CCR7 protein was assessed by 
immunofluorescence microscopy in 15 different cell lines. Since the cells were 
permeablised after fixation, it is expected that antibodies will cross cell membrane 
and can detect not only membrane bound CCR7, but also cytoplasmic CCR7.  
CCR7 was detected by immunofluorescence microscopy in all cell lines except in 
two of the colon cancer cell lines; HT-29 and SW-480, and very little in another 
colon cell line COLO-205 (Figure 20-a). The localization of CCR7 was confined to 
the cytoplasm and the cell membrane in all of the cell lines. Of note, the membrane 
bound expression was more significant in OSC-19, SCC-4, FaDu, Detroit 562, A-
253 and PANC-1. To ensure specificity of binding of secondary antibody to primary 
antibody, negative control (-ve) was achieved by adding secondary antibody to 
slides that had no anti CCR7 antibody (Figure 20-b). 
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Figure 20: Subcellular location of CCR7 in cell lines.  
(a) Immunofluorescence demonstrates the expression and localization of CCR7. CCR7 was 
expressed in all cell lines apart from HT-29 and SW-480 at different locations ranging from 
membrane bound, cytoplasmic or both, without nucleus staining. (b) Immunofluorescence of -
ve control demonstrates no CCR7 staining, confirming that staining is selective and due to 
binding of the secondary antibody to primary anti CCR7. Scale bar = 25 μm. 
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 Quantitative analysis of CCR7 and CXCR4 expression on cancer cell 2.3.1.2
lines 
Flow cytometry was used to detect the membrane bound expression of CCR7 in a 
panel of cell lines as well as the membrane bound expression of CXCR4 in order to 
compare the spread of its expression with CCR7 expression in cancer cell lines 
(Figure 21). Since the cells were not permeabilised after fixation, it is expected that 
antibodies will not cross cell membrane and can only detect membrane bound 
CCR7. We chose 9 cell lines from the 13 cell lines that were used to evaluate 
CXCR4 expression for this comparison. 
The protein expression level of CCR7 (Figure 21, a, c) was evaluated in, FaDu, 
OSC-19, SCC-4, PANC-1, U-87 MG, MCF-7, MDA-MB-231, DLD-1, HT-29, 
SW480, COLO-205, PC-3 and DU-145 cell lines. CCR7 protein was found in all 
cell lines apart from COLO-205, SW-480 which broadly agrees with IF results. The 
expression level of CCR7 was highest, with more than 3 fold increase compared to 
isotype control, in SCC-4, FaDu, OSC-19, PANC-1 and PC-3 cell lines, followed by 
U87-MG, MCF-7, MDA-MB-231, DLD-1, DU-145 and HT-29 (Figure 21, a, c).  
CXCR4 was expressed in most cell lines (Figure 21, b, d) but its expression level 
was lower than CCR7, except for FaDu and PC-3. The highest expression was in 
PC-3 (20 fold increase) followed by FaDu, OSC-19, MCF-7, MDA-MB-231 and 
DLD-1) cells. In these experiments, HT-29 cell lines showed no expression of 
CXCR4 (Figure 21, b, d).  
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Figure 21: CCR7 and CXCR4 membrane bound protein expression.  
(a) CCR7 is expressed in most of the cell lines tested (pink unfilled curves). The more shifted 
the unfilled curve (CCR7 stained) from the filled curve (isotype control in purple) the higher 
the expression. (b) CXCR4 is expressed in 8 cell lines (in green). Only HT-29 did not express 
CXCR4. (c-d) Analysis of flow cytometry data using mean fluorescence intensity. CCR7 or 
CXCR4 immunofluorescence intensity mean was normalized to its isotype control. Values are 
the mean of 3 independent experiments and error bars represent standard deviation (SD). 
 
 Expression of CCR7 using western blot 2.3.1.3
After the membrane bound evaluation of CCR7 using flow cytometry, we 
investigated the expression of CCR7 using the semi quantitative western blot 
technique as described in section  2.2.9. β-Actin was used as a loading control. The 
(d) 
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western blot technique does not differentiate between protein expressions at 
different locations because all the proteins present in the cell lysate are extracted. 
The western blot was used to confirm the results of the flow cytometry and to see if 
there is any difference between the expression of membrane bound CCR7 and the 
whole cell expression of CCR7. Our western blot results (Figure 22) confirmed the 
flow cytometry results. The expression of CCR7 was highest in SCC-4. Cell lines 
OSC-19, FaDu, PC-3, PANC-1, U-87 MG, MCF-7 followed by MDA-MB-231 and 
DU-145. The expression of CCR7 in colon cell lines was highest in DLD-1, followed 
by HT-29, SW-480 and COLO-205. The expression of CCR7 of SW-480 and 
COLO-205 was the lowest in all of the cell lines but was different from the flow 
cytometry results that showed no membrane bound expression of CCR7.This 
agrees with previous literature date on different membrane bound expression to 
whole cell expression of CCR7 in colon cell lines (Na et al., 2008).  
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Figure 22: Expression of CCR7 using western blot.  
(a)The expression of CCR7 was evaluated using the western blot technique and β-Actin was 
used as a loading control. All cell lines expressed CCR7 at different levels and the colon cell 
lines SW-480 and COLO-205 had the lowest expression.(b) An example of a whole western 
blot membrane showing only one specific CCR7 band at 47 kDa.  
(a) 
(b) 
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 Expression of CCR7 in xenografts  2.3.1.4
Tumours encounter different conditions to cells cultured in vitro such as nutrient 
deprivation, hypoxia, confined space and cell-cell and/or cell-matrix interactions 
that are not present in vitro. Hence, cells grown in vivo are exposed to conditions 
which are more similar to real life tumours than those grown as a monolayer. 
Expression of individual proteins in cell lines growing as monolayer cultured cells 
may not necessarily be the same as those grown as a 3D spheroid or xenograft. 
So we next set out to study the effect of 3D spheroids (described later in 
section  2.3.14) and xenotransplantation on CCR7 expression which also facilitates 
the choice of suitable 3D spheroid model and in vivo model for future testing of 
CCR7 antagonist compounds. Paraffin embedded xenografts were stained using 
IHC as described in section  2.2.10. Hematoxylin-eosin stained sections are shown 
in (appendix V). Staining for the CCR7 protein was identified in the cytoplasm and 
cell membrane of OSC-19, Detroit 562, U-87 MG, DLD-1, PANC-1, HT-29, DU-145 
and PC-3 (Figure 23). However, MCF-7, MDA-MB-231 and A-253 cell lines 
showed only cell membrane staining whilst FaDu cell line showed mainly 
cytoplasmic expression with very little membrane bound expression and colon cell 
line COLO-205 showed only a little staining in the cytoplasm (Figure 23). The 
membrane bound expression of CCR7 was the highest in the head and neck cell 
lines (OSC-19, Detroit 562 and A-253) along with the pancreatic PANC-1 and 
prostate PC-3. The intensity of the expression (intensity of the brown colour and 
the spread of the staining) was the highest in OSC-19, FaDu, Detroit 562, PANC-1 
and PC-3. These results were in agreement with the flow cytometry, western blot 
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and IF results described earlier in section  2.3.1.2. On the other hand, COLO-205 
had the lowest cytoplasmic expression amongst the xenografts models 
investigated and no membrane bound expression confirming the results from flow 
cytometry. All the -ve controls, in which no primary anti CCR7 antibody was added, 
showed no positive brown colour staining (Figure 23, right sided photos). 
Evaluation of difference of CCR7 expression between xenografts and cell lines is 
present under section 2.4 (Discussion). 
 CCR7 staining -ve control 
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Figure 23: Immunohistochemical staining of CCR7 in tumour xenogafts. 
The xenografts (OSC-19, FaDu, Detroit 562, A-253, PANC-1, U-87 MG, MCF-7, MDA-MB-231, 
DLD-1, HT-29, COLO-205, PC-3 and DU-145) were evaluated for CCR7 expression. Brown 
colour indicates positive staining of CCR7 expression. Membrane bound staining (M) and 
cytoplasmic staining (C).The scale bar = 100 μm at 40x objective lens. 
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 Effect of CCL19/CCL21 on cell migration 2.3.2
Following on from the demonstration of CCR7 expression in culture and 
xenografted cancer cell lines, we explored the functional activity of the receptor in 
various pharmacological assays. First, we performed the scratch assay in order to 
determine whether CCL21 and CCL19 have a functional role in cell migration and 
to select a model for testing the CCR7 small molecule antagonists that are 
synthesized in house (Chapter 4). For this purpose, we measured the free surface 
area 14-42 h after generation of a wound/scratch in the absence of chemokine 
(used as control) to that in the presence of 100 nM of CCL21 or CCL19. We 
selected 6 cell lines with different levels of CCR7 expression; SCC-4, OSC-19, PC-
3, FaDu, DLD-1, and SW-480 which does not express any membrane bound 
CCR7 according to our flow cytometry results as a -ve control. We chose the 100 
nM dose because it lies within the physiological concentration for these ligands (10 
nM - 2 μM) (Shannon et al., 2010). After scratching the monolayer, the cells were 
left to migrate for the optimal time determined by the fastest migratory cells, i.e. the 
CCL21 containing wells. Hence, SCC-4, OSC-19, FaDu, DLD-1, SW-480 and PC-3 
were left to migrate for 24, 18, 24, 42, 21, and 14 h, respectively. 
The before and after migration results of all the examined cell lines are represented 
below (Figure 24-a). CCL21 (100 nM) increased cell migration by 58%, 33%, 29% 
and 18% respectively for SCC-4, OSC-19, PC-3 and FaDu compared with control 
(no ligand added) (Figure 24-b). However, CCL21 did not affect the cell migration 
of DLD-1 or SW-480 cells; (Figure 24-b). The increase in cell motility correlates 
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with the membrane bound expression result of CCR7 in section  2.3.1.2 in these 
cell lines.  
Interestingly, addition of the same concentration of CCL19 (100 nM) had no effect 
in cell migration in any of the cell lines used compared with the control (no CCL19 
added) (Figure 24-b). This differential response of cell migration towards CCL21 
and CCL19 at similar concentrations was observed earlier in DC (Haessler et al., 
2011). 
From these experiments, we concluded that the highest migratory cell lines, after 
the addition of CCL21 were SCC-4 and OSC-19. We selected OSC-19 cell line as 
our model for further investigation of migratory aptitude because we could not have 
grown SCC-4 as a xenograft and hence further progression with this cell line for in 
vivo work would not be useful. In addition, as shown below in section  2.2.21.1, we 
could grow OSC-19 as compact spheroids to study CCR7 invasion in 3D, whereas 
SCC-4 cells on the other hand, form loose spheroids. 
Please note that in chapter 4 we report the effects of in house CCR7 antagonists 
on the CCL21 and CCL19 induced migration/invasion of OSC-19 spheroids.  
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Figure 24: Effect of CCL21 and CCL19 in wound healing assay.  
(a) Scratches were made on confluent monolayers of SCC-4, OSC-19, FaDu, DLD-1, SW-480 
and PC-3 cells. Cells were treated with CCL19 100 nM, CCL21 100 nM or no ligand added 
(control). Free surface area was measured after the migration of cells on 2 fields per well and 
averaged and normalized to free surface area at 0 h. (b) Data expressed as % of free surface 
area after migration. Error bars represent SD of 2 independent experiments. The scale bar = 
100 μm at 10x objective lens using lumascope 488 microscope. 
 
To further demonstrate that the increase in cell motility was chemokine induced, 
the effect of CCL21 at 100 and 10 nM and CCL19 at 100 and 10 nM on the 
migration of OSC-19 were also compared (Figure 25-a). As shown, CCL21 at 100 
nM significantly increased the cell migration compared with control (no ligand 
added) after 18 h. The percentage of the free surface area fell by 33% when 
CCL21 100 nM was added. The results are statistically significant, with P < 0.05 
(Figure 25-b). However, we found no great difference between 100 nM and 10 nM 
of CCL21 in the percentage of the free surface area. The acceleration in gap 
(b) 
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closure determined by the free surface area between the CCL21 10 nM and the 
control (no CCL21 added) was also statistically significant with P = 0.016. 
Unfortunately, due to limited time available, we were not able to further reduce the 
concentration of CCL21 to establish a dose response curve. On the other hand, 
CCL19 had no effect in cell migration compared with control at the concentrations 
used. 
 
 
 
0 h 18 h 
Control 
 
  
CCL21 (100 nM) 
  
CCL21 (10 nM) 
  
(a) 
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CCL19 (100 nM) 
  
CCL19 (10 nM) 
  
 
 
Figure 25:CCL21 increased wound healing.  
Scratches were made on confluent monolayers of OSC-19 cells. Cells were treated with CCL21 
at 100 nM and 10 nM, CCL19 at 100 nM and 10 nM or no ligand added (control).Free surface 
area was measured after 18 h on 2 fields per well and averaged and normalized to free surface 
area at 0 hrs. (b) Data expressed as % of free surface area after migration. Error bars 
represent SD of 3 independent experiments. *P < 0.05 compared with control group. 
(b) 
* 
* 
  
   
 
 129 
 
In order to clarify whether the effects seen in the wound healing assay are due to 
migration rather than proliferation, Ki-67, a proliferation marker, was used to stain 
cells at the beginning and end of scratch assay experiment. OSC-19 cells grown in 
2% FBS media as a confluent monolayer in the wound healing assay showed no 
significant proliferation, compared with positive (+ve) control OSC-19 cells that 
were grown at sub-confluency in 10% FBS on coverslips for 2 days before staining 
for Ki-67 (Figure 26). Sub-confluent cells which are grown in 10% FBS will stain 
+ve for Ki-67. Furthermore, we stained for CCR7 after cell migration to confirm that 
the migratory cells are still expressing CCR7 after the 18 h of migration as shown 
in Figure 27.  
 
Figure 26: Movement of OSC-19 cells in the wound healing assay is due to migration rather 
than proliferation. OSC-19 cells at 0h and 18h showed no Ki-67 staining compared with +ve 
control. The scale bar = 100, 50, 25 μm at 10x, 20x, 40x objective lens respectively. 
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Figure 27: Expression of CCR7 in wound healing assay after 18 h of migration. 
The expression of CCR7 (red) is shown in migratory cells in which nucleus is counterstained 
with DAPI. The scale bar = 50 μm at 20x objective lens. 
 
 Neither CCL21 nor CCL19 increase the proliferation of OSC-19 cells. 2.3.3
In order to evaluate the proliferation effect of CCL21 on OSC-19 and FaDu cell 
lines, we initially performed a growth curve of both cell lines using different cell 
concentrations to determine the conditions in which cells were in the log phase 
when we studied the effect of CCL21. This information was also useful later in 
chapter 4, when we added small molecules CCR7 antagonist compounds. The 
absorbance (which correlates to cell numbers) was measured and plotted against 
the day of reading (see Figure 28). Most cells have common characteristics of 
growth, which is an initial lag time when they adapt to their environment, and then 
start to increase in numbers, usually after 24 h. Following the initial lag stage, cells 
enter the log growth phase, in which the cell numbers grow exponentially. In this 
phase any drugs or agents that modulate cell survival or proliferation would have 
the most pronounced effect. After that, cells enter the plateau phase, where little or 
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no growth of the cells is observed. The length of each phase depends on the 
starting concentration. The lower the cell concentration, the longer the initial and 
log growth phase and (Figure 28-a). This, we determined that based on their 
characteristics of cell growth, the cell density of 1 x104 cell/ml is appropriate for the 
required duration of testing ligands or compounds in OSC-19 and FaDu cell lines. 
Briefly, after 24 h of seeding the cells at 1 x104 cell/ml, CCL21 and CCL19 at (100 
and 10 nM) were added and after 72 h, MTT solution was added and relative cell 
numbers were measured as described in section  2.2.12. The effects of CCL21 or 
CCL19 on OSC-19 or FaDu cells are presented by % increase of proliferation 
versus control where no chemokine was added (Figure 28-b). Our results indicated 
that addition of CCL21 resulted in a minor increase (20 %) of proliferation 
compared to control in OSC-19, however this effect was not observed at 100 nM 
with P ≥ 0.05. Likewise, CCL21 did not cause any significant effect on the 
proliferation rate compared with control in FaDu cells. CCL19 also did not induce 
any significant increase of proliferation in either cell lines (see later for 
precedence).  
 
 
(a) 
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Figure 28: Effect of CCL21 and CCL19 on OSC-19 and FaDu cells. 
(a) Osc-19 and FaDu growth curve. (b) Effect of CCL21 and CCL19 on cell proliferation. The 
assay was quantified using the MTT proliferation assay. The growth curves were a result of 
one time experiment (n=1) and hence no error bar. CCL21 and CCL19 at 100 nM did not induce 
increase of proliferation P ≥ 0.05. Error bars represent SD of 3 independent experiments. P 
value represent T-student test. 
(b) 
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 CCL21 or CCL19 induced receptor activation that was detected by an 2.3.4
increase in cytoplasmic Ca2+ moblisation  
Our results so far showed that only CCL21 has a functional effect in cells. 
Therefore, we decided to look at the effects of CCL21 and CCL19 at the receptor 
activation level. For this, the activation of CCR7 on OSC-19 cell line using a Ca2+ 
mobilisation assay was studied (Figure 29). Ca2+ release from endoplasmic 
reticulum is an early event in the chemokine signalling cascade that precedes cell 
migration. Activation of CCR7 typically results in at least a 10 fold increase in the 
intracellular concentration of Ca2+. In a calcium mobilisation assay, cells are 
labelled with Fluo-4 NW (Invitrogen; a dye which fluoresces upon binding to Ca2+, 
before adding CCL21; 100 nM in well concentration), CCL19 (100 nM in well 
concentration) or assay buffer as control. The fluorescence of stimulated cells is 
shown in (Figure 29). Both CCL21 and CCL19 caused an increase of mobilized 
Ca2+ (flux) compared with the control (assay buffer) in which no ligands were 
added to the cells. There was 40 and 17 times increase in the relative fluorescence 
change for CCL21 (P < 0.01) and CCL19 (P < 0.05), respectively compared to 
assay buffer. 
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The mobilized Ca2+ flux in response to CCL21 (100 nM) was 2.4 times higher than 
CCL19 (100 nM) (P < 0.01) in OSC-19 cells. These results indicate that CCR7 is 
functional in OSC-19 cells and responded to treatment with its ligands. However, it 
is interesting to note that the effect of CCL21 is more pronounced that the effect 
caused by CCL19 the same concentration. This mirrors the observations in DC 
chemotactic sensitivity for these two chemokines at this tested concentration 
(Haessler et al., 2011). 
 
 
(a) 
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Figure 29: Elicitation of Ca2+ flux in OSC-19 cells.  
Relative fluorescence change was calculated by normalizing each time point to the zero point 
of adding CCL21 or CCL19 (a) Ca2+ flux was measured with adding CCL21 (100 nM), CCL19 
(100 nM) or assay buffer. An increase in fluorescence change was detected after adding 
CCL21 or CCL19 compared with adding only assay buffer. (b) Relative fluorescence change at 
its highest point was higher in CCL21 treated cells compared with CCL19 treated cells and 
both were higher than control (assay buffer). Error bars represent SD of 3 independent 
experiments. *P < 0.05 and **P < 0.01 compared with control (assay buffer). 
 
 Increase of CCR7 expression after serum deprivation  2.3.5
So far, we have shown that OSC-19 cells, which we had chosen as a model 
system, express CCR7 and functionally respond to CCL21 and to a lesser extent to 
CCL19. We next set out to investigate how various stress factors can influence the 
expression of CCR7. 
First, we set out to determine the effect of serum deprivation on CCR7 expression, 
in order to simulate the conditions in which tumours grow in vivo. OSC-19 cells 
were cultured in either in 0% or 10% FBS for 24 h before analysing them using flow 
cytometry as described earlier in section  2.2.8 (Figure 30-a). Our results showed 
(b) 
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that CCR7 expression was increased from 3.7 fold change in fluorescence intensity 
in relation to isotype, for serum enriched (10% FBS) OSC-19 cells, compared to 
4.6 for serum deprived (0% FBS) OSC-19 cells Figure 30-b). The difference of the 
fold change between 0% and 10% was 0.91 with (P< 0.05). 
 
 
 
 
(a) 
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Figure 30: CCR7 expression is increased after serum deprivation. 
(a) The upper graph shows the expression of CCR7 for cells cultured in 10% FBS (unfilled pink 
curve) over the filled curve isotype control in purple. The lower graph shows the expression of 
CCR7 for cells cultured in 0% FBS (unfilled yellow curve) over the filled curve isotype control. 
On the right side, cells cultured in 10% FBS was overlaid with 0% FBS to show the shift of 
CCR7 expression for cells in 0% FBS (yellow) from 10% FBS (pink). (b) Analysis of flow 
cytometry data using mean fluorescence intensity. CCR7 immunofluorescence intensity mean 
was normalized to its isotype control. Error bars represent SD of 3 independent experiments. 
*P < 0.05 of 0% FBS group compared with 10% FBS.  
(b) 
* 
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 Production of CCL21 after mechanical stress and xenograft tissues 2.3.6
  CCL21 release from cells after induced stress by scratch assay 2.3.6.1
 In order to broaden our understanding of the role of CCR7 in stress conditions, we 
evaluated the production of CCL21 after stressing the OSC-19 cells; initially we 
scratched the cells and left them to heal in 2% FBS for 18 h and 24 h. The 
supernatant was collected after the scratches at 18 and 24 h and control (no 
scratches). We assayed the supernatant to determine whether CCL21 was 
produced by using a CCL21 Elisa detection kit as described in section  2.2.16. Our 
data showed that CCL21 concentration was 64.9 and 82.3 pg/ml after 18 and 24 h 
respectively (Figure 31). The fold change of CCL21 concertation was 1.59 and 
1.64 for 18 and 24 h respectively compared with the control (no scratches) with (P 
< 0.05) and (P <0 .01) respectively for 18 and 24 h. 
 
Figure 31: CCL21 was detected after cell wounding. 
OSC-19 was wounded and supernatant was collected after cell migration or healing at 18 and 
24 h for wounded cells and unwounded cells (control). CCL21 was detected by Elisa at 18 and 
24 h. Error bars represent SD of 3 independent experiments. *P < 0.05 and **P < 0.01 
compared with control.  
  
   
 
 139 
 
 Production of CCL21 in 3D xenografts  2.3.7
Cells growing as 3D encounter different types of stress which they try to escape in 
order to survive. We have seen in section 2.3.1.4 that head and neck xenografts 
express CCR7 and therefore expression of CCL21 in these xenografts might 
indicate the presence of autocrine activation of CCR7 that might results in increase 
tumour growth and immunetolerant reaction as proposed by others before 
(Balkwill, 2012, Wang et al., 2008).  
Figure 32 shows that head and neck xenografts produce CCL21 and its expression 
is confined to the cytoplasm and nucleus on tumour cells with little expression on 
stromal cells in cytoplasm OSC-19, FaDu and Detroit 562. However, in A-253 
xenografts, the stromal cells show high expression of CCL21. 
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Figure 32: Expression of CCL21 in head and neck xenografts. 
OSC-19, A-253, Detroit 562 and FaDu xenografts express CCL21 in tumour cells (T) and its 
expression is confined to the cytoplasm and nucleus. Furthermore, CCL21 is also expressed 
on stromal cells (S) in the cytoplasm. The scale bar = 100 μm at 40x objective lens. 
 
OSC-19 A-253 
  
Detroit 562 FaDu 
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 Increase of CCR7 expression in hypoxic cultured cells compared to 2.3.8
normoxia 
As mentioned earlier in section  2.1.2, the effect of hypoxia on CCR7 expression 
has been studied by other groups in breast, prostate and lung cancers. We 
decided to look for the effect of hypoxia on CCR7 expression in head and neck cell 
lines by comparing CCR7 expression of cells under hypoxia compared with cells 
cultured in normoxia. OSC-19, FaDu, Detroit 562, A-253 and SCC-4 cells were 
incubated under hypoxia or normoxia as described in section  2.2.17.1 for 24 h 
before analyzing them by flow cytometry for evaluating CCR7 expression (For 
growth curve of head and neck cell lines see appendix IV). At the same time cells 
were also studied for HIF-1α, as it is well known that HIF-1α is upregulated under 
hypoxia. We intended to use HIF-1α as a positive control however we could not 
directly detect HIF-1α in our analyzed samples. Therefore, we looked instead for 
LDH-A to confirm the induction of hypoxia. LDH-A is a well-established biomarker 
for the induction of hypoxia indirectly indicates the presence of actively and 
functionally expressed HIF-1α, and others have shown that expression of LDH-A 
correlates with HIF-1α expression (Denko, 2008, Hu et al., 2003, Semenza, 2013, 
Elkashef et al., 2016).  
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Our results showed that the expression of LDH-A was upregulated under hypoxia 
compared with normoxia (Figure 33-c), indirectly indicating the presence of HIF-1α 
(positive control). Furthermore, CCR7 expression was significantly increased in 3 
cell line OSC-19, FaDu and Detroit 562 (Figure 33-a, b). The fold change of CCR7 
expression was (3.2 vs 6.5) with (P < 0.05), (4.1 vs 5.8) with (P < 0.01), and (2.1 vs 
3.0) with (P < 0.05), for normoxia vs hypoxia in OSC-19, FaDu and Detroit 562, 
respectively. The changes in A-253 and SCC-4 were not significant and the least 
change in expression was seen in SSC-4 (Figure 33-a, b), which already highly 
expresses CCR7. 
 
 
 
(b) 
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Figure 33: Effect of hypoxia on CCR7 expression. 
(a) The expression of CCR7 for cells cultured in under normoxia (unfilled pink curve) and 
under hypoxia (unfilled red curve) over the filled curve (isotype control in purple). (b) Analysis 
of CCR7 expression from flow cytometry data using mean fluorescence intensity. CCR7 
immunofluorescence intensity mean was normalized to its isotype control. The expression of 
CCR7 was upregulated under hypoxia significantly in OSC-19, FaDu and Detroit 562. Error 
bars represent SD of 3 independent experiments. *P < 0.05 and **P < 0.01 for cells cultured 
under hypoxia compared with normoxic cells. (c) Expression of LDH-A in normoxia (left band) 
and hypoxia (right band). 
 
 Reduction of ROS under hypoxia 2.3.9
There is controversy surrounding the level of cellular reactive oxygen species 
(ROS) in cells growing under hypoxic conditions and whether the level of ROS 
increases or decreases during hypoxia (Kondoh et al., 2013, Liu et al., 2004). On 
the other hand, the role of high level concentration of ROS in increasing cell 
migration is well established in the literature (Hurd et al., 2012). For instance, the 
migration of lung cancer cell lines A549, H1299 and H460 was increased by 
inducing ROS production (Huang et al., 2014). Therefore, we evaluated the level of 
ROS under hypoxia and normoxia to see whether the observed reduction in 
migration that we have seen under hypoxia (section 2.3.11) might be related to the 
ROS levels.  
(c)
0 
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H2O2 is well known to induce ROS generation and hence we used it as a positive 
control (Hurd et al., 2012). The ROS levels were measured using flow cytometry as 
described earlier in section  2.2.20. Our results showed that hypoxic cells have less 
ROS compared to normoxic cells. Furthermore, addition of H2O2 (200 μM) to 
hypoxic cells resulted in an increased ROS generation which actually can surpass 
that observed in normoxic cells. The fold change of ROS generation between 
normoxic and hypoxic cells is illustrated in (Figure 34- b).   
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Figure 34: Comparison of ROS level between hypoxic and normoxic OSC-19 cells. 
(a) H2O2 increased the ROS production compared with cells cultured under normoxia. (b) 
Hypoxia conditions resulted in ROS level reduction in OSC-19 cells. (c) Fold change of ROS 
generation was calculated by normalizing fluorescence intensity mean (the geometric mean of 
area under the curve) obtained from flow cytometry data to normoxia fluorescence intensity 
mean (the geometric mean). Error bars represent SD of 3 independent experiments. **P < 0.01 
for cells cultured under hypoxia compared with normoxic cells.   
(a) 
(b) 
(c) 
FL1-H = ROS staining 
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 Induction of HIF-1α using CoCl2 and its effect on CCR7 expression and 2.3.10
ROS 
Our results from previous section showed that CCR7 is upregulated under hypoxia 
in OSC-19, FaDu and Detroit 256. Since CCR7 gene has hypoxia response 
elements at the promoter region (Li et al., 2009), and HIF-1 and HIF-2 have been 
shown to induce their effects on genes by binding to this hypoxia response element 
(Tsai and Wu, 2012), we postulate that hypoxia induces HIF-1 and HIF-2 
expression and promotes transcription of the CCR7 gene. 
To investigate whether the expression of CCR7 is regulated by HIF-1, OSC-19 
cells were treated with a known stabiliser of HIF-1α protein, CoCl2 (Han et al., 
2015).  
The concentrations of CoCl2 were selected according to the results of the MTT 
assay. The dose response curve of OSC-19 cells treated with CoCl2 for 24 h is 
shown in (Figure 35). We chose 2-fold concentration below the IC50 (200 and 100 
μM) to make sure that none of the observed effects were associated with 
cytotoxicity.  
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Figure 35: Dose response curve of 24 h CoCl2 treatment. 
(a)The OSC-19 cells were treated for 24 h with CoCl2. After 24 h media was removed and 
exchanged with fresh media before adding the MTT solution 72 h later. Values are the mean of 
3 independent experiments and error bars are SD. 
 
Figure 36: Western blot analysis of HIF-1α protein expression upon treatment with CoCl2 in 
OSC-19 cells.  
Induction of HIF-1α expression upon treating cells with CoCl2 Compared with normoxic cell (N) 
with no CoCl2 treatment. Actin was used as internal control protein. 
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The CoCl2 treatment induced significant expression of HIF-1α at 200 μM (Figure 
36). The effect of CoCl2 is not limited to HIF-1α induction; others have shown that 
CoCl2 may also affect ROS levels within the cells by increasing or decreasing them 
(Oh et al., 2014, Kotake-Nara and Saida, 2007). Because we have seen a 
reduction in ROS generation in the hypoxia chamber, so we decided to investigate 
whether CoCl2 at the same concertation used, affects the ROS levels. Again, we 
used H2O2 (200 μM) as a positive control for ROS generation. The samples treated 
with or without H2O2 or CoCl2 were also checked for CCR7 expression. Our results 
indicate that CoCl2 treatment caused a significant reduction of the ROS levels, as 
expected, H2O2 addition resulted in an increase in the ROS levels (Figure 37-a). 
The fold change observed is illustrated in Figure 37-b).  
 
  
(a) 
FL1-H = ROS staining 
  
   
 
 150 
 
 
 
Figure 37: Detection of ROS after H2O2 or CoCl2 treatment. 
(a) H2O2 increased the ROS level but CoCl2 decreased the ROS level after 24 h treatment 
compared with untreated cells. (b) Fold change of ROS generation was calculated by 
normalizing fluorescence intensity mean (the geometric mean of area under the curve) 
obtained from flow cytometry to fluorescence intensity mean of untreated OSC-19 cells. Error 
bars represent SD of 3 independent experiments. **P < 0.01 *P < 0.05 for cells compared with 
untreated OSC-19 cells.  
(b) 
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(a) 
Interestingly, the expression of CCR7 was increased significantly after treating the 
cells with 200 μM of H2O2 or CoCl2 (Figure 38-a). It should be noted however that 
100 μM of CoCl2 did not cause any significant changes in CCR7 expression. The 
fold change was 6.3, 4.3 and 3.3 respectively for H2O2 treated cells, CoCl2 treated 
cells or untreated cells relative to the isotype control (Figure 38-b). 
 
 
 
  
FL1-H = CCR7 staining 
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Figure 38: CCR7 expression level after H2O2 or CoCl2 treatment.  
CCR7 expression is upregulated after H2O2 or CoCl2 .The more shifted the unfilled curve 
(CCR7 stained) from the filled curve (isotype control in purple) the higher the expression.(b) 
Analysis of flow cytometry data using mean fluorescence intensity. CCR7 
immunofluorescence intensity mean was normalized to its isotype control. Error bars 
represent SD from 3 independent experiments. **P < 0.01 *P < 0.05 for cells compared with 
untreated OSC-19 cells. 
 
  
(b) 
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 Migration of OSC-19 cells under hypoxia 2.3.11
In section 2.3.2 we have shown that the addition of CCL21 on CCR7 expressing 
cell lines increases the migration of a number of cell lines including OSC-19 under 
normoxic conditions. Furthermore, we observed that CCR7 expression increases 
under hypoxia in OSC-19, FaDu and Detroit 562 head and neck cell lines, with the 
highest increase observed with OSC-19 cells (section 2.3.8). So we next set out to 
investigate if the increase in OSC-19 expression under hypoxia corresponds to a 
larger functional response in cell migration. 
As described in section  2.1.2, hypoxia leads to a complex series of cellular 
changes. Whilst the role of hypoxia as a driving force for aggressive tumours that 
eventually leads to metastasis is well described in the literature, the impact of 
hypoxia in increasing or reducing migration of cells in vitro, in comparison of 
normoxia, remains contradictory (Qu et al., 2005, Fujiwara et al., 2007). Therefore 
we were keen to know which way hypoxia could affect the migration of OSC-19 
cells compared with the migration under normoxia. 
We first cultured cells under normoxia and after forming the scratches, one plate 
was moved to the hypoxia and 18 h later the migration was compared with cells 
allowed to migrate under normoxia (Figure 39-a). In fact, the migration of hypoxic 
cells in 10% FBS media, and with CCL21 added, was slower than normoxic cells 
as determined by larger free surface area remaining after migration; (Figure 40-a). 
There was no change when CCL19 was added but that was to be expected as 
CCL19 did not influence cell motility even under normoxia. The increase of surface 
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area after hypoxia incubation compared to normoxia was statistically significant (P 
< 0.05) for 10% FBS and CCL21 groups as shown in (Figure 40-a). 
It could be argued that the duration of the experiment was too short to allow any 
cellular changes, e.g. increase in CCR7 expression, to be sufficiently effective. To 
confirm our results, cells were incubated inside the hypoxia chamber for 24 h 
before scratches were made. The plates were only taken out for less than 10 min 
for taking images (0 h) and returned back to the hypoxia chamber and later again 
at the end of the experiment at 18 h. Again, the migration of the hypoxic cells was 
slower than the normoxic cells (Figure 39-b).  
The increase of surface area after hypoxia incubation compared to normoxia was 
significant (P < 0.05 and P < 0.01) for 10% FBS and CCL21 groups respectively as 
shown in (Figure 40-b). This means that whilst the migration under hypoxia was 
lower than normoxia, it was not related to CCR7/CCL21 axis. 
 
 
(a) 
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Figure 39: Hypoxia decreased the cell migration of OSC-19 cells after CCL21 treatment 
compared with cells cultured under normoxia. 
(a) Scratches were made on confluent monolayers of OSC-19 cells. Cells were treated with 
CCL21 or CCL19 at 100 nM or no ligand added (control) in both normoxic and hypoxic cells. 
Free surface area was measured after the migration of cells on 2 fields per well and averaged 
and normalized to free surface area at 0 h. Hypoxia decreased the cell migration of OSC-19 
cells after CCL21 treatment. (b) Scratches were made inside the hypoxia chamber on 
confluent monolayers of OSC-19 cells after 24 h of incubating cells in hypoxia chamber. Later 
Cells were treated with CCL21 or CCL19 at 100 nM or no ligand added (control) in both 
normoxic and hypoxic cells. Free surface area was measured after the migration of cells on 2 
fields per well and averaged and normalized to free surface area at 0 h. Hypoxia decreased the 
cell migration of OSC-19 cells after CCL21 treatment. 
 
  
(b) 
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Figure 40: % of free surface area both under normxia and hypoxia after migration. 
Data expressed as % of free surface area after migration under hypoxia and normoxia for 18 
(a) or after 18 of migration after incubating cells for 24 h under hypoxia (b). Smaller bars 
indicate more migration. Error bars represent SD of 3 independent experiments. *P < 0.05 and 
**P < 0.01 for cells cultured under hypoxia compared with normoxic cells for each treatment 
group.   
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 Effect of CoCl2 on cell Migration 2.3.12
As was the case in hypoxia, the effect of CoCl2 on cell migration has been shown 
to be controversial (Han et al., 2015, Jeong et al., 2016). Our results showed that 
CoCl2 increased CCR7 expression, but caused a reduction on the ROS level. 
Although one could expect that an increase of CCR7 can cause an increase in cell 
migration, we could not be certain if this effect on migration due to the increase in 
CCR7 will be observed because of the ROS reduction caused by CoCl2 treatment. 
The increase in ROS levels have been shown by others to be important for cell 
migration (Liou and Storz, 2010). Therefore, we looked for the effect of a ROS 
inducer (H2O2 at 200 μM) and a ROS reducer (CoCl2 100 and 200 μM), on the cell 
migration aptitude of OSC-19 cells. Our results showed that H2O2 increased the 
cell migration by 40% compared with control (no treatment) decreased the free 
surface area after migration (Figure 41-a). However, CoCl2 treatment did not 
increase the migration, 200 μM CoCl2 did not decrease the free surface area 
compared with control, 135% vs 100% respectively for CoCl2 at 200 μM vs control. 
CoCl2 at 100 μM also did not result in any significant increase of cell migration 
compared with control (the free surface area was 88.6% vs 100% respectively for 
CoCl2 at 100 μM vs control). The addition of CCL21 (10 nM) to CoCl2 (200 or 100 
μM) facilitates migration, decreasing the free surface area after migration 
compared with CoCl2 (200 or 100 μM) with no CCL21. The migration level resulting 
from the addition of CCL21 (10 nM) to CoCl2 (200 or 100 μM) was increased 
significantly by 44% and 37% compared with no CCL21 addition with P < 0.05 or P 
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(a) 
< 0.01 respectively for CoCl2 at 200 or 100 μM. The % of free surface is shown 
below in Figure 41-b. 
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Figure 41: Effect of CoCl2 on cell migration. 
(a) CoCl2 with or without CCL21 did not cause increase of cell migration compared with CCL21 
10 nM group. However, H2O2 decreased the free surface area after migration compared with no 
H2O2 cells. CCL21 increased wound healing in CoCl2 treated cells compared with CoCl2 treated 
cells with no CCL21. Scratches were made on confluent monolayers of OSC-19 cells. Free 
surface area was measured after 18 h on 2 fields per well and averaged and normalized to free 
surface area at 0 h. (b) Data expressed as % of free surface area after migration. Error bars 
represent SD of 3 independent experiments. **P < 0.01 *P < 0.05 for each comparison shown in 
the graph.  
(b) 
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 Proliferation of OSC-19 cells under hypoxia 2.3.13
Hypoxia results in a number of cellular changes but overall, is known to cause a 
reduction in cell proliferation in most cell types (Hubbi and Semenza, 2015). We 
have shown previously that CCL21 had no effect on cell proliferation under 
normoxia in 2 cell lines; FaDu and OSC-19 see section  2.3.3 
Therefore, we investigated if CCL21 would equally not affect proliferation under 
hypoxia. Cells were cultured under normoxia and hypoxia for 24 h before adding 
CCL21 100 nM for another 72 h and then MTT solution was added for 4 h as 
described in section  2.2.12.2. Similar to the results we have seen under normoxia, 
CCL21 did not cause any increase of cell proliferation as shown in Figure 42.  
 
Figure 42: CCL21 did not cause any increase of cell proliferation under hypoxia. 
Error bars represent SD of 3 independent experiments.   
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 Correlation between hypoxia, CCR7 and Ki-67 in spheroids model  2.3.14
So far, the investigations we had carried out were all in 2D cultured cells. As 
discussed in chapter 1, 3D in vitro model are better representatives of tumours as 
the intracellular cellular contacts and interactions more closely resembles that in 
real life tumours. Therefore we decided to investigate the relationship between 
hypoxia and CCR7 first in multicellular spheroids, and then xenografts and clinical 
tissues. For the photos of head and neck cell lines grown as spheroids see 
appendix IV. 
 Growth curve of OSC-19 and SCC-4 spheroids 2.3.14.1
We initially cultured two cell lines OSC-19 and SCC-4 as spheroids, First growth of 
OSC-19 and SCC-4 spheroids with different cell seeding concentrations; the 
diameter, solidity and circularity were investigated. Figure 43 shows representative 
images of OSC-19 and SCC-4 spheroids with different cell seeding concentrations 
(2000 and 10000) for OSC-19 and 2000 cells for SCC-4 per well. The 
morphological changes during spheroid formation are different in the two cell lines 
investigated. In the initial stage, OSC-19 and SCC-4 form spontaneously compact 
spheroids or cell aggregates in each well, respectively. Afterwards, the OSC-19 
spheroids start to form a more solid structure with smooth and continuous 
surfaces.  
Although the SCC-4 spheroids were growing, they were not as solid as the OSC-
19 spheroids (day1-day3). After day4, there was no apparent change in the SCC-4 
spheroids morphology. Figure 44 shows the change of mean spheroid diameter in 
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the OSC-19 and SCC-4 spheroids. The spheroid diameter of all spheroids 
increased sequentially after an initial slight decrease. After a while, the diameter 
reached a plateau. Nevertheless, the plateau phase appeared earlier in OSC-19 of 
larger sizes spheroid (day5), and the growth rate of smaller spheroids was higher 
than that of larger ones. 
 
 
Figure 43: OSC-19 and SCC-4 spheroids cultured over a period of 7 days.  
The scale bar = 100 um at 10x objective lens. 
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Figure 44: Growth curve of OSC-19 SCC-4 spheroids. 
The diameter of OSC-19 and SCC-4 spheroids was measured using calibrated graticule fixed 
to the light microscope at 10 × objective lens. Error bars represent SD of 3 independent 
experiments.  
 
 CCR7 is upregulated in the hypoxic core of OSC-19 spheroids 2.3.14.2
Therefore, we decided to use the OSC-19 spheroids as they were more spherical 
and compact, compared with SCC-4 spheroids which appeared as an aggregate 
mass. We harvested OSC-19 spheroids from day1 and day7 from the cultured 
2000 cells spheroids to stain for CCR7 (Figure 45). Our results showed uniform 
expression of CCR7 spheroids of day1 (Figure 45-b) in which there’s no hypoxic 
core developed due to the small size of the spheroids ~230 μm. The maximum 
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diffusion limit of O2 is ~200 μm and because of the small size of the spheroids, 
there was no lack of oxygen or nutrients at day1. On the other hand, CCR7 
expression was differential between the spheroid layers with brighter intense 
staining towards the hypoxic core in ~500 μm at the day7 spheroids (Figure 45-a). 
To demonstrate that we have an increase of fluorescence intensity in the core of 
~500 μm compared to the rim and that the fluorescence intensity was uniform in 
~230 μm spheroids, we used Image J to record the fluorescence intensity along a 
central strip of the Tritc staining of the spheroid see (Figure 45-c). 
Due to the differences in CCR7 staining between smaller and bigger spheroids and 
to confirm the presence of hypoxic areas in the larger spheroids ~500 μm, we 
stained with pimonidazole for hypoxia and Ki-67 for proliferation. Pimonidazole, is a 
well-used hypoxia marker and forms adducts with hypoxic cells by binding to thiol 
group present in the hypoxic cells as it becomes activated after reduction under 
low O2 level. These adducts can be detected by IF, IHC and flow cytometry (Varia 
et al., 1998). The pimonidazole adducts were detected in the hypoxic core and 
were not present on the periphery of the spheroids (Figure 45-d). Furthermore, Ki-
67 straining was higher at the periphery from the rest of the spheroid indicating the 
progressive decrease of the proportion of proliferative cells from the surface to the 
center of the spheroid (Figure 45-d). The expression of CCR7 was higher towards 
the core of the spheroid in comparison with the most outward layer, thus, we have 
seen an upregulation of CCR7 in the hypoxic core (Figure 45-d).  
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(b) 
(c) 
  
   
 
 167 
 
 
 
  
Figure 45: Detection of CCR7 in OSC-19 spheroids by IF technique. 
(a) Differential expression of CCR7 is observed in ~500 μm with intense expression towards 
the core at 20x objective lens with scale bar 25 μm. (b) Homogenous expression of CCR7 in ~ 
230 μm at 40x objective lens with scale bar 50 μm.(c) Fluorescence intensity along a central 
strip of Tritc staining in ~ 230 and 500 μm spheroids (d) In ~500 μm OSC-19 spheroids, 
hypoxia was detected by pimonidazole (green) staining in the core of the spheroid with no 
staining at the proliferating rim that was detected by Ki-67 (red).The staining of CCR7 (red) 
was upregulated towards the core of OSC-19 spheroid at 40x objective lens with scale bar 50 
μm. Periphery region (PR) and hypoxic region HR (HR).  
(d) 
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 Evaluation of CCR7, HIF-1α and Ki-67 expression in xenografts 2.3.15
Tumours grown as xenografts provide a further degree of sophistication to cell-
matrix and cell-cell interactions observed in multicellular spheroids. To see if our 
observations in monolayer cultured cells and multicellular spheroids also extends 
to xenograft tissue; we evaluated the expression of Ki-67 and HIF-1α in head and 
neck xenografts that already showed high expression of CCR7 as we saw in 
section 2.3.1.4. This investigation is also important later on, as it allows us to 
choose a good xenograft model for testing of our in house synthesized CCR7 
antagonist molecules compounds in vivo. We stained for HIF-1α because it is 
expressed in low oxygen environments, and its expression has been associated 
with resistance to chemo/radiotherapy, increased angiogenesis and poor patient 
prognosis, Ki-67 staining was chosen to differentiate between hypoxic and non-
hypoxic regions. Hypoxic cells will show low Ki-67 staining compared with non-
hypoxic cells (Couture et al., 2002).  
We anticipate that a good model for testing CCR7 compounds would be one that 
represents the situation from patients in which chemotherapy and radiotherapy 
effects are compromised. In sequential sections, it is difficult to identify tumour cells 
that preferentially express HIF-1α, CCR7 and/or Ki-67 by individual 
immunostaining procedures. However, we can still see a pattern of expression as 
described below. Xenograft of OSC-19, A-253 and Detroit 562 are known to exhibit 
high levels of differentiation, compared with the poor levels of differentiation of 
FaDu (Vaughan et al., 2010, Bhattacharya et al., 2004, Kawahara et al., 1993, 
Caamano et al., 1993). OSC-19, Detroit 562 and A-253 xenografts contain well/ 
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moderately differentiated areas, without (OSC-19) or with little micro-vessels (A-
253 and Detroit 562) compared with FaDu that contains a high amount of micro-
vessels. Tumour cells in these highly to moderate differentiated xenografts were 
strongly positive for CCR7 (mainly membrane bound localization). In addition, at 
these regions, HIF-1α staining was predominant with very little Ki-67 staining 
(Figure 46). However Ki-67 was predominant in areas that were less or poorly 
differentiated.  
For instance, in OSC-19 cells, we can detect keratin pearls; which is a well-known 
histological observation that is seen in well-differentiated cells. We can see that the 
cells around these keratin structures highly express membrane bound CCR7 and 
HIF-1α, but not Ki-67 (Figure 46). On the other hand, the poorly differentiated FaDu 
cell line showed CCR7 expression that was mainly cytoplasmic, with no HIF-1α 
staining, with Ki-67 being expressed in all of the cells intracellularly in the nucleus 
(Figure 46).  
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Figure 46: Expression of CCR7, HIF-1α and Ki-67 in head and neck cancer xenografts.  
Representative bright field images are shown for the immunohistochemical staining (brown) 
for CCR7, HIF-1α and Ki-67 in head and neck cancer cell lines. Scale bars indicate 100 μm at 
10x, 20x and 40x magnification lens. KP “keratin pearls”, MV “ Micro-vessles”.T “Tumour 
cells” and S “ Stromal cells”. 
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 Evaluation of CCR7 and HIF-1α in head and neck clinical samples 2.3.16
So far we have seen that CCR7 expression is upregulated under hypoxia in 
different head and neck cell lines. Furthermore in our chosen model, OSC-19 cell 
line, we observed that CCR7 is upregulated by ROS induction, serum deprivation 
and CoCl2 treatment that mimic hypoxia in cell culture. Since CoCl2 is used to 
stabilize HIF-1α, we can infer that the increase of CCR7 expression is regulated by 
HIF-1α. Furthermore, our staining in xenografts of head and neck cell lines showed 
a trend of HIF-1α and membrane bound CCR7 expression where low Ki-67 
expression is present in (OSC-19, Detroit 256 and A-253) xenografts compared to 
FaDu xenograft that showed cytoplasmic CCR7 with no HIF-1α staining compared 
to high levels of Ki-67. 
These in vitro studies were sufficiently encouraging for us to extend our 
investigation to correlation between HIF-1α and CCR7 in cancer patients at 
different stages of the disease. We used head and neck microarrays with n=80 
patients’ sample that were scored independently by two head and neck 
pathologists using the H-score system. For representative photos of CCR7 and 
HIF-1α staining see (Figure 47 and Figure 48) respectively. First we evaluated if 
CCR7 or HIF-1α expression is different in cancer samples from normal tissue 
samples using Mann-Whitney U test Figure 49. The increase of CCR7 expression 
was significantly different from normal patients with P < 0.01. We did observe a 
decrease of HIF-1α expression however, that was shown to be not significant with 
P = 0.16. Next, we set to evaluate if high expression of CCR7 or HIF-1α (H-score > 
150) is associated with cancer clinical stages and histological grades compared to 
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normal tissues. Table 11 shows number of tissues expressing high or low level of 
CCR7 or HIF-1α. Our results showed that high expression of CCR7 is associated 
with cancer in stage 1 and stage 4 compared to normal (See Table 12). However, 
high expression of HIF-1α was not associated with cancer in any clinical stages 
compared to normal (See Table 12). Furthermore both the high expression of 
CCR7 and HIF-1α was associated with cancer in grade 1 compared with normal 
with P = 0.0001 and 0.018, respectively for CCR7 and HIF-1α (Table 13). Finally a 
correlation between CCR7 and HIF-1α was evaluated in each stage and grade. An 
increase in correlation (R) between CCR7 and HIF-1α was observed with increase 
in clinical stage (Figure 50). Similarly, expression of CCR7 was highly correlated 
with HIF-1α in lymph node metastases (Figure 50). Furthermore, there was a 
correlation between CCR7 and HIF-1α in all grades with the highest correlation 
observed in grade 1 (R=0.68, P=0.004) Figure 51. 
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Figure 47: Expression level of CCR7 in tissue microarrays. The CCR7 expression was 
membrane bound and cytoplasmic in tumour cells. 
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Figure 48: Expression level of HIF-1α in tissue microarrays. The HIF-1α expression was found 
in the nucleus and the cytoplasm of tumour cells. 
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Figure 49: Difference of expression for CCR7 and HIF-1α between normal and cancer patients. 
P- values were calculated using Mann-Whitney U test. 
 
Table 11: Number of patients expressing high and low of CCR7  
and HIF-1α 
 
 
 
 
 
 
 
 
  
CCR7 
 
 
HIF-1α 
 
 
 Low 
(n) 
High 
(n) 
Low 
(n) 
High 
(n) 
 
Normal 9 2 9 2  
Malignant 28 41 53 16  
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Table 12: Association of high expression of CCR7 or HIF-1α with cancer in 
different stages of cancer. (LN) = lymph nodes 
 CCR7 
 
 HIF-1α 
 
 
 Low 
(n) 
High 
(n) 
 
P 
Low 
(n) 
High 
(n) 
 
P 
Normal 9 2  9 2  
Stage 1 0 6 P=0.002** 2 4 P=0.1 
Stage 2 12 11 P=0.14 18 5 P=1 
Stage 3 8 11 P=0.06 17 2 P=0.6 
Stage 4 5 8 P=0.05* 10 3 P=1 
LN metastasis 3 5 P=0.07 6 2 P=1 
 
Table 13: Association of high expression of CCR7 or HIF-1α with cancer in 
different histological grades of cancer. (LN) = lymph nodes. 
Grade CCR7 
 
 
 
HIF-1α 
 
 
 
 Low 
(n) 
High 
(n) 
 
P 
Low 
(n) 
High 
(n) 
 
P 
Normal 9 2  9 2  
Grade 1 1 15 P=0.0001** 5 11 P=0.018* 
Grade 2 11 15 P=0.26 23 3 P=0.6 
Grade 3 9 7 P=0.23 16 0 P=0.16 
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Figure 50: Correlation between CCR7 and HIF-1α in different clinical cancer stages. The 
correlation is increased with the increase of the stage. Correlation (R) and P-values are 
calculated using Pearson test. 
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Figure 51: Correlation between CCR7 and HIF-1α in different histological grades. The 
correlation is only observed in grade 1 with **P < 0.01. Correlation (R) and P-values are 
calculated using Pearson test. 
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2.4 Discussion 
The involvement of the chemokine receptors in the metastatic process is well 
demonstrated in the literature (chapter 1). In particular, the expression of CCR7 on 
cancer cells facilitate their homing to the lymphatic system, at which CCL21 is 
abundantly expressed whilst CXCR4 expression assists metastasis to brain, lungs, 
liver and bones where CXCL12 is abundant (Muller et al., 2001). 
The present investigation was aimed at studying the expression levels of CCR7 in 
different cancer cell lines, 3D models and clinical tissue; and about how the level of 
expression changes upon stress, mainly hypoxic stress; and the CCR7 mediated 
functional changes in cells as a result of those stress factors. Here the discussion 
of this chapter is divided in subsections in order to make it easier to follow for the 
reader. 
 Expression of CCR7  2.4.1
We used three techniques to assess expression of CCR7 in a number of cancer 
cell lines including; breast (MCF-7 and MDA-MB-231), head and neck (SCC-4, 
OSC-19, FaDu, Detroit 265 and A-253), pancreatic (PANC-1), glioma (U-87 MG), 
prostate (PC-3 and DU-145) and colon (SW-480, COLO-205, DLD-1 and HT-29). 
Immunofluorescence (IF) is a readily available staining technique that allows us to 
detect the expression of proteins by visualising a protein in the cell, and to 
determine if it is present in the cell membrane, the cytoplasm or/ and nucleus. 
CCR7 is a cell surface receptor but is synthesised and “recycled” through 
mechanisms that take it into cytoplasm. In our method, cells were permeabilized 
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after fixing. This allows antibodies to cross into the cytoplasm and interact not only 
with any protein which is membrane bound, but also in the cytoplasm. Our results, 
indicate that CCR7 was present in all the investigated cell lines, except for SW-
480, HT-29, and that its expression was confined to the membrane or/and the 
cytoplasm. As chemokine receptors are GPCRs 7TM receptors, it is expected that 
the protein is mostly found on the membrane. However, some cytoplasmic 
expression is also expected resulting from the de novo synthesis of CCR7, or 
internalised receptor. Failure to see a relatively larger membrane bound expression 
compared with cytoplasmic expression, as was the case with U-87 MG and DU-
145 cells can be the result of receptor internalization, protein translocation, 
degradation or a defect in the signal peptide domain that results in membrane 
bound translocation failure as proposed by (Na et al., 2008). Indeed in the previous 
study, the CCR7 protein expression was only detected in the cytoplasm and not on 
the cell membrane in 15 colorectal cell lines including COLO-205, SW-480 and HT-
29, suggesting that this is not uncommon for CCR7.  
We used IF at first to give us a hint in which cell lines we should expect expression 
in order to eventually find a good model for in vitro studies. Whilst IF provides an 
easy visual means of detecting CCR7, it does so selectively for those cells within a 
field of view under a microscope and is qualitative. Therefore, to confirm and 
validate these IF results, we quantified membrane bound CCR7 expression using a 
qualitative technique (flow cytometry) in the same cell lines. In this experiment, 
cells were fixed but not permeablised. Hence, only the expression on the cell 
surface is detected.  
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We showed that the expression of CCR7 was highest in pancreatic and head and 
neck cancer cell lines and lowest in the colon cell lines. These results were in 
agreement with previous studies. Pancreatic cell lines were shown to be 
expressing CCR7 and functionally respond to CCL19 and CCL21 in 2D and 3D cell 
migration models (Sperveslage et al., 2012). Similarly, it has been shown that 
CCR7 is highly expressed on human tongue cell line SCC-4 and contributes to 
migration and invasion in vitro (Xia et al., 2014).  
Another chemokine receptor that is often co-expressed along with CCR7 in 
cancers, including breast, melanoma, pancreatic and head and neck cancer, is 
CXCR4 (Pinto et al., 2014, Guo et al., 2013, Ueda et al., 2010, Su et al., 2014); 
and in addition the high expression of both correlates to poorer prognosis than high 
expression of either of them alone. Thus, both CCR7 and CXCR4 presence can be 
utilised as a biomarker for metastasis, we can therefore infer that developing 
antagonists that target either or both receptors might potentially have better 
therapeutic benefits, reducing LN metastasis and increasing patient survival  
It has been reported that whilst CCR7 mRNA was expressed in 9 HNSCC (head 
and neck squamous cell carcinoma) cell lines whereas only 3 of them expressed 
CXCR4 (Ueda et al., 2010). The expression of CCR7 on patient derived tissues 
correlates highly with lymph node metastasis in pancreatic and head and neck 
cancers (Ueda et al., 2010, Guo et al., 2013, Nakata et al., 2008).  
Our results showed a correlation between CCR7 and CXCR4 expression in many 
of the cell lines. Notably however, CCR7 expression was higher in all of the cell 
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lines apart from the prostate cell lines DU-145, PC-3 and the head and neck FaDu, 
in which CXCR4 expression was higher than CCR7. We note that the expression 
of CXCR4 in DU-145 and PC-3 has been shown also by some others to be high 
(Sun et al., 2003, Taichman et al., 2002, Dehghani et al., 2014, Arya et al., 2004). 
Even though Engl et al (Engl et al., 2006) reported low expression of CXCR4 on 
DU-145; they nonetheless showed CXCR4 functional responses on DU-145 cells. 
Our results showing no CXCR4 expression on HT-29 is in agreement with previous 
literature data (Nimmagadda, 2012, De Silva et al., 2011). 
Also in agreement with previous studies (Na et al., 2008, Kawada et al., 2007), our 
results indicate that the membrane bound expression of CCR7 on colon cell lines 
was the lowest among the panel of the cell lines tested and that 2 cell lines, namely 
COLO-205 and SW-480 showed no expression at all.  
Western blot data confirm the pattern of expression results from IF and flow 
cytometry; showed that CCR7 is expressed on the COLO-205 and SW-480 colon 
cell lines, but as the method we used is only semiquantitative, the differences in 
CCR7 expression levels among the cell lines was not seen to the same degree as 
was in the flow cytometry. Western blots were carried out on cell lysate and hence, 
unlike flow cytometry, total protein content of the cell is analysed.  
Whilst, generally speaking, the data from the three different techniques used to 
determine CCR7 protein expression were in agreement, there were some 
discrepancies. These discrepancies in expression observed in some cases could 
be attributed to the different experimental techniques between the different 
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methods used to detect CCR7 expression, for instance, in the western blot method; 
the intracellular and membrane bound expression of CCR7 was detected whereas 
in flow cytometry only membrane bound expression was shown since cells were 
not permeabilised. In addition, the underlying reason for some of the discrepancies 
may have to do with localisation of the CCR7 and the inability of the cells to 
translocate it from the cytoplasm to the membrane.  
This is exemplified by the following observation from the literature. Western blot 
had been used as a detection method for the expression of CCR7 on colon cell 
lines (Li et al., 2011, Yu et al., 2008). However, a more recent investigation by Na 
et al has shown that CCR7 is expressed intracellularly but not on cell membrane 
on colon cell lines (CaCo2, COLO-205, COLO-206F, COLO-320, Cx2, Cx94, DLD-
1, HCT116, HT-29, LS174T, SW-403, SW-480, SW620, SW948, SW1116). In this 
case, because of defects in the signal peptide domain that are responsible for 
translocation of CCR7 to the cell membrane, there is no significant membrane 
bound CCR7 (Na et al., 2008). In addition, the authors examined the migratory 
ability of two cell lines; COLO-205 and COLO-320, and showed that in spite of 
CCR7 whole cell expression they observed, the cells were not responsive to 
CCL21 or CCL19 in migratory assay, an observation which is similar to our result 
with SW-480 and DLD-1. From our results and published data, it is unclear why 
colon cell lines produce relatively high amounts of intracellular CCR7, hence it’s 
been speculated by Na et al., that if CCR7 ligands are produced within these cell 
lines that could feed in autocrine loop activation of CCR7 proliferation/ survival. 
Another possibility is that these defects cause CCR7 to remain within the 
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cytoplasm, having completely different functions from the membrane bound 
variant, as proteins that undergo structural changes could either retain their known 
physiological functions or have different functions (Lee et al., 2003, Lasagni et al., 
2003).  
Following on from determination of CCR7 expression in cultured monolayered 
cells, we turned out attention to the expression on the same cells when grown as 
xenografts. The tumour microenvironment consists of tumour cells and non-
malignant cells within a matrix that communicate and interact with the cancer cells. 
This cross-talk between malignant and non-malignant cells may alter the 
expression of different proteins (Balkwill et al., 2012). Furthermore, it is known that 
cancer cells growing in vivo face stress conditions very different to the one’s 
encountered in monolayerd cultures, such as hypoxia and lack of nutrients, they 
also avoid immune responses, and in order to do so, may alter protein expression 
(Kawada et al., 2007) (However, please note that our xenografts were grown in 
immunedeficient mice). For example, in melanoma cells, the expression of the 
chemokine receptor CXCR4 is decreased and the expression of CCR7 is 
increased, after xenotransplantation (Pinto et al., 2014). Therefore, it becomes 
critical to confirm CCR7 expression in the tumours after transplantation, as is 
important to realise that the expression may change in vivo.  
Using immunohistochemistry, we have demonstrated that in fact, cell lines retained 
CCR7 expression in xenografts. There were some differences however. Earlier we 
showed membrane bound expression of CCR7 in cultured FaDu cell line. After 
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transplantation, although CCR7 expression was detectable in the membrane, it 
appears to be mostly present in the cytoplasm. 
In xenografts, the colon cell lines (DLD-1, HT-29) showed membrane bound and 
cytoplasmic expression of CCR7 that was lower than the other cell lines grown as 
xenografts. COLO-205 showed very little cytoplasmic expression of CCR7 
compared with the other cell lines. From the literature, we found no investigation of 
the expression of CCR7 in xenoplanted colon cancer cells; however, data from 
colon clinical samples is somewhat contradictory. Some authors have shown that 
the expression of CCR7 on colon tissues was lower than for other chemokines 
receptors, namely CXCR3 and CXCR4, and that there was no correlation with 
lymph node metastasis (Kawada and Taketo, 2011). However, others have shown 
that CCR7 expression on colon clinical samples is strongly correlated with LN 
metastasis (Gunther et al., 2005). This contradiction could be related to different 
cellular distribution of CCR7 rather than level of CCR7 expression.The former 
study used flow cytometry as the detection method while the latter one used IHC. 
In summary, regarding CCR7 expression data, the head and neck cell lines (OSC-
19, Detroit 562) showed the highest membrane bound expression xenografts which 
agree with the data from flow cytometry.  
It is very important to use the correct technique to look for the membrane bound 
expression of CCR7, as some techniques can show high expression of only 
intracellular protein and that could be misleading, assuming that this will also 
correlate to membrane bound expression. It is sometimes difficult to precisely 
differentiate between membrane bound and cytoplasmic expression of CCR7 in 
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IHC/IF staining. Therefore, the expression of membrane bound CCR7 cannot be 
judged only by immunohistochemical studies especially when choosing models to 
study the functional role of the receptor, as this can lead to false negative results. 
In regard to our expression studies of CCR7 in clinical samples, our results showed 
that the difference of CCR7 expression in head and neck cancer patients 
compared to normal patients was significant and its high expression in primary 
tumours was correlated with the clinical stage 1 and 4, grade 1 and lymph node 
metastasis. Our results are in agreement with CCR7 clinical studies in breast (Liu 
et al., 2010), tongue carcinoma (Xia et al., 2014), lung (Takanami, 2003), colon 
and pancreatic (Nakata et al., 2008). Of note, scoring was performed blind to 
patient clinical characteristics by two pathologists independently.  
Finally, all of the expression results in head and neck cancer were encouraging to 
start functional studies and learn more about CCR7 regulation in cancer in attempt 
to find a good model for evaluating CCR7 antagonists. 
 Effect of CCL21/CCL19 on CCR7 activation 2.4.2
Activation of chemokine receptors by its ligands can stimulate chemotaxis, cell 
growth, migration and invasion (Balkwill, 2012) through activation of a number of 
intracellular signalling cascades (see chapter 1). However, the presence of the 
CCR7 receptor on the surface of a cell, does not necessarily guarantee that the 
cell can respond to CCR7 signalling. There can be a number of reasons that the 
binding of the chemokine ligand would not initiate a G-protein mediated 
intracellular signalling cascade. Therefore, it is important to establish that any 
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receptors which are expressed on the cell surface are “functionally active” meaning 
that the binding of the chemokine results in a measurable pharmacological 
response, such as growth, migration and invasion. For this reason, we also 
assessed functional response of CCR7 expressing cells to chemokines CCL19 and 
CCL21. 
We found increased migration (compared to control) of OSC-19, PC-3, SCC-4 and 
FaDu cells but not of SW-480 and DLD-1 upon addition of CCL21 in a scratch 
assay. The inability of SW-480 to migrate was consistent with the lack of 
membrane bound expression of CCR7. However, DLD-1 cells did not show 
increased migration, despite the fact that they do express CCR7. As mentioned 
earlier colon cell lines including DLD-1 have defects in the signal peptide domain 
resulting in a truncated variant of CCR7 that is unable to be translocated at the cell 
membrane and are therefore unresponsive to external ligands. This supports the 
speculation that in colon cell lines loss of function variant or post translational 
defects of CCR7 might be translocated to the cell membrane. Further studies will 
be necessary to determine whether this is the reason behind unresponsive 
membrane bound CCR7 in colon cell lines. 
The CCL21/CCR7 axis in cancer has been shown to play a significant role of 
migration in vitro. In a recent study, Xia et al., SCC-4 head and neck cell line 
showed increased migration in a wound healing assay in SCC-4 expressing CCR7 
compared with siCCR7 SCC-4 cells (Xia et al., 2014). Furthermore, SCC-4 failed to 
migrate to the same extent in CCR7 knockdown cells, upon addition of CCL21. 
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These findings are consistent with our findings in head and neck SCC-4, OSC-19 
and FaDu cells.  
Our results also showed a difference between cell migration upon addition of 
CCL21 (100 nM) and CCL19 (100 nM). OSC-19 cells migrated more readily upon 
CCL21 addition but not with CCL19 addition. 
This difference between CCL19 and CCL21 has been previously mentioned in the 
literature regarding dendritic cell migration. DCs migrate towards CCL21, but not 
CCL19 at concentration higher than 20 nM (Steen et al., 2014, Ricart et al., 2011, 
Nandagopal et al., 2011). Furthermore, Catusse et al., have shown that migration 
of leukaemia cells towards CCL19 is dependent on the expression of the atypical 
chemokine “decoy” receptor CRAM (more commonly known as CCRL2) but not 
CCR7 (Catusse et al., 2010). Whereas, the migration towards CCL21 was not 
affected by CRAM expression. Therefore, studies on the expression of CRAM in 
cells which are unresponsive for CCL19 are important.  
Regarding CCL19/CCR7 axis, only a few studies have been reported on the role of 
this interaction in the migration of cancer cells. The only previous report of 
migration towards CCL19 in a wound healing assay in head and neck cancer was 
an increase the migration of metastatic PCI-4B and PCI-37B cell lines, (i.e. 
decreased the free surface area) after migration (Liu et al., 2014). Therefore, 
CCL19 can enhance migration in some cell lines. However, in none of the five cell 
lines we assessed, was an increase in migration was detectable upon addition of 
CCL19. The observed difference between our results and those of Liu et al results 
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can be either due to different cell lines (PCI-4B and PCI-37B are derived from the 
metastatic lymph nodes of head and neck patients) behaving differently but further 
investigation may be warranted.  
Regarding the wound healing assay, a key point to be answered is if the cells 
movement is a result of proliferation, migration or both. To clarify this, we stained 
the cells with proliferation marker Ki-67 using the immunofluorescence technique. 
The expression of Ki-67 protein is associated with cell proliferation (Scholzen and 
Gerdes, 2000). Ki-67 is expressed in the nucleus, mainly in the nucleoli during the 
interphase of cell cycle (Pathmanathan and Balleine, 2013). Our Ki-67 staining in 
the wound healing assay revealed that the OSC-19 cells did not express Ki-67; 
hence, the cells are not proliferating during the wound healing experiment. The 
migrating cells do express CCR7; indicating its role in cancer cells migration. 
In order to clarify that CCR7 is activated by both ligands and that the effect seen in 
migration is related to differential roles of the ligands depending on cell type or/and 
differential binding to other receptors that eventually might lead to internalization 
and degradation. We used the Ca2+ flux as an indication of receptor activation in 
OSC-19 cells. Both ligands resulted in CCR7 activation with the response induced 
by CCL21 being higher than that induced by CCL19. This difference in receptor 
activation can be due to the different binding affinity of CCL19 and CCL21(Yoshida 
et al., 1998). We had previously shown that EC50 for CCL19 and CCL21 in Ca
2+ 
flux mobilisation is 28 and 13.5 nM respectively (AHMED, 2016). 
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It is clear from our results that the CCR7/CCL21 axis is important for cell migration 
and also might indicate a different role for CCL19 and CCL21 in the migration of 
tumour cells. Of note, it has also been reported that lymph nodes express CCL21 
to a significantly higher level than CCL19 (Muller et al., 2001). It could be inferred 
from our in vitro results that CCR7 expressing tumour cells may migrate to the 
lymph nodes where CCL21 is highly expressed. 
  Evaluation of CCR7 role in proliferation and tumour growth  2.4.3
The data regarding the role of chemokines CCL19 and CCL21 and CCR7 on cell 
proliferation is contradictory. It has been reported that CCL21 induced cell growth 
in bladder and lung cancer cell lines (Mo et al., 2015, Xu et al., 2011). Similarly, in 
thyroid carcinoma it was observed that the proliferation rate was higher with cells 
cultured with CCL21 than cells cultured without CCL21 in free serum (Sancho et 
al., 2006). However, a recently published study in another head and neck cell line, 
SCC-4 (Xia et al., 2014), in which CCR7 knockdown had no significant effect on 
cell proliferation. 
We examined the effects of CCR7 activation on the proliferation in OSC-19 and 
FaDu cells. We choose these cell lines because of their contrasting Ki-67 staining 
in xenografts. The Ki-67 expression was very low in OSC-19 in comparison with 
FaDu (See section 2.3.14). We found that neither CCL21 nor CCL19 increased cell 
growth after 72 h treatment in either cell lines. Furthermore, differential effect of 
exogenous and endogenous CCL21 has been described in melanoma cell lines 
(Shields et al., 2010). In this publication, shRNA was used to knockdown CCL21 or 
overexpress CCL21 endogenously within the melanoma cell lines. Interestingly, 
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high CCL21 expressing cells grew significantly larger than low CCL21 expressing 
cells. However, the addition of exogenous CCL21 had the same effect on the 
growth of both high and low expressing CCL21 cell lines. Altogether, our results 
indicate that activation of CCR7 has no or little effect on the proliferation of head 
and neck cancer cells, in comparison with other cancer types like thyroid and 
bladder, this might be related to differential effects of exogenous and endogenous 
activation of CCR7 as shown by (Shields et al., 2010) or different effect of CCL21 
in different cancer. 
 Increase of CCR7 expression and production of CCL21 under stress 2.4.4
As mentioned above, stress conditions may alter the expression of chemokine 
receptors and their response to their cognate ligands. Accordingly, we examined 
the effect of serum deprivation on the expression of CCR7 on OSC-19 cells. Our 
results indicate an increase by 24% significant change in expression; thus, it is 
possible to assume that the increase in CCR7 expression helps the cells to survive 
under stress by autocrine activation. Sancho et al., have also shown that CCR7 
expression is increased upon serum starvation for 72 h by 53% in thyroid 
carcinoma (Sancho et al., 2006). 
Chemokines and their receptors are major players in cancer related inflammation 
(Allavena et al., 2011). A variety of chemokines have been detected in tumour 
cells. For instance, the increased expression of CCL2, CCL5 and CCL17 by 
tumour and stromal cells was correlated with recruitment of monocytes, leukocytes 
and lymphocytes that eventually promote tumour progression and immune evasion 
(Allavena et al., 2011). Therefore, to stress cell mechanically, we wounded the 
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cells several times and incubated them in low serum conditions. The OSC-19 cells 
were able to generate statistically significant amounts of CCL21, compared with no 
wounded control, indicating the importance of CCL21 in the cellular stress process 
and its role in supporting tumour progression. It was reported that cells of head and 
neck cancer secrete CCL19 after serum starvation that was detected by Elisa 
which leads to the activation of CCR7 and promotes tumour growth and 
progression (Wang et al., 2008). Furthermore, endogenously expressed CCL21 
can increase tumour growth and recruitment of host immune cells that support 
tumour progression by immune evasion in melanoma (Shields et al., 2010). A 
substantial amount of clinical data in cancer has indicated that infiltration of certain 
immune cells is correlated with poor prognosis (Kitamura et al., 2015, Yaguchi et 
al., 2011). Furthermore, we have observed that head and neck xenografts express 
CCL21. The expression of CCL21 in tumour cells was reported in breast cell lines 
(Tutunea-Fatan et al., 2015) and head and neck cell lines and clinical 
samples(Wang et al., 2008).  
The expression of CCL21 has shown to be involved in recruiting T regulatory cells 
that suppress the immune respones that eventually support tumour progression 
(Shields et al., 2010). Therefore, secretion of CCL21 under stress will provide 
survival and progression cues for the tumour growth. 
 Role of hypoxia in the regulation of CCR7 2.4.5
We have mentioned earlier that tumours growing in a body encounter different 
conditions to cells cultured in vitro (Herrmann et al., 2014, Nyga et al., 2011). One 
of the key differences is that solid tumours usually develop a hypoxic centre that 
  
   
 
 198 
 
accounts for major component of the tumour mass. When tumours grow beyond 
200 μm, they have reduced blood supply, resulting in oxygen and nutrient 
deprivation. Clearly, understanding how hypoxia can influence cancer cells is 
highly relevant to development of new therapeutics. However, because it is difficult 
to analyse cells in the tumour microenvireonmnet, we have to rely on simpler 2D 
and 3D models and artificial conditions that can mimic the intratumoural 
environment. So we first looked at the expression of CCR7 on head and neck 
cancer cell lines under low oxygen (hypoxia) conditions. 
Our results under hypoxia showed that CCR7 was upregulated significantly in the 
head and neck cell lines we tested (OSC-19, FaDu and Detroit 562). Our 
observations are consistent with studies on CCR7 upregulation under hypoxia in 
lung and breast cancer (Li et al., 2009, Wilson et al., 2006). However, in SCC-4 cell 
lines, which showed the highest expression under normoxia, there was no 
significant increase of CCR7 expression under hypoxia. Reasons for this are 
unknown but it could be because the expression of CCR7 under normoxia was 
already very high to start with.  
Growing cell lines as 3D multicellular spheroids mimics the tumour in terms of 
oxygen and nutrient diffusion better than monolayer culturing. However, as there is 
no blood supply in spheroids, xenografts would still be a better model to study the 
behaviour of cells in vivo, and to gain a better understanding of how efficient our 
therapeutic agents can be in reducing cancer progression.  
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We grew OSC-19 spheroids of about 500 μm diameter. As stated before, 200 μm 
is the limit of oxygen diffusion, so we did expect the cells in the core of the 
spheroids to experience hypoxia. We observed that the regionalization of 
pimonidazole staining matches with the proliferation parameters Ki-67. 
Furthermore, the CCR7 expression was more intense in the hypoxic core 
compared with the outermost layer. To our knowledge, the only other study of 
CCR7 in spheroids was conducted in pancreatic cell lines, in which it has been 
shown that CCR7 expression was upregulated when the pancreatic cell lines were 
grown as spheroids (Sperveslage et al., 2012). Although the authors have not 
looked for the reason of the CCR7 upregulation in the spheroids, they assumed 
that because the CCR7 gene bears a hypoxia response element that HIFs can 
bind to it, therefore the CCR7 upregulation could be potentially hypoxia related.  
Our results in 2D and 3D showed that CCR7 expression was upregulated under 
hypoxia. The effect of hypoxia is characterized by changes in the expression of a 
large number of genes, many of which are regulated directly or indirectly by HIFs. 
HIFs are α/β heterodimeric DNA binding complexes that direct extensive 
transcriptional responses, involving the induction of genes with important roles in 
several aspects of tumor biology, such as angiogenesis, metabolic reprogramming, 
growth, survival and metastasis. The HIF system is regulated by the activity and 
abundance of HIF-α subunits (see section 2.1.2). To date, the best characterized 
known HIFs are HIF-1α and HIF-2α.  
In order to identify whether the CCR7 upregulation under hypoxia is controlled by 
HIF-1α, we treated OSC-19 with CoCl2. It is known that CoCl2, directly hinders the 
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interaction between pVHL and hydroxylated HIF-1 causing the stabilization of HIF-
1α even in the presence of oxygen. Thus, HIF-1α escapes degradation and 
subsequently heterodimerises with HIF-1β leading to the active HIF-1 transcription 
factor binding to the hypoxic response element of the promoter region of many 
target genes. Hence, CoCl2 is used to mimic HIF-1α dependent transcription 
changes seen during hypoxia. 
We showed that CoCl2 caused significant induction of HIF-1α at 200 μM as well as 
CCR7 upregulation compared with cells untreated with CoCl2. This confirms that 
HIF-1α is involved in the upregulation of CCR7. 
However, this increase of CCR7 expression caused by hypoxia and CoCl2, did not 
increase the cell migration in response to CCL21 compared with cells treated only 
with CCL21. On the contrary, hypoxic or CoCl2 treated cells has higher free surface 
area after migration upon CCL21 addition compared with cells treated with CCL21 
alone. These contradictory effects of hypoxia and CoCl2 might be related to a 
reduction of ROS caused by CoCl2 or hypoxia. 
Since the role of ROS in cell migration is well known in the literature (Hurd et al., 
2012, Panieri and Santoro, 2016), we decided to investigate this more. Cancer 
cells exhibit increased levels of ROS production compared with normal cells. The 
ROS in cancer cells serves different functions. At low concentration ROS may lead 
to stimulation of cellular pathways for proliferation, cell migration and invasion (Ma 
et al., 2013). For instance, it has been reported that the increase in ROS level 
resulted in increase of cell migration in prostate and breast cancer (Ma et al., 2013, 
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Polytarchou et al., 2005). The exact mechanisms how ROS are involved in 
tumorigenesis are unclear. It has been shown that ROS can activate the 
PI3K/Akt/mTOR survival pathway as well as promoting tumour cell survival through 
the activation of NF-κB and NRF2, transcription factors that increase the 
expression of antioxidants to avoid ROS-dependent mechanism of cell death 
(Zablocka and Janusz, 2008). The best characterized mechanism of ROS induced 
tumour progression and metastasis is HIF-1α stabilization (Sullivan and Chandel, 
2014). Furthermore, the increased ROS levels lead to proteases and MMPS 
activation that are involved in the recognition and degradation of basement 
membranes as well as in the formation of invadopodia (Tafani et al., 2016). 
Moreover, ROS also triggers the recruitment of a series of actin-associated 
proteins such as cofilin and fascin as well as integrins and signalling proteins such 
as c-Src tyrosine kinases that also assemble together to form the invadopodia 
(Tafani et al., 2016). These findings suggest that an increase in ROS levels below 
the threshold for cell death is involved in causing structural changes and adaptive 
responses in tumour cells to stimulate cell migration and invasion Figure 52. 
Moreover, tumour cells also express increased levels of antioxidant proteins such 
as glutathione and superoxide dismutase to help to detoxify from ROS to keep 
ROS at the required level for cancer progression rather than cell death (Poljsak et 
al., 2013, Liou and Storz, 2010).  
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Figure 52: Effect of ROS level on cells. 
 
Our data showed that CoCl2 and hypoxia caused a reduction in ROS levels in 
OSC-19 cells. This reduction was observed in spite of the upregulation of HIF-1α 
detected directly in CoCl2 experiment and indirectly in hypoxia (0.1% O2 related 
experiments). Therefore, we can speculate that in OSC-19 model system, the cell 
migration was decreased despite the stabilization of HIF-1α and the accompanying 
CCR7 upregulation, presumably perhaps through a ROS-associated mechanism. 
We have not carried out any experiments to shed light on this mechanism, but we 
can speculate that one reason can be either a strong feedback loop from HIF-1α or 
directly through HIF-1α mediated decrease in ROS levels. We note that the 
decrease of cell migration caused by CoCl2 was shown by others in HSC-3 and 
SCC-4 cells (Han et al., 2015) indicating that the reduction of migration caused by 
CoCl2 in OSC-19 cells might not be cell line specific. Further investigation using 
SCC-4 to explore whether a reduction of ROS is observed after CoCl2 treatment is 
warranted. 
In contrast, CoCl2 in HT-29 colorectal cancer cell line, are reported to cause an 
increase in cell migration through an increase in the intercellular level of ROS and 
by HIF-1α stabilization (Jeong et al., 2016). This could mean that the relationship 
between hypoxia, HIF and ROS levels may not necessarily be the same in different 
cell lines and models. Collectively, the effect of CoCl2 on cell migration might 
depend on the net outcome between ROS production and HIF-1α stabilization; 
which could be cell type dependent.  
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Similarly to the CoCl2 results, our data under hypoxia (0.1% O2) has shown 
reduction of ROS level that resulted in deceased cell migration of OSC-19 cells, 
compared to cells cultured under normoxia. This effect of decrease ROS 
production under hypoxia may be expected from the low level of O2 (Lopez-Barneo 
et al., 2001, Archer et al., 1993, Fan et al., 2007, Fan et al., 2008, Vaux et al., 
2001, Fandrey et al., 1994). Others however, have found that ROS can be 
increased under hypoxia (Kondoh et al., 2013, Bell et al., 2007, Guzy et al., 2005). 
Even though the precise mechanism through which hypoxia increases ROS is still 
a matter of debate, it seems that ROS is possibly increased through release by the 
mitochondria electron transport (Qutub and Popel, 2008). 
Mirroring the paradoxical effect of hypoxia on ROS production, the migration under 
hypoxia seems nearly as conflicting. While some groups have demonstrated 
increased level of migration under hypoxia, for example in glioblastoma and breast 
cancer (Nagelkerke et al., 2013, Joseph et al., 2015), others have shown 
decreased or no increase of migration ability of cells under hypoxia (Raheja et al., 
2011, Turner et al., 1999, Qu et al., 2005, Dai et al., 2011). Our data in OSC-19 
cells showed a decrease in cell migration in hypoxic cells, compared to normoxic 
cells despite the significant increase of CCR7. This might be due to reduction of 
ROS levels as described earlier, changes in the cellular metabolism that can 
supress cell migration or/and through downregulation of migration-related genes, 
such as matrix metalloproteinases (MMPs) as previously reported in other studies 
(Riches et al., 2009, Zhao et al., 2005). Moreover, it has been shown in bladder 
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cancer that migration of cells under hypoxia was ROS dependent (Shin et al., 
2015). 
As mentioned above, depending on the ROS level produced, NFκB and HIF-1α 
can be activated and stabilized respectively. Furthermore, ROS can also affect 
chemokine and chemokine receptor expressions (Tafani et al., 2016). Our results 
showed a significant induction of CCR7 expression in OSC-19 after induction of 
ROS by treating the cells with H2O2. Our result on the relationship between ROS 
and CCR7 is novel and has not been observed before both in cancer and normal 
cells; thereby further investigations are needed to understand the underlying 
mechanism in which ROS can affect the expression of CCR7. To our knowledge, 
we are first in describing a link between ROS and CCR7 in cancer, which may 
suggest a potential mechanism of how cells may acquire increased CCR7 and a 
metastatic phenotype. It has been reported that ROS increases expression of 
CXCR4 in cancer and immune cells (Tafani et al., 2016, Lee et al., 2007, Chetram 
et al., 2011). Furthermore, ROS increased prostate cancer cell migration and 
invasion through CXCR4, which was abolished with CXCR4 antagonist AMD3100 
(Chetram et al., 2011). Our data in migration showed a decrease of free surface 
area after H2O2 treatment in which CCR7 and ROS levels were elevated, 
compared to cells untreated with H2O2. Therefore, we can assume that this 
increase of migration upon H2O2 treatment is CCR7 dependent. Future studies are 
needed to confirm the link between oxidative stress and CCR7 on cell migration by 
inducing ROS in cells in which CCR7 is blocked by CCR7 antibodies or small 
molecule antagonists and observe changes in cell migration. 
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Our evaluation of the expression of CCR7, HIF-1α and Ki-67 in xenografts also 
informs on the choice of suitable in vivo model for testing potential therapeutic 
agents. It is well documented that human tumours generally show significant 
phenotypic and genotypic heterogeneity (stage, various level of differentiation, 
chaotic neo-vasculature, differences in expression of genes, etc). It is generally 
agreed that using preclinical animal xenograft tumour models is useful for modeling 
the growth and spread of disease, acquiring information about the mechanisms of 
action and therapeutic efficacy of new anti-tumour agents. Our results showed that 
differentiated cells of OSC-19, A-253 and Detroit 562 xenograft express higher 
level of membrane bound CCR7, but not the poorly differentiated FaDu that 
expressed predominantly cytoplasmic CCR7. Previously, Bhattacharya et al., 
reported that CD31, a marker for micro-vessels showed no staining in A-253 but 
showed positive staining in FaDu xenografts (Bhattacharya et al., 2004). This 
finding is consistent with the fact that normal squamous epithelium also lacks 
microvessels. Because A-253 originates from the squamous epithelium, it is not 
surprising that well-differentiated tumour regions share this aspect of the normal 
differentiation process that was not seen in the poorly differentiated xenograft 
FaDu. Furthermore, A-253 showed positive staining of hypoxic marker (carbonic 
annhydrase IX and pimonidazole) at the well-differentiated regions in A-253 and 
the lack of hypoxia marker staining almost in the entire FaDu tumour (Bhattacharya 
et al., 2004, Vaughan et al., 2010). Hypoxic tumour cells are expected to be 
positive for HIF-1α. It was found that most of the less differentiated tumours, 
namely FaDu express high Ki-67 staining, but not HIF-1α. Our results in FaDu and 
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A-253 showed the same pattern of HIF-1α expression as shown by (Vaughan et 
al., 2010). Therefore in vivo, the FaDu model may not be a good representative of 
oropharyngeal cancers, and OSC-19, A-253 and Detroit 562 may make better in 
vivo models to represent the heterogeneity of human tumours. We do of course 
note that this was a limited study with low specimen numbers of xenografts and 
therefore did not allow on definitive correlation between HIF-1α and CCR7. In 
addition, we can postulate that there is a possible correlation of membrane bound 
CCR7 expression with HIF-1α encouraging enough to investigate if this correlation 
is present in patient tissue samples. 
 As expected, our evaluation on CCR7/ HIF-1α correlation in head and neck 
patients’ samples was shown to be significant and increase with the stage level 
and in lymph node metastasis. Of note, this correlation was highly significant in 
grade 1 tumour samples indicating that the level of differentiation of tumours play a 
role in the CCR7/HIF-1α cycle. Our results agree with lung cancer studies in which 
the CCR7 expression correlated with HIF-1α expression.(Li et al., 2009), our study 
demonstrates that Hypoxia-HIF-1α/CCR7 is likely to regulate the invasion and 
migration of head and neck cancer cells under hypoxic microenvironments. CCR7 
activation might play a role in promoting a more malignant phenotype of head and 
neck cancer and represents a therapeutic target. 
In summary, CCR7 was expressed in different cancer cell lines, xenografts and 
clinical head and neck patients. Furthermore, conditions to mimic tumour growth in 
vivo; hypoxia, serum deprivation, cell damage stress, ROS production and 3D 
growth as spheroids and xenografts, highly supports the increase of CCR7 or 
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CCL21 in the cell lines where examined. The increase of CCR7 under hypoxia was 
suggested to be HIF-1α related. The activation of CCR7 by its ligands results in 
Ca2+ mobilization. The addition of exogenous CCL21, but no CCL19, caused 
increased in migration in different head and neck and prostate cell lines. In this 
context, the interaction between CCR7 and ECM to facilitate cancer cells invasion 
and migration is important more specifically binding to GAGs such as heparan 
sulfate which will induce the localization of CCL21 and activation of CCR7 receptor 
to start the metastatic cascade (for more information on GAGs binding see chapter 
1). Furthermore, both ligands had no effect on cell proliferation implying differential 
effects of endogenous or exogenous ligands, autocrine/paracrine activation or cell 
type activation.  
Accordingly, the CCR7/CCL21/CCL19 in OSC-19 cells was also further studied in 
knockdown studies to confirm the role of CCR7 in cell migration (chapter 3), and 
we investigated the role of CCL21/CCL19 in cell invasion in 2D and 3D assays 
(chapter 4) and finally, we evaluated the ability of CCR7 small molecule 
antagonists to reduce CCR7/CCL21 induced cell migration and invasion (chapter 
4).  
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 The main findings of this chapter are:- 
- CCR7 is highly expressed in different cancer cell lines, xenografts and head 
and neck clinical tissues. 
 
- CCR7 was found to be upregulated under hypoxia in head and neck cell 
lines. Its expression was also elevated at the hypoxic core of OSC-19 
spheroids. Furthermore, the expression of CCR7 and HIF-1α was positively 
correlated with clinical stages and histological grade 1. 
 
- CCR7 was upregulated after serum deprivation and CCL21 was detected 
after cell damage in 2D cells or in head and neck xenografts. 
 
- CCR7 was shown for the first time, to the best of our knowledge, to be 
upregulated in cancer, after ROS induction. 
 
- CCR7/CCL21 binding results in receptor activation that translates into 
increased cell migration. 
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3 Chapter 3: 
Effects of CCR7 knockdown using 
siRNA transfection method  
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3.1 Introduction 
We showed in the previous chapter that CCR7 is expressed in different cancer 
cell lines, particularly head and neck cancer cell lines, both in cultured cells 
and in 3D spheroids and xenografts, as well as in clinical tissue; and that the 
activation of CCR7 by CCL21 contributes to cell migration in prostate and head 
and neck cancer cell lines. Moreover, we showed that the expression of CCR7 
is upregulated under conditions of serum deprivation, hypoxia and ROS 
increase, potentially through induction of HIF-1α. However, we observed that 
the increase in CCR7 expression under hypoxia did not necessarily result in 
increased cell migration compared with cells cultured under normoxia in our 
model system of OSC-19. We hypothesized that the effects on migration might 
be triggered by, or connected to a reduction in reactive oxygen species (ROS) 
under hypoxia in this cell line (see chapter 2). We note that this reduction in 
ROS under low oxygen atmosphere may not be a general feature of tumours, 
because it has long been suggested that under physiological conditions, 
cancer cells continuously promote production of ROS even under hypoxia, or 
indeed as a consequence of hypoxia (Panieri and Santoro, 2016). 
Nevertheless, taken our data in chapter 2 together with literature findings, we 
felt encouraged to further our investigations to examine the following aspects:- 
(1) Our data so far also showed no significant change in the proliferation rate of 
head and neck cancer cell lines, in contrast with some reports available in the 
literature of such effects in other cancer types, for example prostate and 
bladder cancer (Peng et al., 2015, Mo et al., 2015). This discrepancy might be 
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due to different experimental settings, but may also be associated with different 
autocrine/paracrine roles in the activation of CCR7 receptor, as discussed in 
the previous chapter and later in the discussion section of this chapter. Based 
on this observation and intrigued by other studies that suggested a role for 
CCR7 signaling in anti-apoptotic mechanisms in lung and bladder carcinoma 
cell lines (Xu et al., 2012, Mo et al., 2015); we set out to study if CCR7 
mediates survival through anti-apoptotic pathways, rather than by promoting 
proliferation. (2) It’s been suggested that chemokines can induce chemo-
resistance (Park et al., 2014). Chemotherapy using platinum containing 
complexes has been shown to eventually induce resistance in head and neck 
cancers. It has also been demonstrated that this resistance may be mediated 
through CCR7/CCL21 interaction (Wang et al., 2008). Likewise, colon cancer 
cell lines treated with CCL21 are more resistant to doxorubicin and 5- 
fluorouracil, compared with non CCL21 treated cells (Park et al., 2014, Lu et 
al., 2016). Therefore, we hypothesized that silencing CCR7 in OSC-19 cells 
may result in increasing cisplatin sensitivity in OSC-19 cells. (3) To evaluate 
whether the knockdown of CCR7 expression would result in reducing the 
movement of cells and hence influence the disease progression in OSC-19 
head and neck cancer cells, as a suitable in vitro model for studying the effect 
of small molecules antagonist ICT13069 targeting CCR7. To our knowledge no 
prior CCR7 small molecule antagonist has been investigated as a modulator of 
the metastatic process, despite the substantial evidence that CCR7 expression 
is associated with lower patient survival and poor prognosis (Irino et al., 2014, 
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Xia et al., 2014). Our data suggested that the hypoxic upregulation of CCR7 
did not increase the migration of cells compared to cells cultured under 
normoxic conditions. On the contrary, OSC-19 cells moved at a slower rate 
under hypoxia. Therefore, it is vital to study the effect of silencing CCR7 on the 
cell migration rate under hypoxia. 
Therefore, we decided to knockdown CCR7 to disrupt its gene expression and 
study the resulting cells’ phenotype (Mittal, 2004, Boettcher and McManus, 
2015). The discovery of the RNA interference to reduce the expression of a 
specific gene was a spectacular achievement and after its discovery nearly two 
decades ago, has become a method of choice for target validation. Since then, 
many methods have been developed to reduce (knockdown) or completely 
silence (knockout) gene expression.  
There are 2 main categories for manipulating the gene expression :- (1) The 
knockdown RNAi method by siRNA or shRNA or (2) the more recent knockout 
methods, that include the zinc finger nucleases, transcription activator–like 
effector nucleases and the more recent CRISPR/Cas method.  
The choice of the suitable strategy to disrupt the gene expression depends on 
the experimental goals. Since our ultimate goal is to eventually develop 
antagonists against CCR7 to stop the metastatic process, we concluded that a 
transient knockdown by RNAi would better mimic the inhibitory effects of an 
antagonist than the knockouts strategies.  
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Figure 53: RNAi mechanism for siRNA and shRNA.  
shRNA transcripts are transferred into the cytoplasm to be loaded onto the Dicer and 
processed to siRNA. Both synthetic and endogenously produced siRNA are then loaded 
onto RISC that eventually lead to mRNA degradation or translational inhibition. From 
(Mittal, 2004).  
 
There are two types of RNAi; (1) the short interfering siRNA or (2) the short 
hairpin RNA shRNA. Initially the introduced siRNA with 21 base duplexes or 
the longer shRNA hairpin transcripts that are synthesized endogenously in the 
nucleus will be transported to the cytoplasm and then loaded into RNA-induced 
silencing complex (RISC) that eventually promotes the mRNA degradation 
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Figure 53 (Mittal, 2004). RNAi is a straightforward technique to produce a 
knockdown in a very short time with less costly tools compared to other 
techniques. In addition, there is no need for prior genetic manipulation, 
because RNAi exploits the natural silencing machinery that exists in every 
mammalian cell. In this chapter, we utilised siRNA to silence CCR7 and used 
scramble siRNA as control. The siScramble has the same nucleotide 
composition, but with a different sequence that is achieved either by 
randomizing the siRNA of the target gene or reversing it.  
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 Aims and objectives 3.1.1
The expression of CCR7 on cancer cells can promote growth, invasion and 
migration that lead to the development of secondary metastases particularly to 
the lymph nodes (chapter 1 and chapter 2).  
 The main aims and objectives of this Chapter were:  
- To carry out siRNA knockdown studies on OSC-19 cells and evaluate its 
efficacy at gene and protein level under normoxic and hypoxic 
conditions. 
- To evaluate the effect of CCR7 knockdown on the: proliferation, 
apoptosis, migration, ROS generation and cisplatin sensitivity.  
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3.2 Materials and methods  
 Preparation of siRNA 3.2.1
siRNA of CCR7 and non-silencer control RNA scramble were pre-designed 
and validated by Fisher Scientific with sequences specifically targeted to 
CCR7. The oligonucleotide sequence of CCR7 and Scramble siRNA were:  
- CCR7 sense, 5’-GCGUCAACCCUUUCUUGUATT-3’ 
- CCR7 antisense 5’-UACAAGAAAGGGUUGACGCAG-3’ 
- Scramble sense 5’UUCUCCGAACGUGUCACGUTT-3’ 
- Scramble antisense 5’-ACGUGACACGUUCGGAGAATT-3’ 
 
The CCR7 and the scrambled oligonucleotide (20nmol) were dissolved in 1 ml 
of 1x Dharmacon siRNA resuspension buffer to produce a 20 µM or 5 µM 
solution of siCCR7 or siScramble respectively. Solutions were shaken for 1 h 
to ensure complete, homogenous solution. The stock solutions were kept at -
80˚C. On the day of transfection, further working solutions of 2 µM were also 
prepared, aliquoted and kept at -80˚C.  
 Cell seeding 3.2.2
Early passage (2-5) of OSC-19 cells were seeded at a density of 2.1 × 105 
cells per 25 cm2 flask in 5 ml complete RPMI medium or at 1.6× 104 cells/ well, 
or 8.0 x 104 cells/well in 24 or 6 well plates respectively. Cells were incubated 
at 37˚C and 5% CO2 for 24 h.  
 Transfection 3.2.3
On the day of transfection, cells were examined under the microscope to 
ensure that they are evenly distributed in the flasks and have a confluency of 
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30%-40%. This level of confluency is important to maximize the efficiency of 
siRNA transfection. Next, solutions of 2 μM of siRNA were brought to R.T. and 
for each transfection sample, 30 μl of siCCR7 or siScramble were added to 
525 μl of Opti-MEM reduced serum medium (Fisher scientific). Solutions were 
mixed very well by up and down pipetting. Afterwards, the transfection reagent 
oligofectamine (Fisher scientific) was first homogenised by up and down 
pipetting, and then diluted into Opti-MEM at a ratio of 1:5, mixed gently and 
incubated for 30 min at R.T. After incubation, the diluted oligofectamine should 
turn cloudy. 45 μl of this mixture was combined with the diluted siCCR7 or 
siScramble and mixed by gentle pipetting 30 times and incubated for 45 min at 
R.T. The volumes used ensure that (the concentration of oligofectamine should 
always be 7.5%v/v). Meanwhile, medium was removed from samples to be 
transfected and 5, 2 or 1 ml of Opti-MEM was added to 25cm2 flasks, 6 wells 
and 24 wells plates, respectively. Cells were washed twice with opti-MEM to 
ensure complete removal of any 10%FBS RPMI medium. Then, 2 ml, 800 μl or 
160 μl Opti-MEM was added to each 25cm2 flasks, 6 wells and 24 wells plates 
respectively. After 45 min, 500, 200, 40 μl of (siRNA/oligofectamine) was mixed 
20 times and added to the 25cm2 flasks, 6 wells and 24 wells plates, 
respectively. Cells were incubated at 37˚C and 5% CO2 for 4 h. After 
incubation, 2.5 ml, 1 ml, 200 μl of RPMI medium that contains 20%FBS, was 
added to each flask/well in the 25cm2 flasks, 6 wells and 24 wells plates, 
respectively, without removing the transfection mix. Finally, cells were 
incubated at 37˚C and 5% CO2 for 24 h, 48 h, 72 h or 96 h before harvesting 
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cells for CCR7 gene and protein expression as well as other transfection 
related assays. For transfection assays under hypoxic conditions, the 
transfection was carried out outside the hypoxic chamber for 72 h. Afterwards, 
cells were incubated for another 24h in the hypoxic chamber (0.1% O2) for 
gene and protein expression or other transfection related assays. 
 Cell harvesting  3.2.4
At each time point, images were taken to compare siScramble and siCCR7 for 
any phenotypic changes. Next, the medium was collected into 25 ml universal 
tubes to ensure collection of any floating cells and then cells were washed 
twice with 5 ml PBS, trypsinised, combined with the floating cells into the 25 ml 
tube and centrifuged at 1,000 rcf for 5 min. Then, medium was removed (any 
residual medium was removed with a Gilson pipette), next cells were re-
suspended into 5 ml PBS and centrifuged for 5 min at 1000 rcf. Finally, another 
PBS wash was carried out and the dry cell pellet with no PBS was kept at -
80˚C for gene and protein expression, to confirm the knockdown at gene and 
protein levels. 
 CCR7 gene expression after knockdown 3.2.5
 RNA extraction and quantification  3.2.5.1
Cell pellets that were transfected with siCCR7 or siScramble were taken out 
from -80˚C and kept on ice for total RNA isolation using RNeasy Mini Kit 
(Qiagen) following the manufacturer’s instruction. Cells were loosened by 
flicking the tube and the cells were lysed by adding 350 μl of RLT lysis buffer 
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and vortexed. Cells were then homogenized by pipetting the cell lysate into a 
QIAshredder spin column (Qiagen) and placed into a 2 ml collection tube and 
centrifuged for 2 min at 8,000 rcf. Next, 1 volume (350 μl) of 70% ethanol was 
added to the homogenized cell lysate and mixed well by up and down 
pipetting. The cell lysate was added to an RNeasy spin column (Qiagen), 
placed in a 2 ml collection tube (Qiagen) and centrifuged for 15 s at 8,000 rcf. 
The flow through was discarded and 350 μl RW1 buffer was added to the 
RNeasy spin column and centrifuged for 15 s at 8,000 ruff. Again, the flow 
through was discarded and the 80 μl of DNase I mix (10 μl of DNase I stock 
(Qiagen) with 70 μl of RDD buffer (Qiagen) added to RNeasy spin column and 
incubated for 15 min at R.T. Afterwards, another 350 μl of RW1 were added to 
RNeasy spin column and centrifuged for 15 s at 8,000 rcf. The flow through 
was discarded and 500 μl of RPE buffer was added to the RNeasy spin column 
and centrifuged for 15 s at 8,000 rcf. Again, another 500 μl of RPE buffer was 
added and centrifuged for 2 min at 8,000 rcf, after discarding the flow through, 
the RNeasy spin column was placed into a fresh 2 ml collection tube and 
centrifuged for 1 min at 8,000 rcf to ensure that no ethanol was carried over. 
Finally, 40 μl of RNase-free water was added to elute RNA into 1.5 ml 
collection tube after centrifugation for 1 min at 8,000 rcf. The amount of the 
eluted RNA was measured by NanoDropTM 100 spectrophotometer (Thermo 
Scientific). Total RNA was then used to synthesize single-stranded cDNA and 
RNA samples were stored at -80˚C. 
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  Complementary DNA synthesis  3.2.5.2
Single-stranded cDNA was synthesized using high capacity cDNA reverse 
transcription Kit (fisher scientific). Kit components were allowed to thaw on ice 
to prepare the 2x reverse transcription (RT) master mix by mixing kit 
components (table 1). Then, 2 µg of total RNA in 10 µl nuclease-free H2O were 
added to another 10 µl 2X RT master and mixed 2 times by pipetting to 
produce a 20 µl reaction per Eppendorf. Tubes were then loaded to MJ 
Research PTC-200 Peltier thermal cycler. The samples were run in the thermal 
cycler following conditions suitable with high capacity cDNA reverse 
transcription Kit. Samples were run at 25˚C, 37˚C, 85˚C and 4˚C for 10 min, 
120 min, 5 min and infinity, respectively. Finally, cDNA RT samples were 
stored for short term storage 24h before use at 4˚C or long term at -80˚C.  
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Table 14: reverse transcription (RT) master mix components 
Component Volume/reaction (μl) 
10X RT buffer 2 
25X dNTP Mix 0.8 
10X RT random 
primers 
2 
MultiScribeTM 
reverse 
transcriptase 
1 
RNase inhibitor 1 
Nuclease-free H2O 3.2 
Total volume 10 
 
 Real-time quantitative PCR  3.2.5.3
 Real-time quantitative PCR (qPCR) was performed using pre-designed 
primers (Fischer scientific) of 20X TaqMan® probe with an Applied 
Biosystems™ CCR7 FAM™/MGB probe (Hs01013469_m1) and 20X 
TaqMan® probe with an Applied Biosystems™ Human ACTB (beta actin) 
Endogenous Control FAM™ ⁄ MGB Probe, Non-Primer Limited. For a single 
reaction 12.5 μl of CCR7 or ACTB primer mixed with 1.25 µl of 2X Taqman 
Universal PCR Master Mix (Fischer scientific) was added to QRT-PCR 96-well 
plate (MicroAmpTM) in triplicate for each gene of interest in a UV- irradiated 
hood on 7500 RT-PCR System (Applied Biosystem). 11.25 μl of 40 ng cDNA 
was added to the PCR mix (cDNA 2 µg was diluted using RNase-free H2O). 
Water only and no reverse transcriptase were included as negative control. 
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The PCR conditions were as follows: Pre-denaturation at 50°C for 2 min and 
then at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s 
and annealing/extension at 60°C for 1 min. 
 Data analysis 3.2.5.4
The amplified genes by qPCR are measured by producing fluorescence as 
they are amplified. The fluorescence intensity that is produced from cycles 3-
15 is usually not significant and is referred to as a baseline. As more templates 
are amplified, the fluorescence intensity will increase significant above the 
baseline at a point called Ct. The method that is used for analyzing qPCR 
results is comparative quantification ΔΔCt. Therefore to evaluate the efficiency 
of siCCR7, the following calculations were followed:-  
 ΔCt= (Ct of siCCR7 or siScramble sample) – (Ct of β-actin sample) (The higher 
the ΔCt the lower the expression of CCR7) 
 ΔΔCt = (ΔCt of siCCR7) – (ΔCt of siScramble) (ΔΔCt is used to calculate the 
fold change FC or RQ) 
 RQ = 2 - ΔΔCt 
 % of expression = RQ * 100% 
 
 Expression of CCR7 protein after siRNA  3.2.6
To evaluate the efficacy of siRNA at the protein level western blot and flow 
cytometry were used. Briefly, the protein expression of OSC-19 cells after 
siRNA was carried out using flow cytometry as described in (section 2.2.8) for 
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all time points after transfection (24 h, 48 h, 72 h, and 96 h). At each time point 
the relative fluorescence intensity of siCCR7 was compared to siScramble. 
Samples after 24h and 72h of transfection were chosen for further analysis 
using western blot technique. Protein extraction, Bradford assay and western 
blot were performed as previously described in (section 2.2.9). 
 Cell proliferation and viability  3.2.7
 Trypan blue assay  3.2.7.1
To evaluate the role of CCR7 in proliferation, cells were seeded in 6 well plate 
and transfected with siCCR7 or siScramble as described in (section 3.2.2 and 
3.2.3). 24 h later CCL21 (10 nM) was added to appropriate wells for 72 h. 
Afterwards, cells were washed with PBS, trypsinised and centrifuged. Media 
was discarded and cells were resuspended in 1 ml of RPMI media, and 
vortexed. Finally 100 μl of the cell suspension was added to 100 μl of 0.4 % 
trypan blue solution (Fisher scientific). Trypan blue stains non-viable cells with 
blue color and leaving the viable cells colourless. Live cells were counted 
under bright field microscope. 
 Annexin V –FITC Apoptosis detection assay 3.2.7.2
In order to investigate the effect of CCL21/CCR7 interaction on apoptosis of 
OSC-19 cells after transfection, annexin V–FITC apoptosis assay was 
conducted. During early apoptosis, phosphatidylserine (PS) residues are 
usually translocated from the cytoplasmic side of plasma membrane to cell 
surface side. In late apoptosis, the integrity of plasma membrane is lost due to 
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apoptotic or necrotic cell death. annexin V-FITC and propidium iodide (PI) are 
typically used to detect these events, Annexin-V has a high binding affinity to 
PS residues at the cell surface and thus reflecting the amount of apoptotic 
cells, while PI binds to DNA and is only able to penetrate the cell after loss of 
the cell membrane integrity. Therefore, viable cells are negative for both 
annexin-V and PI, early apoptotic cells are only positive for annexin-V and late 
apoptotic cells are positive for both annexin-V and PI.  
After 24 h of transfection, media containing transfection reagents was removed 
and OSC-19 cells (siCCR7 and siScramble) were incubated with fresh media 
with or without CCL21 (10 nM) for 72 h. Then, media was collected in 25 ml 
tubes and cells were washed with PBS and trypsinised. Trypsinised cells were 
combined with the collected media and spinned down at 1000 rcf for 5 min. 
Media was discarded and cell pellet was resuspended in 1 ml of PBS and 0.5 x 
106 cells were centrifuged and re-suspended in 100 μl of binding buffer 
(Abcam). Next, 5 μl of annexin V-FITIC and 2 μl of PI were added for 15 min at 
R.T. in the dark. Finally, another 400 μl of binding buffer were added to each 
tube before analysing the samples using flow cytometry. The percentage of 
apoptosis was analyzed using CellQuest analysis software. 
 Data analysis 3.2.7.3
Samples were analysed by flow cytometry, (annexin V-FITC binding by flow 
cytometry (excitation/emission): ~488/530 nm using FITC signal dectector 
FL1H and PI staining by the phycoerythrin signal detector FL2H (excitation/ 
emission): ~535/617 nm.  
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The cell populations were separated into 4 groups: Live cells with no staining - 
lower left, early apoptotic with annexin V-FITC staining -lower right, late 
apoptotic with annexin V-FITC and PI staining - upper right and dead cells with 
PI staining - upper left, as shown in Figure 54. 
 
Figure 54: Annexin V-FITC apoptosis Quadrants.  
 Detection of reactive oxygen species (ROS)  3.2.8
As mentioned above, ROS play important roles in many cellular signaling 
pathways, including cell migration. OSC-19 cells were seeded in phenol red 
free RPMI medium (Gibco) in 25 cm2 flasks and transfected with CCR7 and 
Scramble siRNAs as described previously (section 3.2.3) using Opti-MEM 
phenol red free medium (Gibco). After 24 h of transfection, cells were treated 
with or without CCL21 (10 nM) for another 72 h. The medium of 1 flask was 
replaced with new medium containing H2O2 (200 μM) for another 24 h. H2O2 is 
known to cause increase of ROS levels and therefore is used as positive 
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control. On the following day, any floating cells were collected into 20 ml 
universal tubes and adherent cells were washed with 5 ml PBS, trypsinized, 
neutralised with phenol red free medium and combined with the floating cells, 
and centrifuged at 1,000 rcf for 3 min. The medium was discarded and cells 
were washed with 5 ml of PBS and centrifuged again at 1,000 rcf for 3 min. 
Afterwards, the cell pellets were re-suspended into 2 ml of phenol red free 
RPMI medium containing 5 μM of 6-carboxy-2',7'-dichlorodihydrofluorescein 
diacetate (carboxy-H2DCFDA, Fisher scientific). In the presence of ROS, the 
carboxy-H2DCFDA (a non-fluorescent compound), is converted into a green 
fluorescent dye and the fluorescence intensity could by measured using flow 
cytometry. Cells were mixed well, transferred to 6 well plates and incubated 
with carboxy-H2DCFDA for 30 min at 37°C with gentle shaking to prevent cell 
adhesion to the well surface. Finally, cells were collected, spinned down, 
washed in 5 ml PBS, spinned again and re-suspended in 500 μl of PBS and 
analysed using flow cytometry through signal detector FL1H at 
excitation/emission: ~ 488/530 nm. 
 Scratch assay under normoxia  3.2.9
We have demonstrated that the presence of 10 nM CCL21 increased the 
migration of OSC-19 cells in a number of migration (chapter 2) and invasion 
(chapter 4) assays; however whether the absence of CCR7 would stop the 
migration of cells was not considered. Therefore, the knockdown of CCR7 can 
provide valuable information on the relevance of developing antagonists 
against CCR7 and eventually increase patient survival.  
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Briefly, OSC-19 cells were seeded and transfected in 24 well plates as 
described in (section 3.2.3). After 72 h of transfection, a confluent monolayer of 
OSC-19 cells was obtained and scratched with a p200 pipet tip as described 
before in section 2.2.13 Finally, the cell free surface area (at t = 0 and 18 h) 
was measured and % of cell free surface area was calculated as before in 
section 2.2.13. 
 Scratch assay under hypoxia 3.2.10
We have observed in the previous chapter that CCR7 expression was up-
regulated under hypoxia, in comparison with cells cultured under normoxia. 
However, this upregulation did not translate to increase in migration. Therefore, 
to clarify if this reduction of migration under hypoxia is or not related with the 
CCR7 expression, OSC-19 cells were transfected to knockdown CCR7 for 72 h 
under normoxia, scratched and photos were taken before transferring to the 
hypoxia chamber (t = 0 h for scratch assay). In the hypoxia chamber, siCCR7 
or siScramble cells were washed with pre-hypoxic (kept in the hypoxia 
chamber) BPS and then pre-hypoxic 2% FBS media with or without CCL21 (10 
nM) was added and incubated for 18 h 37oC, 0.1% O2, CO2 before capturing 
images and calculating the % of free surface area as described before in 
2.2.13. 
 Effect of siCCR7 on cisplatin sensitivity  3.2.11
The IC50 of cisplatin was measured by using MTT assay as described before in 
section 2.2.12. Briefly, OSC-19 were seeded at 2000 cells/ well in 96 well 
plate, after 24 h of seeding, Cisplatin (Sigma) was dissolved in water to 
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produce a stock solution of 3.415 mM. This stock was further diluted with RPMI 
medium to give final concentrations of 50, 25, 12.5, 6.25, 3.125, 1.562, 0.781 
and 0.391 μM in the wells. Finally, 96 h after seeding, MTT solution was 
added, incubated and the blue-purple formazan colour read by using a 
colorimetric plate reader at 540 nm.  
In order to see if CCR7 is involved in cisplatin resistance, siRNA was 
performed to see whether knockdown CCR7 will increase cisplatin sensitivity 
i.e. increase cell death. To detect the level of apoptosis, OSC-19 cells were 
seeded in 6 well plates and after 24 h cells were transfected with siRNAs as 
described in (section 3.2.3). After 24 h of transfection, cells were washed with 
1 ml of BPS and then treated with or without cisplatin at IC50 ~ 1.5 μM for 
another 72 h.   
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 Statistical data analysis  3.2.12
The significance of the results was assessed through a comparison of means 
using two-tailed student t-test. Results were expressed as the mean ± standard 
deviation. P values were calculated to determine statistical significance of the 
results. *P < 0.05 and **P < 0.01.  
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3.3 Results: 
 OSC-19 cells retain their morphological appearance after siRNA 3.3.1
transfection. 
Cell images were taken 24 h, 48 h, 72 h and 96 h after transfection with 
siCCR7 and siScramble. Images showed no morphological changes between 
siCCR7 and siScramble cells Figure 55. Knockdown of siCCR7 did not cause 
any change to OSC-19 polygonal shaped cobblestone pattern compared to the 
siScramble negative control.  
 
Figure 55: Representative images of OSC-19 after transfection 
Cells maintain their normal phenotype after siRNA of CCR7. (a) Cells density before 24h 
of transfection. (b-e) Phenotypic appearance of OCS-19 cells after 24 h, 48 h, 72 h and 96 
h of siCCR7 transfection. (f-j) Phenotypic appearance of OCS-19 cells after 24 h, 48 h, 72 
h and 96 h of siScramble transfection. Cell were examined at 10x (photos shown) and 20x 
and 40x objective magnification lens but were not photographed   
a b c
ed f
g h i
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 Downregulation of CCR7 mRNA by siCCR7 reduces cell surface protein 3.3.2
levels of CCR7 
Following transfection with siCCR7 and siScramble for 24 h, 48 h, 72 h and 96 
h, cells were harvested and analysed by qPCR to evaluate CCR7 mRNA level. 
CCR7 expression was significantly down-regulated in OSC-19 cells transfected 
with siCCR7, in comparison with the cells transfected with siScramble. There 
was significant degradation of CCR7 mRNA by siRNA by 60 %, 72%, 85% and 
88% after 24 h, 48 h, 72 h and 96 h, respectively (Figure 56). The effect of 
siCCR7 on protein expression was assessed by flow cytometry. As shown in 
(Figure 57-a, b), the results demonstrated that siCCR7 significantly 
downregulated the protein level in comparison to the control siScramble. The 
fold change of the mean fluorescence intensity after normalization to 
siScramble was 0.42, 0.39, 0.32, and 0.21 for 24 h, 48 h, 72 h and 96 h, 
respectively. In addition, the protein expression was also confirmed at two time 
points 24 h and 72 h by western blot analysis (Figure 57-c). The band density 
that corresponds to the siCCR7 cells was reduced compared with that of the 
siScramble cells at both time points. 
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Figure 56: Knockdown of CCR7 at mRNA. 
 After transfection, the efficiency of siCCR7 at gene level was evaluated by qPCR. CCR7 
expression was decreased and maintained up to 96 h. Results represent 3 independent 
experiments and error bars represent SD. 
 
 
(a) FL1-H = CCR7 staining 
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Figure 57: The downregulation of the protein level of CCR7. 
The efficiency of the siRNA at protein level was evaluated by flow cytometry at 24 h, 48 h, 
72 h, and 96 h. (a) siCCR7 (the blue filled curve) was shifted to the left of the siScramble 
(the unfilled pink curve) indicating decrease in expression. (b) Analysis of flow cytometry 
data using mean fluorescence intensity, siCCR7 samples were normalized to siScramble 
samples and represented as fold change. (c) Western blot evaluation of siCCR7 at 24h 
and 72h showed decrease in expression in siCCR7 compared with siScramble. Results 
represent 3 independent experiments and error bars represent SD.  
(b) 
(c) 
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 Downregulation of CCR7 mRNA and protein level by siCCR7 is 3.3.3
maintained under Hypoxia 
Before we can examine whether the presence of CCR7 is important for cell 
migration, we ought to confirm that the level of knockdown is maintained under 
hypoxia. We showed in Chapter 2 that under hypoxia, the expression of CCR7 
protein is increased. So it is important for us to demonstrate that mechanisms 
that increase CCR7 expression under hypoxia cannot override the knockdown. 
Transfection was performed under normoxia and 72 h later cells were 
transferred to the hypoxia chamber for another 24 h (this time point was 
chosen because we have seen an increase in CCR7 expression under hypoxia 
at this particular time point, for results see chapter 2 section 2.3.8) and 
checked for gene and protein level of CCR7. The CCR7 was downregulated by 
72% and 78% at mRNA and protein level, respectively (Figure 58 ). 
 
 
(a) 
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Figure 58: The knockdown of CCR7 using siCCR7 was maintained under hypoxia.  
Silencing of CCR7 mRNA decreased the expression level of CCR7 in OSC-19 cells at the 
gene level. (b) The protein level of CCR7 after transfection was assessed by flow 
cytometry. The siCCR7 (blue filled curve) was shifted to left compared with siScramble 
(red unfilled curve (c) analysis of flow cytometry data using mean fluorescence intensity, 
siCCR7 samples were normalized to siScramble samples and represented as fold change 
Results represent 3 in dependent experiments and error bars represent SD. 
 
 Downregulation of CCR7 expression inhibits cell migration both under 3.3.4
normoxia and hypoxia 
We recall from Chapter 2 that the migration level of OSC-19 cell was increased 
upon CCL21 addition under normoxia compared to control, but not under 
hypoxia. We studied cell migration under normoxic and hypoxic conditions with 
and without CCL21 in siCCR7 and siScramble cells, to clarify whether CCR7 
plays a role in of cell migration under hypoxia or not.  
Figure 59-b shows the cell migration under normoxia and the % of free surface 
area is represented in Figure 59-a. The % of free surface area of siCCR7 
group after CCL21 addition was similar to the control group in which no CCL21 
(b) (c) FL1-H = 
CCR7 staining 
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was added (101% vs 100%). However, the siScramble group with CCL21 has 
significantly less % of free surface area compared with its control (39% vs 
105%), respectively. Furthermore, the % of the free surface area was 
significantly higher in the siCCR7 added group (101%) compared with 
siScramble group (39%) after the addition of 10 nM CCL21 (P < 0.01). On the 
other hand, the addition of 10 nM CCL19 did not cause any significant 
difference in the % of free surface area of OSC-19 between siCCR7 or 
siScramble groups, 93 % versus 102% respectively (P > 0.05). 
The effect of siCCR7 on OSC-19 cells was also studied under 10% FBS 
without the addition of CCL21, the migration of OSC-19 cells was reduced by 
58% under the knockdown of CCR7.  
Under hypoxia however, the % of free surface area of siCCR7 group is 115% 
vs 89% for the siScramble Figure 60. This 26% difference was significant with 
a P < 0.05. This indicates the significance of CCR7 expression both under 
normoxia and hypoxia Figure 60. 
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Figure 59: Migration of OSC-19 cells after the knockdown of CCR7 under normoxia.  
Free surface area was measured after 18 h on 2 fields per well and averaged and 
normalized to free surface area at 0h. Cells were treated with CCL21 at 10 nM, CCL19 at 
10 nM or no ligand added (control). (a) Data expressed as the mean of % of free surface 
area after migration. Scale bar represents 100 µm and **P < 0.01 compared with 
siScramble-CCL21 group. Results represent 3 in dependent experiments and error bars 
represent SD. (b) Representative images of OSC-19 cell before (0h) and after (18h) 
migration. 
 
(a) 
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(b
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Figure 60: Migration of OSC-19 cells after the knockdown of CCR7 under hypoxia.  
Free surface area was measured after 18 h on 2 fields per well and averaged and 
normalized to free surface area at 0h. Cells were treated with CCL21 at 10 nM or no ligand 
added 2% FBS (control). (a) Data expressed as the mean of % of free surface area after 
migration. Results represent 3 in dependent experiments and error bars represent SD. *P 
< 0.05 compared with siScramble-CCL21 group. (b) Representative images of OSC-19 cell 
before (0 h) and after (18 h) migration.  
(a) 
(b) 
  
   
 
 240 
 
 Effect of CCR7 downregulation on cell proliferation and apoptosis  3.3.5
It has been shown that CCR7/CCL21 is involved in cell survival and 
proliferation in different types of cancers (see chapter 1). However, in wildtype 
OSC-19 cells we could not see a significant increase in cell proliferation as 
determined by MTT assay (section 2.3.3 and 2.3.13). Whilst MTT assay is a 
robust and reliable method for the determining the number of metabolically 
active cells, it does not provide any information on the fate of cells or 
mechanisms by which cell numbers are suppressed. Therefore we wondered if 
using another type of assay would provide us with information about the 
mechanisms by which CCR7 axis is involved in controlling cell proliferation. To 
investigate the effect of proliferation on cells transfected with siCCR7 and un-
transfected cells, the trypan blue exclusion assay was performed as described 
previously in section 3.2.7.1. Our results showed that knockdown of CCR7 
caused no significant difference of total live cells number compared to the 
siScramble cells (p > .05) Figure 61 Moreover, the addition of CCL21 (10 nM) 
on siCCR7 transfected and un-transfected cells had no significant increase on 
cell proliferation rate with P values = 0.79 and 0.54, respectively Figure 61. 
This agrees with our result in MTT assay (chapter 2) in which CCL21 had no 
effect on proliferation in OSC-19 wild type cells. 
Trypan blue exclusion assay provides information on cell viability, as did our 
MTT assay results on proliferation rate, but does not give any information on 
the mechanisms of cell death. Therefore, we decided to use an annexin V-
FITC assay to look for the effect of CCL21 on apoptosis and to investigate if 
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CCL21 would decrease or have the same % of apoptotic cells compared to the 
cells with no CCL21 Figure 61-b,c).  
To ensure the annexin V-FITC assay was working properly and able to detect 
apoptosis, we first treated one siScramble OSC-19 cells flask with H2O2 and 
observed a 19.1% increase in apoptosis (Figure 61-c). We then tested the 
treated siScramble and siCCR7 transfected cells with CCL21. CCL21 did not 
change the % of apoptosis in siCCR7 or siScramble cells. The % of apoptotic 
cells was 11.2% and 10% for siCCR7 transfected OSC-19 cells with or without 
CCL21, respectively (Figure 61-c). Moreover, addition of CCL21 had no effect 
on the % of apoptosis in siScramble cells (9.1% for siScramble and 9.3% 
siScramble/CCL21 group (Figure 61-c). 
 
 
(a) 
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(b) 
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Figure 61: Effect of siCCR7 on cell proliferation and apoptosis. 
Number of live cells after siCCR7 with or without CCL21 using trypan blue assay. Values are 
the mean of 3 independent experiments and error bars are SD (b) Representative images of 
apoptosis level after treating cells with or without CCL21 10 nM. OSC-19 cells were treated 
with CCL21, 24 h after transfection. After treatment with CCL21 for 72 h, apoptosis was 
measured using annexin V staining. (c) Values are representing the % of early and late 
apoptotic cells of the mean of 3 independent experiments and error bars are SD. *P < 0.05 
compared with siScramble group. 
 
It has been suggested by others that CCR7 activation can provide anti-
apoptotic cues in lung cancer cells (Xu et al., 2012), however, based on our 
data, we must conclude that CCL21/CCR7 axis has no such effect in OSC-19 
cells. However, this result ought to be revisited as it has been suggested that 
the activation of survival pathways is observed either by autocrine activation of 
(c) 
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the chemokine receptors (Balkwill, 2012) or as a result of the loss of cell 
attachment (Xu et al., 2012). 
 Effect of siCCR7 and CCL21 on ROS level  3.3.6
We saw in the previous chapter (section 2.3.10) that addition of H2O2 (ROS 
inducer) in OSC-19 cells resulted in CCR7 upregulation. Furthermore, ROS 
can have a complex and often contradictory effects on cancer cells, for 
instance either increasing cell apoptosis or survival (Zablocka and Janusz, 
2008).  
Hence the link between ROS and chemokines, we decided to investigate 
whether the lack of anti-apoptotic effects of CCL21 (10 nM) is in itself 
associated with an increase in ROS that counteract the CCL21 effect on cell 
proliferation/survival. We performed siRNA transfection to look for the effect of 
CCR7 downregulation on ROS production upon CCL21 addition. Again, 
addition of H2O2 was used as a positive control for ROS production and caused 
a 0.45 fold increase of mean fluorescence intensity compared with siScramble 
group, P < 0.01 (Figure 62). 
In fact, we observed that the knockdown of CCR7 had no significant effect on 
the baseline ROS levels in cells, compared with siScramble group, P = 0.75 
(Figure 62). Furthermore, the addition of CCL21 to siScramble or siCCR7 
groups did not cause any changes on the ROS levels with P = 0.34, 0.83 
compared with siScramble and siCCR7 groups with no CCL21 added, 
respectively. We can therefore conclude that whilst an increase in ROS results 
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in an upregulation of CCR7 expression, the activation of CCR7 by CCL21 or 
the knockdown of CCR7 had no effect on ROS production. 
 
 
(b) (a) 
(c) (d) 
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Figure 62: Detection of the ROS level after the knockdown of CCR7.  
siScramble and siCCR7 were treated with or without CCL21 10 nM for another 72h after 
transfection. (a-d) Images represent the change of ROS level (green unfilled curve) in 
H2O2, siScramble with CCL21, siCCR7 or siCCR7 with CCL21 compared to siScramble 
(purple filled curve). (e) Analysis of flow cytometry data using mean fluorescence 
intensity Values are the mean of 3 independent experiments and error bars are SD.   
(e) 
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 Impact of CCR7 expression on Cisplatin sensitivity  3.3.7
Chemotherapy resistance either by intrinsic or acquired mechanism typically 
leads to tumour relapse and decrease the overall survival (Lippert et al., 2008). 
In addition, acquired resistance might develop as a result of inducing genetic 
and/or epigenetic mutations or through other mechanisms after continuous 
exposure to radiotherapy and chemotherapeutics agents. Hence, chemokines 
and their receptor might play a vital role in chemotherapy resistance by 
activating anti-apoptotic pathways and blocking pro-apoptotic pathways 
(Sarvaiya et al., 2013). For instance, the increased expression of CXCR4 was 
associated with higher chemo-resistance in pancreatic, ovarian and prostate 
cancer that lead to poorer progression-free survival and a lower overall survival 
(Zhang et al., 2015, Domanska et al., 2012, Li et al., 2014).  
There is direct and indirect evidence to suggest that the CCR7 can contribute 
to resistance in head and neck cancers. In addition, the expression of CCR7 
on metastatic head and neck cell lines contributed to cisplatin resistance 
through Akt activation.  
Therefore, we decided to study the effect of CCR7 activation in head and neck 
cell lines on cisplatin sensitivity and particularly, apoptosis. First, we chose 2 
cell lines FaDu and OSC-19 and determined the IC50 of cisplatin in each by 
MTT assay as 4±1 and 1.5±1 μM, respectively (Figure 63). We then compared 
changes in the apoptosis level by flow cytometry after treating the siCCR7 and 
ScrambleCCR7 cells with cisplatin for 72 h. Our results, showed increase of 
apoptosis after cisplatin treatment both in siCCR7 and siScramble groups 
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(Figure 64-a). The % of apoptosis was increased from 10% to 45% for 
siScramble group and from 12% to 39%) for siCCR7 group. The difference of 
% of apoptotic cells between siCCR7 and siScramble (Figure 64-a) was not 
significant after cisplatin treatment with P > 0.05 as shown in (Figure 64-b). It 
appears based on our results from OSC-19, and the data from others on SCC-
4 (Xia et al., 2014),that CCR7 axis is probably not involved in survival at least 
of these two cell lines.  
 
 
Figure 63: Determination of cisplatin IC50 in OSC-19 and FADU. 
Cells were seeded at 1 x 104 cells/ml in 96 well plate, 24 h later cells were treated with 
cisplatin for another 72 h. After 96 h, MTT solution was added and 4 h later media was 
removed and the formazan crystals were dissolved with DMSO. The absorbance was read 
at 540 nm. OSC-19 error bars are average from n= 3 independent experiments and FaDu n 
=2. 
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Figure 64: Effect of CCR7 downregulation on cisplatin sensitivity. 
Cells were treated with cisplatin for 72h after transfection (a) Images represent the % of 
apoptosis I siCCR7 and siScramble cells with and without cisplatin. (b) Values are 
representing the % of early and late apoptotic cells of the mean of 3 independent 
experiments and error bars are SD.  
(a) 
(b) 
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3.4 Discussion: 
The main challenge to increase patient survival is mainly from the complications 
related to the metastatic process. Thankfully, many aspects of the process and the 
main key players are being elucidated. For example, in different cancer cell lines 
and tissues, the significance of CCR7 expression to cancer progression and its role 
in the metastatic process has been shown (Zhou et al., 2013, Sancho et al., 2006, 
Hong et al., 2016, Li et al., 2014, Hirakawa et al., 2007, Nardone et al., 2016, 
Cunningham et al., 2010, Chen et al., 2015, Maekawa et al., 2008, Zhao et al., 
2011). 
Our findings in the previous chapter indicated the importance of CCR7 expression 
in head and neck and prostate cell lines in cell migration. Altogether, these findings 
encourage the development of agents which tackle the spread of cancer cells 
through prevention of the CCR7 receptor. One of the many strategies to further 
confirm the importance of CCR7 as a valid target to initiate small molecules design 
program against it, is the siRNA technology. Indeed, several studies have used the 
knockdown of CCR7 (Mo et al., 2015, Xu et al., 2011, Chen et al., 2015).  
The use of siRNA technique to knock down CCR7 in our OSC-19 cell line was 
successful at the gene and protein level and maintained during all the experimental 
time points under normoxia. Furthermore, despite the upregulation of CCR7 under 
hypoxia in siCCR7 and siScramble cells, the level of knockdown in the siCCR7 
cells was maintained. In this chapter, we confirmed that the increase of cell 
migration was through CCL21/CCR7 interaction in OSC-19 cells and siCCR7 
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significantly abrogated the effect of CCL21. In addition, cells in which CCR7 was 
knocked down had reduced migration compared to scrambled control in 10% FBS. 
Our observation is consistent with other publications on prostate and tongue 
carcinoma (Xia et al., 2014, Chen et al., 2015). We found that the difference was 
not significant in 2% FBS media, but that is probably because migration of cells is 
much reduced in low serum conditions anyway. This suggests that expression of 
CCR7 may have a wider role in the cell migration, perhaps through cross talk with 
other axes.  
Furthermore, we have observed in chapter 2 that the migration of OSC-19 cells 
under hypoxia was lower than cells cultured under normoxia despite the increase 
of CCR7 expression. This is despite our results showing that the migration of 
siCCR7 cells under hypoxia was less than siScramble. This suggests that whilst 
CCR7 clearly does play a role in migration of OSC-19 cells, reduction of ROS 
under hypoxia can effectively oppose that role.  
Several studies have suggested that expression of CCR7 on cancer cells is pivotal 
for proliferation and survival on bladder, lung, prostate, thyroid, pancreatic and 
breast cancer cell lines (Mo et al., 2015, Xu et al., 2011, Peng et al., 2015, Sancho 
et al., 2006, Zhang et al., 2016b, Boyle et al., 2016). However, our results from 
chapter 2 and 3 have shown that although there is a small trend of CCL21 in 
increasing proliferation (MTT assay and trypan blue results), we observed no 
statistically significant increase of proliferation by adding exogenous CCL21 or 
CCL19. Furthermore, our transfection results showed also that silencing CCR7 by 
siRNA had no significant effect on proliferation. Despite the discrepancy with other 
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cancer types, our data is consistent with Xia et al study on tongue carcinoma cell 
line, where they report no significant increase on proliferation of SCC-4 after 
CCL21 addition (Xia et al., 2014). Furthermore, many studies examined the 
regulatory mechanism of the CCL21/CCR7 interaction on proliferation and survival. 
It has been reported P-ERK and P-Akt are involved in increasing cell proliferation 
in lung and esophageal cancers respectively (Xu et al., 2012, Ye et al., 2011).Xia 
et al reported no increase in P-Akt after treating the SCC-4 cell line with CCL21. 
Therefore, it is possible that the effect of CCL21 or CCL19 on CCR7 in regard to 
cell proliferation and survival might be head and neck cell line specific.  
To determine whether the expression of CCR7 has any anti-apoptotic effects on 
OSC-19 cells despite its insignificant effect on proliferation, the % of apoptotic cells 
were measured using the flow cytometry after the activation of CCR7 by CCL21 on 
siCCR7 and siScramble cells. Our preliminary results showed no effect on 
apoptosis in response to CCL21/CCR7 interaction in contrast to the anti-apoptotic 
effect observed in other cancers (Xu et al., 2012). In addition, silencing CCR7 had 
no significant effect on apoptosis with or without CCL21. In contrast to our findings, 
others have shown anti-apoptotic response to CCL21 in bladder and non-small cell 
lung cancer cells (Mo et al., 2015, Xu et al., 2012). CCL21/CCR7 had anti-
apoptotic in these cell models by up-regulating Bcl-2 and downregulating Bax 
possibly via ERK activation.  
However, in study by Ziegler et al., CCL19 did not affect T cells and HUT78 
lymphoma cell line proliferation at concentrations up to 100 nM but they did report 
an apoptotic effect at concentrations higher than 500 nM of CCL19 (Ziegler et al., 
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2007). The physiologic concentrations of a chemokine in normal tissue or tumour 
are hard to determine precisely. Ziegler’s apoptotic effect could be only valid for the 
physiological environment within lymph nodes in which high chemokine 
concentrations are present. However, it is likely that it will not be observed in 
tumour tissues because such very high concentrations of chemokines are probably 
not present in tumour microenvironment. 
Recently, there is emerging evidence linking the chemokine system to ROS 
(Sozzani et al., 2005, Chetram and Hinton, 2013). Furthermore, depending on the 
level of ROS produced within the tissue, cytotoxic level of ROS can increase the 
cell kill (Ozben, 2007). For instance, anthracyclines and epipodophyllotoxins, are 
used to induce cell death by increasing ROS production. Therefore, we speculated 
that CCL21/CCR7 survival cues might be counteracted by ROS dependent 
mechanism. Our results showed that CCL21 did not increase the ROS level in 
siScramble or siCCR7 transfected OSC-19 cells. Moreover, silencing CCR7 had no 
effect on ROS production. Therefore ROS might be excluded as the underlying 
mechanism to conceal the survival signal triggered by CCL21. Alternatively, we 
could hypothesise that in OSC-19 cells no anti-apoptotic signalling is activated by 
CCL21/CCR7 interaction.  
From this work, it is not clear whether results of our investigation of OSC-19 can be 
more generally applicable. However, considering the limited role of CCL21 in 
increasing survival in SCC-4 (Xia et al., 2014) along with our OSC-19 results, we 
might conclude, at least for head and neck cell lines originating from tongue that 
CCL21 does not increase tumour survival.  
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Another likely interpretation for the compromised role of CCL21 in OSC-19 cells 
can be drawn from CXCR4 studies (Wendt et al., 2008, Wendt et al., 2006). Wendt 
et al., has shown that autocrine activation of CXCL12 on CXCR4 by stable re-
expression of CXCL12 in mammary carcinoma cells inhibited cell migration but 
increased proliferation (Wendt et al., 2008). Furthermore, after re-expression of 
CXCL12 in breast cell line MDA-MB-231, the cell responded very poorly to the 
exogenous CXCL12 in Ca2+ flux and transwell chemotaxis assays. Authors 
propose that the epigenetically silenced CXCL12 in mammary carcinoma cells by 
hypermethylation might give a selective advantage for the paracrine signal to 
promote cell migration and metastasis (Wendt et al., 2008). Furthermore, silencing 
of endogenously expressed CXCL12 in colorectal cell lines promoted their 
metastatic behavior (Wendt et al., 2006).  
Taken together, our apoptosis and proliferation results in OSC-19 supported by 
(Xia et al., 2014) study on SCC-4, the expression of CCL21 in head and neck 
xenografts (chapter 2) and the differential effect of autocrine/paracrine activation of 
CXCR4, we can suggest that exogenous/paracrine or endogenous/autocrine 
activation of CCR7 might result in different effects in head and neck cell lines 
depending on the type of the signalling loop. Therefore, further investigation on the 
effect of autocrine stimulation of CCR7 in head and neck cancer cells on 
proliferation and apoptosis is warranted. 
The conventional standard therapy for head and neck cancer is surgery and/or 
radiotherapy as a primary treatment for non-metastasized cancer, in addition, 
platinum based chemotherapy in combination with radiation is the current standard 
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for surgically inaccessible and metastasized head and neck cancer tumours 
(Vokes and Athanasiadis, 1996, Kelland, 2007). However, patients often gain 
resistance for the platinum chemotherapeutic agents; and therefore only 50%-60% 
of the head and neck patients are cured of the cancer (Sano et al., 2011). 
 Platinum resistance is often acquired after many cycles of therapy or in some 
cases, tumours were intrinsically resistant. Therefore identifying the underlying 
mechanism of chemo-resistance is highly important to increase patient survival. 
Two main mechanisms have been demonstrated to be responsible for platinum 
resistance; insufficient DNA binding or recovery after DNA binding by increased 
survival signalling or increased removal from DNA by excision repair (Kelland, 
2007). 
Cisplatin is one of the most used cytotoxic drugs used to improve patient survival; 
however, chemo-resistance is a major hurdle to its clinical use. Li et al., has 
reported that the expression of CXCR4 is higher in cisplatin resistant ovarian cell 
line A2780/cis compared with A2780 in vitro (Li et al., 2014). In addition, Li et al 
demonstrated that the cisplatin chemo-resistance was reduced in cells transfected 
with siCXCR4 both in parental and resistant ovarian cell lines. 
In regard to CCR7, it has been shown that activation of CCR7 leads to increased 
survival signaling in metastatic PCI-4B or PCI-15B head and neck cancer cell lines 
after treatment with cisplatin, and that the mechanism is through Akt activation 
(Wang et al., 2008). Conversely, our findings showed that siCCR7 had no effect on 
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cisplatin sensitivity of OSC-19 cells suggesting that CCR7 is not involved in the 
chemo-resistance of cisplatin in this cell line.  
Of course, our study on the correlation of CCR7 and cisplatin has several 
limitations. (1) We designed our experiment based on the results of siCXCR4 on 
parental ovarian A2780 cell line, which showed that siCXCR4 increased the 
cisplatin chemo-sensitivity. Hence we only studied the effect of siCCR7 on parental 
OSC-19 cells without developing an OSC-19 resistant cell line to compare with the 
parental cell line. (2) Assuming a differential effect of autocrine and paracrine 
activation of CCR7, a study on the effect of autocrine activation of CCR7 on 
cisplatin sensitivity is necessary. 
In summary, the data generated in this chapter confirmed that importance of 
CCR7/CCL21 in cell migration both under normoxic and hypoxic conditions 
encouraging the development of anti-metastatic compounds to see whether similar 
effect will be achieved using small molecules. In addition, the presence of CCR7 by 
exogenous ligands showed no increase in proliferation or decrease of apoptosis. 
Hence, in order to further study the effect of blocking CCL21/CCR7 axis using 
small molecules developed in house, pharmacological experiments will be carried 
out using OSC-19 as a model for evaluating CCR7 antagonists (chapter 4).   
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 The main findings of this Chapter were: 
- Significant and specific knockdown of CCR7 was achieved at gene and 
protein level. 
 
- CCR7 is involved in increased cell migration of OSC-19 cells under 
normoxic and hypoxic conditions. 
 
- CCR7 is not involved in increasing cell survival and proliferation or 
providing anti-apoptotic signal in OSC-19 by exogenous CCL21.  
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4 Chapter 4: 
Identification and Pharmacological 
evaluation of small molecule CCR7 
antagonists 
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4.1 Introduction  
 Therapeutic implications of targeting CCR7 4.1.1
The role of chemokines and their receptors in cancer is well established and has 
been discussed in the preceding chapters. In particular, it is known that their 
expression on tumour cells facilities the metastatic process at different stages 
(Sarvaiya et al., 2013). Once the metastatic spread of cancer cells to the 
secondary sites has occurred, treatment options become very limited. Therefore, 
preventing chemokine induced migration provides a good opportunity to develop 
new treatments for cancer. 
The association between CCR7 upregulation by tumour cells and lymph node 
metastasis has been validated in different types of cancers (Zhao et al., 2011, 
Zhou et al., 2013). Indeed, CCR7 has been suggested to be used as a biomarker 
to increase reliability of computed tomography to assess the lymph node 
metastasis status in bladder cancer (Chen et al., 2016), and in conjunction with 
CXCR4 as a biomarker for axillary lymph node metastasis in T1 breast cancer 
(Cabioglu et al., 2005). So far, several lines of evidence, including knockout, 
knockdown, anti-sense studies and the use of neutralizing antibodies, have 
supported the validity of CCR7 as an anti-metastatic therapeutic target. Despite 
this evidence, investigating the effect of inhibiting CCR7 in tumours using small 
molecule antagonists has not received much attention probably for a number of 
reasons, namely:- (1) There are small molecule antagonists that target other 
chemokine receptors important in cancer as well as diseases such as acquired 
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immune deficiency syndrome (AIDS) and asthma (Wells et al., 2006). However, 
there are currently no small molecule CCR7 antagonists available that can be used 
as a biological tool, or as a lead in a drug discovery programme (Lazennec and 
Richmond, 2010). The lack of any CCR7 antagonists is unusual. CCR7 belongs to 
the GPCR family of receptors. This makes it an attractive therapeutic target, as 
GPCRs are considered a highly druggable receptor class, indeed 40% of drugs 
currently in the market target GPCRs (Wu et al., 2009). In fact, it appears that our 
group is the only one with access to a CCR7 antagonist (AHMED, 2016) (2) CCR7 
has a well- documented role in adaptive immunity (Comerford et al., 2013). Thus, it 
could be argued that inhibiting the receptor might raise the risk of developing 
autoimmune diseases as an undesired side effect. However, knockout studies in 
mice have demonstrated that the animals remain healthy and show no 
autoimmune disease symptoms within their life span period (Comerford et al., 
2013). In addition, there are now a number of chemokine antagonists have been 
successfully registered by the FDA: Plerixafor, which targets CXCR4 and has 
shown anti-metastatic activity in animal models. It is being evaluated in clinical 
trials for ovarian cancer, osteogenic sarcoma and acute myeloid leukaemia (Lanza 
et al., 2014, Zlotnik et al., 2011); Maraviroc, which is indicated for HIV infection by 
blocking CCR5 (Xu et al., 2014); and Mogamulizumab, a monoclonal antibody 
against CCR4 that is indicated for T lymphoma and some allergic diseases (Ogura 
et al., 2014). All of them have completed initial clinical trials with no toxicity or 
adverse immune response effects observed in healthy adults (Giles and Loberg, 
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2006). Altogether, this is a very encouraging motivation for the development of 
CCR7 inhibitors. 
Recently, there has been a resurgence and renewed interest in looking at the 
beneficial effects of targeting CCR7 in preventing lymph node metastasis in 
cancer. Silencing CCR7 in mice or loss of CCL21 by the natural mutation paucity of 
lymph node T cells (plt) resulted in impaired migration of lymphocytes and DCs to 
the lymph nodes (Legler et al., 2014). We know that tumour cells hijack the normal 
mechanisms by which DCs travel to the lymph node following chemotaxis 
gradients. Therefore, it is reasonable to investigate if the inhibition of CCR7 would 
have an anti-metastatic and anti-migratory effect, and to determine if this effect can 
mirror what has been observed with DCs. (Legler et al., 2014).  
The evidence so far is encouraging. For example, Shuyi et al. have investigated 
the use of double-stranded short interfering RNA (siRNA) to target CCR7 mRNA in 
colon cancer cells both in vitro and in vivo. Silencing CCR7 mRNA by siRNA 
transfection was found to decrease cytoplasmic Ca2+ mobilization and strongly 
inhibit chemotaxis and invasion in vitro. Furthermore, blocking the expression of 
CCR7 on tumour cells in animal models correlated with less lymph node 
metastasis (Shuyi et al., 2008). 
Inhibiting CCR7 using neutralizing antibodies has been shown to block the 
activation of pro-survival signals in head and neck cancer (Kruizinga et al., 2009). 
Recently, inhibiting CCR7 expression using synthetic microRNA, Let-7a, has been 
shown to decrease the invasion and migration of breast cancer cells (Kim et al., 
2012). Furthermore, using anti-CCL21 antibodies blocked metastasis of murine 
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melanoma cells completely (Wiley et al., 2001). Chemotrap-1, an engineered 
soluble receptor utilizing an endogenous human protein sequence that binds to 
CCL21 also blocked the lymphatic metastasis of murine melanoma cells (Lanati et 
al., 2010).  
Of course, whilst antibody and microRNA therapies are more selective, they 
involve high costs of production, and are associated with the potential risk of 
developing immunogenicity (Wu et al., 2009). Similarly, the use of soluble 
receptors as antagonists has some drawbacks; the short half- life and the high 
doses required to achieve good binding (Jones and Rose-John, 2002), Therefore, 
synthesising and developing small molecules to antagonize CCR7 can provide a 
more economical and safer option to prevent metastasis and improve the efficacy 
of treatment and significantly benefit patients.  
 Development of CCR7 antagonists 4.1.2
Taken together, our own results and the published evidence on the role of CCR7 in 
cancer progression encouraged us to identify and develop a series of novel CCR7 
antagonists. Currently, our group at the ICT at University of Bradford is actively 
involved in this line of research and a brief background to our discoveries is 
outlined below. ICT5189 (Figure 65) was discovered by our group as a weak CCR7 
antagonist (AHMED, 2016) and tested in our Ca2+ flux assay. A derivative 
compound, namely ICT5888 lacking the 4- propyl 1,3 oxazole moiety was also 
synthesized. Both compounds showed similar efficacy in the Ca2+ flux assay. We 
decided to carry on with ICT5888, which has a simpler structure, as our lead 
compound and starting point for the medicinal chemistry program.  
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Figure 65: Compound ICT5189 and ICT5888. 
Both compounds reduced the Ca2+ flux induced by CCL21 and therefore identified as hit 
molecules; see Figure 69 for Ca2+ flux IC50. 
 
 Drug Design of Analogues  4.1.3
As mentioned before, ICT5888 was shown to be active by Ca2+ flux assay. The 
next step was to build up a library of ICT5888 analogues in order to identify which 
parts of the molecule are responsible for its biological activity. Our screening 
cascade is outlined in Figure 66. The Ca2+ flux assay was used to determine 
relative potency of compounds and thus determine what effect structural 
modifications have on the biological activity. Next, active compounds are tested for 
cytotoxicity (MTT assay) to confirm that the observed effect is not due to 
cytotoxicity rather than true antagonism. When compounds are not cytotoxic and 
are active in the Ca2+ assay, further biological analysis is performed, to determine 
whether any of the compounds can stop the CCR7 functional effects on cell 
migration and invasion. The cycle of chemical synthesis and biological evaluation 
is repeated in a reiterative fashion in order to discover more potent and drug-like 
compounds. Accordingly, many analogous were prepared to study the ICT5888 
structure activity relationship (SAR) and to find a more potent compound to be 
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used in subsequent studies. All of the analogues synthesis was performed by Dr. 
Mohanned Ahmed (ICT) and MSc students (Anwar Salem and Taher Shalabi). 
Furthermore, The IC50s of compounds from the Ca
2+ flux assay were generated by 
Dr. Victoria Vinader and Dr. Mohanned Ahmed. For Ca2+ flux data see Figure 69.  
 
 
Figure 66: Screening cascade of biological assays in the process of drug discovery of CCR7 
antagonists. Figure courtesy of Dr. Victoria Vinader. 
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 Aims and objectives 4.1.4
CCR7 expression in head and neck cancer cell lines (OSC-19) affected cells 
migration (chapter 2) and invasion in 2D and 3D assays (see sections  4.3.4 4.3.5). 
Therefore, developing small molecule antagonists against CCR7 will enhance our 
understanding of its role in cancer and potentially disrupt migration and invasion 
which will have a strong impact on the survival rate of patients. 
 
 The main aims and objectives of this chapter are:  
 
- To evaluate the effect of CCR7/CCL21/CCL19 axis in 2D and 3D invasion 
assays.  
- To evaluate the effect of CCR7 antagonists on cell proliferation, migration 
and invasion 
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4.2 Materials and methods 
 Materials 4.2.1
Tissue culture materials and reagents were all obtained from (Sigma-Aldrich) 
unless otherwise specified. 
 Cell culture 4.2.2
OSC-19 cells were obtained from as described earlier in chapter 2. Cells were 
cultured at 37°C and maintained at 5% CO2 and 100% humidity. Cells were 
cultured in complete RPMI 1640 medium supplemented with 10% FBS and L-
glutamine (2 mM) and Sodium pyruvate solution (1 mM). Cells were passaged 
when reach 75% confluency as described earlier in section 2.2.5. 
 Synthesis of CCR7 compounds  4.2.3
Small molecule CCR7 antagonists were synthesized in house by the medicinal 
chemistry team at ICT by Dr Victoria Vinader, Dr. Mohanned Ahmed and Msc 
students (Anwar Salem and Taher Shalabi). 
 Ca2+ flux assay 4.2.4
Testing of compounds for ranking by Ca2+ flux assay was done by Dr. Victoria 
Vinader and Dr. Mohanned Ahmed. Briefly, OSC-19 cells were seeded in a 96-well 
black tissue culture treated plate at 1x105 cells/well and left to attach overnight in 
the incubator. The following day, medium was removed and cells were washed 
with 100 μl of the assay buffer twice. Quickly but carefully 100 μl of the loading dye 
(Molecular ProbesTM Fluo-4 NW, Invitrogen) was added to each well and incubated 
for 30 min at 37°C. Serial dilutions of the antagonists were prepared and 20 μl 
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were added to the appropriate wells and incubated for another 30 min. 
Fluorescence intensity was then measured in response to 20 μl of 100 nM of 
CCL21 added using Thermo scientific Flourskan Ascent FL at excitation 
wavelength 485 nm and emission wavelength 538 nm at 37°C 
 Cytotoxicity assay using MTT 4.2.5
The cytotoxicity of CCR7 antagonists was determined by MTT assay. Toxic 
concentrations will cause cell death, leading to a reduction in the colour purple 
color produced by the presence of formazan crystals and consequently less 
absorbance readings. Similarly to the proliferation assay, OSC-19 cells were 
seeded in a 96-well plate at a density of 1 x 104 cells/ ml and were incubated for 24 
h. On the following day, 20 μl of different serial dilutions were added to the 
appropriate wells to achieve the desired concentration in wells of ICT5888 (1mM, 
0.75 mM, 0.5mM, 0.25 mM, 0.1 mM, 10μM, 1μM, 0.1μM), ICT13069 (250μM, 
100μM, 10μM, 1μM), ICT13124 (200 μM, 100 μM, 10 μM, 1uM). (250 μM, 100 μM, 
10 μM, 1 μM) ICT13122 (500 μM, 250 μM, 100 μM, 10 μM, 1μM, 0.1μM) (250 μM, 
100 μM, 10 μM, 1uM), ICT13070 (250 μM, 150 μM, 100 μM, 10 μM, 1 μM), 
ICT13072, (250 μM, 150 μM, 100 μM, 10 μM, 1 μM), ICT13301, ICT13303, 
ICT13309, ICT13310, ICT13311, ICT13312, ICT13313, ICT1325 (250 μM, 150 μM, 
100 μM, 10 μM, 1 μM). Following compound treatment, cells were incubated for 
another 72 h. Then, 20 μl of 5 mg/ ml MTT stock solution (for preparation of MTT 
stock solution see appendix II) was added to the cells and incubated for 4 h. After 4 
h, the medium was removed and 150 μl of DMSO was added to each well, to 
dissolve the purple-blue formazan crystals produced. Absorbance was then 
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recorded at 540 nm using a colorimetric plate reader (Thermo scientific). The % of 
cell viability was determined using the following equation:- 
𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 % =
𝐴 −  𝐵
𝐶 − 𝐵
∗ 100 
Where A is the absorbance of treated cells with specific concertation of each 
compound, B is the absorbance of blank and C is the absorbance of untreated 
cells. 
 Wound healing assay 4.2.6
The non-cytotoxic and active compounds in MTT and Ca2+ flux assays, 
respectively, were tested in a wound healing assay to determine if they are able to 
stop the migration of cells. We chose the wound healing assay because it is 
relatively fast, easy and inexpensive to perform to compare among compounds for 
stopping the migration of cells and can be modified, to incorporate the addition of 
CCR7 ligands. The assay was performed as described earlier in section 2.2.13 
with the adjustment of the addition of compounds. Briefly, OSC-19 cells were 
seeded at a density of 8.5 x 105 cells/well in 24 well tissue culture treated plates 
and allowed to attach overnight and reach confluency. On the following day, the 
supernatant was removed and the wells were washed with PBS. A wound was 
scratched using the tip of a p200 pipette tip. Afterwards, the cells were washed 
twice with PBS and treated with CCR7 antibody or antagonists for 2 h, before the 
addition of CCL21 (10 nM final concentration). We used CCR7 antibody 
(monoclonal anti-human CCR7 antibody, R&D systems) to confirm that blocking 
the CCR7 receptor indeed results in a reduction of the migration ability of cells and 
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that the CCR7 small molecule antagonist can exert a similar effect. The antibody at 
different final concentrations (100, 10, 1, 0.1 μg/ml) was also added to OSC-19 
cells 2 h before adding the CCL21 (10 nM final concentration). We studied the 
effect of different compounds in blocking the migration, namely, ICT5888 and its 
analogues (ICT5888, ICT13069, ICT13070, ICT13072) at a top concentration of 
100 μM for 2 h (note that this at least a IC10 concentration, as determined by MTT). 
Afterwards, CCL21 (10 nM final concentration) or medium was added to wells and 
left in the incubator at 37°C, 5% CO2 and 100% humidity for another 16 h. 
Compound ICT13069 was the most effective at this top concertation and therefore, 
further investigation was taken at different concentrations (100μM, 1μM, 1μM, 
100nM, 10nM, 1nM). Later analogues of ICT13069 were tested at 1μM, along with 
ICT13069 to decide which compound had similar or better activity than ICT13069. 
Images of the scratches were taken using a lumascope 488 microscope at 0 and 
18 h. Image J software was used to determine the free surface area of the wound 
at 0 h and at 18 h, as described earlier in section 2.2.13. Each experiment was 
repeated at least 3 times in independent occasions.   
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 Transwell invasion assay: 4.2.7
The transwell inserts (pore size 8 μm, Corning) were coated with 100 μl of 50 μg/ml 
collagen I (collagen type 1 rat tail, Corning) and incubated at 37°C overnight. The 
following day, the remaining collagen was aspirated, and the inserts were washed 
well with a free serum medium. OSC-19 cell suspension (150 μl) treated with serial 
dilutions of compound ICT13069 (100 μM, 10 μM, 100 nM, 10 nM) was added at a 
density of 6.7 x 105 cells/ml to the top compartment of the inserts. The top inserts 
contained no serum or chemoattractant, whereas the medium in the lower wells 
contained 0, 10 or 100 nM of CCL21 or CCL19 respectively. After 48 h of 
incubation at 37°C, 5% CO2, the cell suspension was removed from the top inserts 
and the cells attached to the upper side of the membrane were wiped off with a 
cotton swab. Cells on the lower side of the membrane were fixed with 70% ethanol 
for 2 min at R.T. and left for air dry. The membrane was carefully cut off using a 
scalpel and placed onto a microscope slide using mounting medium containing 
DAPI (Fischer scientific) to facilitate nuclear staining. Images of the invaded cells 
using 4 representative fields for each membrane were taken using a Leica 
fluorescence microscope at 200x magnification power (Figure 67-a). Invaded cells 
were counted using Image J software as follows: images were opened through 
Image J, the blue channel was selected and converted to binary (Figure 67-b) and 
counted (Figure 67-c). Mean number of cells was calculated from at least 3 
independent experiments. 
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Figure 67: Data analysis of cells able to invade through the collagen coated transwell 
membrane using Image J  
(a) Cells stained with DAPI were analyzed through Image J. (b) Images converted to binary for 
Image J recognition. (c) Cells were counted through Image J.  
 
 Forming spheroids using the hanging drop method 4.2.8
First, a cell suspension of OSC-19 cells at a density of 6.7 x 104 cells/ml was 
prepared. The cell suspension was prepared with or without 20% methylcellulose 
(For the preparation of 20% methylcellulose see appendix III). 30 μl of cell 
suspension was taken using a multichannel pipette and seeded onto the lid of a 60 
mm petri dish, 0. 5 ml of PBS was added to the bottom of the dish to prevent the 
dehydration of the drops. The lid was then carefully inverted and placed on top of 
the PBS filled dish and incubated at 37°C and 5% CO2
 overnight. 
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 Detection of CCR7 in OSC-19 spheroids 4.2.9
In order to confirm that the OSC-19 spheroids that will be used in the invasion 
assay, do express CCR7, we stained them for CCR7 expression. Briefly, spheroids 
of 200 μm diameter were transferred to a 20 ml universal tube and allowed to 
sediment down slowly and treated with Bouin’s solution as described earlier in 
section 2.2.21.3 All the later fixation steps until embedding spheroids in paraffin 
were followed exactly as described before in section 2.2.21. After sectioning of 5 
μm thick sections, the staining by IHC means for detection of CCR7 expression 
was followed as described in section 2.2.10. 
 Spheroid invasion assay  4.2.10
Collagen I (1.5mg/ml, 3ml) was prepared by mixing 600 μl of 5x PBS, 23 µl of 1N 
NaOH ,1455 μl of distilled water and 922 μl of collagen 4.88mg/ml (collagen type 1 
rat tail, Corning). 75 l of this mixture was added to each well of flat bottomed 96 
well plate and incubated for 30 min at 37°C, then 1 spheroid in 2 μl of medium was 
placed onto the collagen bed in each well and overlaid with another 75 μl of 
collagen mixture and incubated for another 30 min at 37oC. Afterwards, serial 
dilutions of compound ICT13069 in 150 μl of 1% FBS medium with or without 
CCL21 or CCL19 at (100 nM) were added to each well. The plate was incubated 
for 20 h. Spheroid invasion was visualized by microscopy. Images were taken at 0 
and 20 h on a lumascope 488 microscope. Data analysis was performed by 
utilising Image J and represented as % area of invasion (Figure 68). The % Area of 
invasion was calculated using the following equation: 
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Where A is the % area before invasion and B is the % area after invasion. 
 
Figure 68: Data analysis of spheroid invasion assay using Image J. 
(a) Spheroids at 0 h were captured using lumascope 488 microscope, converted with image J 
to binary picture of black and white and % area was determined. (b) Invading spheroids after 
20 h were captured through lumascope 488 and converted to binary picture of black and white 
with Image J and the % area determined.  
 
 
 
% 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑖𝑛𝑣𝑎𝑠𝑖𝑜𝑛 = (𝐵 − 𝐴) ∗ 100% 
(a) 
(b) 
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 Spheroid viability assay  4.2.11
We performed a spheroid viability assay to confirm that our spheroids were viable 
during the invasion assay experimental set-up. Calcein (1 μg/ml) was used to stain 
the viable cells and PI (200 μg/ml) to stain dead cells; since PI does not enter intact 
membranes in viable cells it will only stain dead cells. A mixture was prepared by 
adding 1 μl of calcein solution and 4 μl of PI to 995 μl of PBS, 100 μl of this 
solution was added to the wells that contain embedded spheroids and images were 
taken using the time-lapse confocal fluorescent microscope Nikon eclipse 
TE2000e. 
 Statistical data analysis  4.2.12
The significance of results was assessed through a comparison of means using 
two-tailed student t-test. Results were expressed as the mean ± standard 
deviation. P values were calculated to determine statistical significance of the 
results. *P < 0.05 and **P < 0.01. 
  
  
   
 
 275 
 
4.3 Results 
 Determination of IC50 from MTT assay 4.3.1
Before confirming any in vitro data from assays, it is important to determine 
whether the compounds are having their effect at non-cytotoxic concentrations. If 
any compound was exerting its effect in reducing Ca2+ flux at concentration above 
IC10 obtained from MTT assay, the compound would be excluded from further 
analysis. We use the MTT assay to determine the cytotoxicity of our compounds. 
The cytotoxic effect was determined by testing a range of different concentrations 
for compounds (ICT5888, ICT13069, ICT13070, ICT13072, ICT13122, ICT13124, 
ICT13301, ICT13303, ICT13309, ICT13310, ICT13311, ICT13312, ICT13313 and 
ICT13325). Cytotoxicity is expressed as IC50, which is the concentration of the 
compound that caused 50% reduction of the optical density measured at 540 nm 
(Figure 69-a). IC50 were calculated from graphs and represented in the following 
table (Figure 69-b). All compounds inhibited cell proliferation in a dose dependent 
manner. In most cases, cytotoxicity is only observed at very high concentrations. 
For all further assays, compounds were used at estimated IC10 or below.  
Ca2+ flux data were produced by Dr. Victoria Vinader and Dr. Mohanned Ahmed. 
IC50 for Ca
2+ flux is the concentration of the compound that caused 50% reduction 
of the fluorescence intensity caused by CCL21 (Figure 69-b). If IC50 is not available 
(NA), the compound was tested in Ca2+ flux assay at the IC10 or lower 
concentration obtained from MTT. If active at this particular concentration, 
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compound will be evaluated in scratch assay. Our team is currently testing these 
compounds in Ca2+ flux assay to have IC50 values. 
 
 
 
 
(a) 
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Figure 69: Effect of CCR7 antagonists on cell viability and Ca2+flux data  
(a) OSC-19 cells were seeded in 96-well plate and treated with a range of concentrations for 72 
h. (b) Compounds were ordered according to IC50 from higher to lower. Each value expressed 
is the average calculated from 3 independent experiments however for the newest generation 
of compounds only n = 1 was generated. Ca2+ flux data was generated by Dr. Victoria Vinader 
and Dr. Mohanned Ahmed. NA = Not available.*Cytotoxicity and Ca2+ flux release inhibition is 
expressed as IC50 which is the concentration of the compound that caused 50% reduction of 
response. Absorption or fluorescence intensity is proportional to cell viability. Error bars 
represent SD.  
(b) 
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 Effect of CCR7 antagonists on cell migration in wound healing assay 4.3.2
We have shown in chapter 2 that CCL21 increased the cell migration but that there 
was no significant difference between using 100 nM and 10 nM of this chemokine 
in wound closure. We also showed that CCL19 had no effect on cell migration 
compared with control at the concentrations we used. Next, we sought to 
determine whether the induced cell migration caused by CCL21 could be blocked 
by a CCR7 antibody. Cells migrated significantly more in response to CCL21 than 
control (2%FBS medium without CCL21) This effect was abrogated in the 
presence of CCR7 selective antibody (Figure 70-a).  
CCR7 neutralizing antibody blocked CCL21 induced cell migration in a dose 
dependent manner. The effect of CCL21 was abrogated significantly at 100 μg/ml, 
10 μg/ml and 1μg/ml (Figure 70-b). 
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(a) 
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Figure 70: Effect of blocking CCR7 in wound healing assay.  
(a) 52% increase of cell migration was observed after 18 h in the presence of CCL21 compared 
with control. This effect was abrogated by a CCR7-neutralizing antibody in a dose dependent 
manner. (b) Data expressed as percentage of free surface area after migration. Error bars 
represent SD. **P < 0.01 compared with CCL21 10 nM group. 
 
Compounds that showed the highest IC50 in the MTT assay and were the most 
active in the Ca2+ flux assay were selected to investigate for their ability to block 
cell migration and/or invasion. The wound healing assay was chosen for initial 
screening Figure 71. Our results show that CCR7 antagonists ICT5888, ICT13069, 
ICT13070 and ICT13072 can block the migration induced by CCL21 10 nM by 
57%, 88%, 49% and 27%, respectively. This is in agreement with the Ca2+ flux 
results in which ICT13069 showed one of the highest activity (For Ca2+ flux data 
see figure 69). The free surface area after migration was the highest with 
(b) 
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compound ICT13069 compared with control. ICT13072 showed similar activity to 
ICT5888, ICT13070 showed the lowest activity in blocking the migration. 
 0 h 18 h 
Control 
  
CCL21 (10 nM) 
  
ICT13069 (100 μM) + 
CCL21 (10 nM) 
  
ICT13070 (100 μM) + 
CCL21 (10 nM) 
  
ICT13072(100 μM) + 
CCL21 (10 nM) 
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ICT5888 (100 μM) + 
CCL21 (10 nM) 
  
 
 
Figure 71: Comparison of CCR7 antagonists for blocking cell migration in wound healing 
assay. 
(a) CCL21 increased cell migration compared with control. ICT5888, ICT13069, ICT13070, 
ICT13072 blocked the migration induced by CCL21. The scale bar represents 100 μm (b) The 
free surface area after migration was highest with ICT13069 followed by ICT5888, ICT13070 
and ICT13072. Error bars represent SD from 3 independent experiments. **P < 0.01 compared 
with CCL21 10 nM group. 
 
 ICT13069 modulates cell migration in wound healing assay  4.3.3
ICT13069 showed the highest activity in blocking cell migration compared with the 
other analogues (see the previous section). Therefore we decided to investigate 
ICT13069 further over a concentration range to establish that the effect is dose 
dependent; and in other migration/invasion assays. ICT13069 impeded the 
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migration of OSC-19 cells induced by CCL21 in wound healing assay in a dose 
dependent manner Figure 72. The % of free surface area is represented in (Figure 
72-b). 
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ICT13069 (1 μM) 
+ CCL21 (10 nM) 
  
ICT13069 (100 nM) 
+ CCL21 (10 nM) 
  
ICT13069 (10 nM) 
+ CCL21 (10 nM) 
  
ICT13069 (1 nM) 
+ CCL21 (10 nM) 
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Figure 72: ICT13069 inhibits cell migration in a dose dependent manner.  
OSC-19 cells were treated with ICT13069 at different concentrations for 2 h before adding 
CCL21 (10 nM). Images were taken before and after migration. (b) Free surface area was 
measured after 18 h and expressed as percentage compared to control with no ligand added. 
Error bars represent SD from 3 independent experiments.  
 
 ICT13069 modulates cell invasion in transwell assay  4.3.4
In order to analyse the effect of ICT13069 on cell invasion, we first determined 
whether CCL21 and CCL19 would have any effect on cell invasion. Our data 
showed that CCL21 and CCL19 significantly enhanced the invasion ability of OSC-
19 cells through a collagen coated transwell membrane in a dose dependent 
manner, compared to control with free serum (Figure 73-a) medium and no ligand 
added to the lower chamber. Numbers of invading cells were highest at 100 nM of 
CCL21 or CCL19 (Figure 73-b). 
(b) 
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Figure 73: CCL21 and CCL19 induce OSC-19 invasion.  
OSC-19 cells were seeded at on transwell and left for 48 h to invade from the upper membrane 
towards the lower chamber. (a) Cells that had invaded through collagen and face the lower 
chamber were captured using Leica DM 2000 microscope with scale bar 50 μm. CCL21 and 
CCL19 induced the migration of cells compared with the control group. (b) Number of 
migrated cells was counted and averaged using Image J. Error bars represent SD from 3 
independent experiments. **P < 0.01 compared with control group. 
 
Control  CCL21 (100 nM) CCL21 (10 nM) 
   
CCL19 (100 nM) CCL19(10 nM) 
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We tested ICT13069 at different concentrations against CCL21 (at 100 nM). 
ICT13069 inhibited cells invasion towards CCL21 (100 nM) in a transwell assay 
also in a dose dependent manner (Figure 74-a). ICT13069 at 100 μM caused 
significant inhibition of cells invasion towards the lower chamber where CCL21 
(100 nM) was added. The number of migrated cells is presented in (Figure 74-b). 
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Figure 74: ICT13069 inhibits cell invasion in transwell assay.  
OSC-19 cells were treated with or without ICT13069 and seeded on the upper chamber and left 
to migrate towards CCL21 (100 nM) in the lower chamber for 48 h. OSC-19 cells were treated 
with ICT13069 (100 µM), ICT13069 (10 µM), ICT13069 (1 µM) and ICT13069 (100 nM). (a) Images 
of migrated cells that were fixed with 70% ethanol and stained with DAPI, were captured after 
48 h. ICT13069 inhibited cell invasion in a dose dependent manner. (b) Number of migrated 
cells were counted using Image J. Error bars represent SD from 3 independent experiments.  
  
(b) 
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 ICT13069 modulates cell invasion in 3D spheroid invasion assay  4.3.5
 
OSC-19 spheroids (200 μm diameter) form tight round spheroids by the hanging 
drop method using methylcellulose (Figure 75-a, b). To confirm that CCR7 is still 
expressed after growing OSC-19 as spheroids, IHC staining for CCR7 was 
performed on OSC-19 spheroids (Figure 75). OSC-19 spheroids show +ve (brown) 
stain on the cell membrane indicating CCR7 expression (Figure 75-c). -ve controls 
showed no staining of CCR7 (Figure 75-d). Spheroids formed from the hanging 
drop method were transferred and embedded into collagen which was then 
immersed in medium.  
We initially attempted the assay using chemoattractants CCL21 and CCL19 in 
medium containing 10%FBS, however, the migration was so fast that the effect of 
CCL21 on invasion was not clear compared with control (10%FBS). This is 
because 10%FBS itself acts as a chemoattractant and can cause a strong invasion 
in the spheroids on its own. Next, we intended to use 0% FBS to dilute the ligands 
in which we would be able to see the effect of CCL21 compared to control (0%FBS 
in this case), however, the lack of any serum caused the spheroids to lose their 
ability to invade in the presence of CCL21. This is presumably because serum is a 
requirement in matrix invasion experiments so the cells can use the plasminogen 
that is present within the FBS to break through and invade through the matrix. 
Therefore, we decided to conduct the experiments in medium containing 1%FBS.  
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Figure 75: OSC-19 spheroids formed by the hanging drop method.  
Seeding 2000 cells in each drop formed tight unrounded spheroids without methyl cellulose 
added to the cell suspension (a). Adding methylcellulose to the cell suspension induced the 
forming of tight round spheroids (b). (c) IHC staining of OSC-19 spheroids confirms that OSC-
19 spheroids sustain CCR7 expression after growing as 3D. (d) Negative control of IHC. Scale 
bar 125 μm at 10x objective lens.  
 
Next, we sought to determine if OSC-19 were viable after embedding in collagen 
and during the invasion assay. Figure 76 shows that OSC-19 were mainly viable 
(green) after 24 h of invasion for 1% FBS (a), 10% FBS (b) and CCL21 100 nM in 
1% FBS (d) with very few dead cells (red) in the middle of the spheroid. However, 
0% FBS (c) resulted in significant cell death all over the spheroid. 
(a) (b) 
(c) (d) 
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Figure 76: Display images of OSC-19 spheroids embedded in collagen for 24 h with calcein or 
PI. 
To confirm the viability of OSC-19 spheroids during the invasion assay, OSC-19 spheroids 
were stained with calcein (green) indicating viable cells and PI (red) indicating red cells after 
24 h of embedding them into collagen. Spheroid in 1%FBS (a), 10%FBS (b), CCL21 100 nM in 
1% FBS (d) were largely viable with few dead cells (red) in the core of the spheroid. However, 
spheroids left in 0%FBS (c) into collagen were mostly dead. Scale bar represents 100 μm. 
Images were captured using time-lapse confocal microscopy. 
  
The experiments were conducted using 100 nM CCL21 and CCL19 in 1%FBS and 
both showed an increase in the percentage of invasion after 20 h compared with 
control of 1% FBS medium with no ligand added (Figure 77-a). The % area of 
invasion is calculated as described earlier in section  4.2.10 and represented in 
(Figure 77-b).  
 
(a) (b) 
(c) (d) 
  
   
 
 293 
 
 
 0 h 20 h 
10% FBS 
  
1% FBS 
  
0% FBS 
  
CCL21 (100 nM) 
  
CCL19 (100 nM) 
  
 
(a) 
  
   
 
 294 
 
 
Figure 77: CCL21 and CCL19 induced invasion of OSC-19 spheroids embedded in collagen.  
(a) Both CCL21 and CCL19 induced OSC-19 invasion compared with control 1% FBS no ligand 
added. OSC-19 spheroids invaded the collagen in response to 10%FBS, but no invasion was 
observed with 1% or no FBS. Scale bar represents 100 μm at 10x objective lens. Upon adding 
CCL21 (100 nM) and CCL19 (100nM) in 1% FBS medium resulted in increased invasion 
capability of OSC-19 spheroids. In addition, OSC-19 spheroids invaded through collagen to 
higher level when stimulated with CCL21, compared with CCL19. (b) Data expressed as 
percentage area of invasion. Error bars represent SD from 3 independent experiments. 
 
The importance of testing compounds in a 3D spheroid model has been highlighted 
in the literature (Abbott, 2003, Friedrich et al., 2009, Mehta et al., 2012). In 
particular, screening compounds in 3D models can be more predictive for cells that 
are more resistant to chemotherapy and radiation compared to 2D models. 
Therefore, we investigated the effect of ICT13069 in blocking OSC-19 invasion in a 
3D spheroid model. ICT13069 inhibited the spheroids invasion in a dose 
dependent manner (Figure 78). ICT13069 at 100 μM showed complete inhibition of 
(b) 
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cell invasion induced by CCL21 (100 nM). Comparing cell invasion and migration 
inhibition at 10 μM in 2D and 3D indicates that 2D OSC-19 cells showed higher 
sensitivity for ICT13069, compared with OSC-19 spheroids. The % of area of 
invasion is represented in (Figure 78-b). 
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Figure 78: ICT13069 inhibits OSC-19 spheroids invasion in 3D invasion assay. 
(a) OSC-19 spheroids embedded into collagen were left to invade through after adding CCL21 
(100 nM) with or without ICT13069. ICT13069 inhibited cell invasion induced by CCL21 (100 
nM) in a dose dependent manner after 20 h. (b) Data expressed as % area of invasion 
normalized to area invaded by CCL21 (100 nM). Error bars represent SD of 3 independent 
experiments. **P < 0.01 compared with CCL21 group. 
 
 Analogues of ICT13069 4.3.6
ICT13069 was shown to be effective in wound healing, transwell and 3D spheroid 
invasion assays. To understand the SAR better and develop a more potent 
compound, synthesis of ICT13069 analogues was undertaken. All the analogues 
along with ICT13069 were tested in the scratch assay at 1 μM. We choose the 1 
μM to allow for direct comparison and because the majority of the analogues 
showed no significant toxicity at this concentration in the MTT assay. Analogues 
that showed similar or higher activity than ICT13069 were to be tested at serial 
(b) 
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dilutions in order to obtain IC50 and confirm the efficacy of the more potent 
analogues, which will direct the medicinal chemistry team in synthesizing more 
potent and drug-like compounds. The effect of analogues at 1 μM in reducing 
CCL21 induced migration is shown in Figure 79. Compounds ICT13311, 
ICT13309, ICT13325 showed similar activity to ICT13069. Furthermore, ICT13312 
showed better activity than ICT13069 (P < 0.05). The % of free surface area of all 
analogues is presented in (Figure 79-b). 
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Figure 79: Comparison among ICT13069 analogues in blocking cell migration in wound 
healing assay. 
 (a) CCL21 increased cell migration compared with control. Compounds ICT13311, ICT13325, 
ICT13309 and ICT13312 blocked the migration induced by CCL21 similarly or better than 
ICT3069. The scale bar represent 100 μm (b) The free surface area after migration was highest 
with ICT13312. Error bars represent SD from 3 independent experiments. *P < 0.05 compared 
with ICT13069. 
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4.4 Discussion 
Currently, a number of options are available for cancer treatment including surgery, 
cytotoxic chemotherapy, radiotherapy, immunotherapy, and targeted therapy. 
Cytotoxic chemotherapy continues to be the mainstay for many patients; however, 
recently the focus of cancer treatment is shifting towards targeted therapies 
because they aim to act specifically on cancer cells with nearly no effect on normal 
cells, thus reducing side effects. The addition, of newer agents has shown to 
increase the survival rate of patients in some cancers (Tan et al., 2017). 
Chemokine receptor antagonists are amongst one of the most exciting of new 
targeted therapeutics.  
The overexpression of chemokine receptors on cancer cells is detectable on many 
cancer types compared with their normal counterparts (Slettenaar and Wilson, 
2006). These receptors have shown to be involved in increase cell survival, 
proliferation, adhesion, or/and migration as well as direct metastasis to form 
secondary metastases on tissues or organs in which their cognate ligands are 
present (Vela et al., 2015). Since the most common reason of cancer related death 
is metastasis in which chemokine receptors play a significant role, they are 
considered highly relevant targets for the development of potential new anti-
metastatic drugs. As a result, much effort has focused on the development of small 
molecules which inhibit the activation of chemokine receptors. We have seen in 
chapter 3 that knock down of CCR7 using RNA interference technology (siRNA), 
decreased the migration of head and neck cancer cells both under normoxia and 
hypoxia. Our results, along with other successful anti chemokine receptor 
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strategies, such as anti-CXCR4 agents, encouraged us to develop small molecule 
antagonists against CCR7. Our group has committed significant effort to the 
development of small molecule antagonists of chemokine receptors, in particular, 
CCR7 antagonist, particularly since to date, no small molecules CCR7 have been 
described in the literature. 
The role of CCL21/CCR7 axis in cell migration is well documented in different 
types of cancer; our data from chapter 2 has shown that this axis is important in 
cell migration of head and neck and prostate cancer cell lines. In this chapter, we 
look into the effect of CCR7/CCL21/CCL19 in invasion in 2D and 3D before testing 
our in house synthesized CCR7 antagonists. 
To assess the role of CCL21/CCL19 in invasion, we used a Boyden chamber 
transwell assay that requires the cells to travel through collagen to reach the other 
side of the inserts. Our findings indicate significant differences between cell 
movement towards CCL21 and CCL19 compared to control (no ligands added), in 
a dose dependent manner. Our results in OSC-19 cells are consistent with other 
reports in bladder, oesophageal and head and neck cancer cell lines (Xia et al., 
2014, Cheng et al., 2014, Mo et al., 2015, Shi et al., 2015). In all the reported 
studies, tumour cells invade towards CCL21 in a dose dependent manner. In 
addition, CCR7 knockdown or inhibition using CCR7 antibodies, reduces cell 
invasion towards CCL21. Regarding the CCL19 axis, it has been reported in head 
and neck cancer metastatic cell lines such as PCI-4B, that CCL19 induced 
significant cell invasion in a transwell assay in vitro compared to medium lacking 
CCL19 (Wang et al., 2005). 
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As previously discussed, cells grown in a 3D environment represent more closely 
the normal cellular function in the tumour (Achilli et al., 2012). Furthermore, 
spheroids are used as a “negative selection” tool to reduce testing drugs in animal 
models and for “positive selection” of compounds for further drug development 
(Katt et al., 2016). Therefore the more we learn from in vitro models that mimic 
tumours in vivo for drug screening, the higher chance to succeed in vivo. 
The effect of CCL21/CCL19 in 3D spheroid models of the head and neck cancer 
has not been published before, so we investigated the effect of CCR7 ligands on 
the invasion ability of OSC-19 spheroids. The hanging drop method allows the 
production of tight OSC-19 cells spheroids of controlled sizes, this method was 
chosen because of its simplicity and reliability (Achilli et al., 2012).  
Although we had confirmed the expression of the receptor on single cells by flow 
cytometry, we stained the OSC-19 spheroids for CCR7 as well, to confirm its 
expression on 3D OSC-19 cells before performing our invasion assays. After 
growing them for 24 h by the hanging drop method, spheroids were transferred and 
embedded in collagen and immersed under medium (containing 1% FBS) with or 
without CCR7 ligands (CCL19 and CCL21), after 20 h incubation, we observed a 
clear increase of invasion in response to both ligands. The choice of 1% serum 
medium is critical in this assay. Initially, we observed no invasion of OSC-19 
spheroids upon adding CCL21 or CCL19 in serum free medium. In contrast, OSC-
19 spheroids invaded the collagen towards 10% FBS even in the absence of 
CCL19 or CCL21. In 1% FBS we saw no significant invasion in our 3D model 
invasion assay, making it a good control. Therefore, we decided to dissolve CCL21 
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and CCL19 in 1% FBS in this assay. We speculated that one reason embedded 
spheroids do not invade collagen is perhaps because they do not survive in 0% 
FBS medium. This is in agreement with our viability results. In contrast, we showed 
that embedded OSC-19 spheroids into collagen and topped up with 1% FBS 
medium were largely viable, as demonstrated by the calcein and PI labelling. 
Hence these spheroids could invade after the addition of CCL21 or CCL19. Indeed, 
viable OSC-19 spheroids invasion through collagen increased significantly, 
following CCL21 or CCL19 addition in 1% FBS medium (compared with our control 
1% FBS with no ligand added). Our results demonstrate that OSC-19 spheroids 
are quite sensitive to the serum levels, more so than monolayer cultures. However, 
this is not surprising; cells or spheroids invading through basement membranes are 
in need of a source of plasminogen to breach through such matrix. However, the 
lack of nutrients in tumours grown in vivo, along with other stress factors will on the 
contrary to in vitro OSC-19 spheroids, stimulate the cell invasion and migration 
since proteases including plasminogen are present within the tumour 
microenvironment.  
It is clear from our results that the CCR7/CCL21 axis is important for cell migration 
and invasion in 2D and 3D models. Our results also point towards a different role 
for CCL19 and CCL21 in the migration of tumour cells. We have observed that 
CCL21 has also a stronger stimulating effect in inducing Ca2+ flux mobilisation 
(chapter 2) and cells invasion in 2D and 3D than CCL19 in OSC-19 cells. Of note, 
it has also been reported that lymph nodes express CCL21 to a significantly higher 
level than CCL19 (Muller et al., 2001). It could be inferred from our in vitro results 
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that CCR7 expressing tumour cells may migrate to the lymph nodes where CCL21 
is highly expressed. 
Due to the strong association that we observed between CCR7 and CCL21 in 
migration and invasion in OSC-19 cells, we decided to investigate whether the 
modulation of CCR7 in these cells would abrogate the observed effects. 
Initially, we used a CCR7 monoclonal antibody in our wound healing assay. CCR7 
monoclonal antibody showed complete abrogation of CCL21 induced migration at 
100 μg/ml and 10 μg/ml concentration. The CCR7 antibody inhibited the effects of 
CCL21 in a dose dependent manner. This encouraged us to use the small 
molecule CCR7 antagonists which are prepared by the medicinal chemists in our 
team at ICT. Our screening cascade to evaluate these compounds starts by 
determining if they are able to abrogate the Ca2+ flux triggered by CCL21 addition 
to the cells. If positive, to confirm if the activity observed is related to CCR7 
inhibition or just cytotoxicity, compounds are evaluated in an MTT assay. This is a 
necessary step, as cytotoxic compounds cause cell death and therefore would 
reduce the fluorescence response in the Ca2+ flux assay leading to false positives.  
The Ca2+ flux data, together with the MTT cytotoxicity information, allows the 
selection of CCR7 antagonist compounds that are effectively non-cytotoxic. For the 
selected compounds, the cytotoxicity IC50s from the MTT assay were in most cases 
at least 20 times higher than the IC50s from the Ca
2+ flux assay.  
Ca2+ flux is a functional assay, but it does not show if the antagonist compounds 
have the desired effects on cellular functions like migration or invasion. Therefore, 
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our next step was to evaluate if these compounds would reduce migration and 
invasion of OSC-19 cells. We chose the scratch assay as our first secondary 
functional assay, because its advantages in terms of cost and ease of experimental 
design. Initial lead compound ICT5888 produces inhibition of CCL21-induced 
activity of the OSC-19 cell line in Ca2+ flux assay and completely abrogates CCL21 
induced migration at 100 µM in the wound healing assay.  
In order to identify more potent compounds and to understand the SAR better, we 
extended the study to follow up compounds by testing at a single concentration 
(100 µM), non-cytotoxic in the MTT assay. We eliminate ICT13122 and ICT13124 
from our study because they expressed the lowest IC50 from the MTT assay and 
were least soluble in medium and therefore lacked the desired drug-like properties. 
Our results indicate that ICT13072 had similar activity to ICT5888 in blocking cell 
migration. ICT13070 resulted in less free surface area after migration compared to 
ICT5888. ICT13070 had relatively lower free surface area compared with 
ICT13072. Notably, ICT13069 showed enhanced inhibition of migration, 66% 
difference in free surface area between ICT13069 and ICT5888. The information 
gained from these results were used to establish a SAR for this class of CCR7 
inhibitors by other members of our lab, but since that is not discussed here as it is 
beyond the scope of this dissertation. 
Next, we tested ICT13069 at different concentrations to obtain a dose response 
curve. ICT13069 inhibited the migration induced by CCL21 (10 nM) even at 1 nM 
concentration. Our results indicate that ICT13069 reduced CCL21 induced cell 
migration not only back to control level but even greater than the control. The 
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reason for this is not known. It has been reported that chemokines are secreted 
after wounding cells in wound healing assay (Behm et al., 2012, Ghosh et al., 
2012). Ghosh et al., confirmed the secretion of CXCL12 after creating a wound in 
the cell monolayer, and we have seen increase of CCL21 secretion after wounding 
the OSC-19 monolayer (chapter 2). Although the concentration of secreted CCL21 
was fairly low, other chemoattractants and molecules involved in cells migration 
could also have been excreted and contributed to migration. Furthermore, by 
blocking CCR7 we could also prevent any cross talk by CCR7 with other pathways 
such as transforming growth factor β1 (TGF-β1) (Ma et al., 2015) and integrin (Li et 
al., 2011) thus further reducing the migratory aptitude of cells. For example, it has 
been reported in Li et al study that there is a cross talk between CCR7 and αvβ3 
integrin in head and neck metastatic cancer cell line (Li et al., 2011). Binding of 
CCR7 ligands to its receptor causes transactivation of αvβ3 and inhibition of αvβ3 
integrin resulting in inhibition of migration of tumour cells. In accordance with our 
results it has been shown that IS201, αvβ3 inhibitor, blocked the migration of cells 
in CCL19 added wells with 40% higher inhibition compared to the control where no 
ligand was added, in a wound healing assay (Li et al., 2011).  
As ICT13069 was the most active antagonist in the CCL21 mediated wound 
healing assay for stopping the migration of OSC-19 cells, we decided to progress it 
for further investigation in a Boyden chamber transwell migration assay that has an 
invasion component (the inserts were coated with collagen). In our transwell assay, 
ICT13069 was able to modulate cell invasion in a dose dependent manner, 
confirming that ICT13069 not only can block CCL21 induced migration but also 
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invasion in a head and neck cancer cell line. A similar experiment in bladder 
cancer, but using a CCR7 monoclonal antibody has been reported in the literature 
(Mo et al., 2015). ICT13069 was more potent in blocking migration in the wound 
healing assay than in the transwell invasion, this however can be due to the fact 
that they are basically two different assays. 
We next moved onto the assess potency of ICT13069 in a 3D model. It has been 
shown that many drugs lose their efficacy in 3D compared to 2D experimental 
conditions. On the contrary, others have shown the opposite effects (Desoize et al., 
1998, Edmondson et al., 2014). The use of CCR7 antagonist molecules in 3D 
invasion assays has not been reported in the literature. Here we were able to 
demonstrate that ICT13069 at 100 µM caused complete inhibition of invasion of 
OSC-19 collagen embedded spheroids induced by CCL21 at 100 nM. This effect is 
consistent with what was seen in the wound healing and the transwell assays. 
However, ICT13069 at 10 µM was less effective in blocking the invasion compared 
with the 2D assays. At 10 µM ICT13069 caused 15% reduction in invasion 
triggered by 100 nM CCL21. 
Next a series of ICT13069 analogues were developed and tested initially in the 
wound healing assay. Compounds ICT13301, ICT13303, ICT13310 and ICT13013 
showed lower activity in the migration assay compared with ICT13069. 
Compounds; ICT13325, ICT13309, ICT13011 had similar activity as ICT13069 and 
ICT13312 shower higher activity than ICT13069. Of course, to better elucidate the 
SAR, we need to perform dose response curves with all the compounds that had 
similar or higher activity than ICT13069 in order to compare their IC50 in reducing 
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the migration of cells. Compounds showing higher activity than ICT13069 would be 
further analysed with serial dilutions and in different assays. Of note, some 
compounds have exhibit an increase of free surface, higher than 100% (control) 
level, while the particular reasons are currently unknown, we can speculate that 
this effect could be attributed to cross talk between CCR7 and other pathways (see 
above) or that the compounds are able to block other chemokine receptors or 
GPCRs. Therefore, cross talk as well as selectivity studies in OSC-19 cells are 
warranted. 
In conclusion, we demonstrated that functional CCR7 is expressed on OSC-19 
squamous carcinoma cells, and its ligands CCL21 or CCL19 caused an increase in 
cell migration and invasion in vitro. Neutralizing CCR7 by using a commercially 
available monoclonal antibody and CCR7 small molecule antagonists developed in 
house results in decreased cell migration and invasion induced by its ligands. Of 
note, ICT13069 resulted in significant inhibition of cell migration and invasion. So 
far, our investigations suggest that ICT13069 effects are caused by blocking 
CCR7. Taken together, these findings support the use and development of CCR7 
antagonists for the potential treatment of lymph node metastasis to increase 
patient survival. 
 
 
 
  
   
 
 309 
 
 The main findings of this chapter:- 
 
- CCL21 and CCL19 increased the cell invasion in transwell assay. 
 
- To the best of our knowledge, this is the first report of CCL21 and CCL19 
can increase cell invasion in a 3D assay. 
 
- Blocking CCR7 receptor by ab and small molecules antagonists resulted in 
reduced CCL21 induced migration and invasion in 2D and 3D in vitro 
models.  
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5 Chapter 5: 
General discussion, conclusion 
and future work  
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5.1 Discussion 
Cancer remains one of the major causes of global mortality (Siegel et al., 2017). 
Cancerous cells differ from other normal cells with their unlimited replication and 
proliferation potential, persistent ability to promote angiogenesis, evasion of 
apoptosis, and invasion of neighboring and/or distant tissues and metastasis 
(Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011). Head and neck 
cancer is the sixth most common cancer type worldwide (Bianchini et al., 2011). 
Surgery, radiotherapy and chemotherapy, alone or in combination, are the 
mainstay therapeutic approaches in head and neck cancers. Despite this, survival 
rates and prognosis have not improved significantly (Bianchini et al., 2011). The 
majority of patients develop local and/or regional recurrences. Furthermore, distant 
metastases occur in 20%–30% of head and neck patients (Vermorken and 
Specenier, 2010). Metastasis accounts for the majority of cancer related deaths 
including head and neck cancer (Mehlen and Puisieux, 2006). 
Cancer metastasis is a complex multistep process. It has been proposed that 
cancer cells are able to “hijack” the molecular mechanisms of directional migration 
of leukocytes by chemokines, to direct themselves to specific organs (Balkwill, 
2012). Chemokines and their receptors, facilitate tumor growth, promote EMT and 
increase angiogenesis. Indeed, the expression of certain chemokine receptors on 
the surface of cancer cells has be shown as a key for the promotion of metastasis 
and particularly, organ specific metastasis (Steeg, 2016). 
Two chemokine receptors, CXCR4 and CCR7, have been shown to be highly 
involved in the metastatic process (Balakin et al., 2008). Cancer cells expressing 
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CCR7 receptors on their surface, home to the lymphatic system, where its ligand 
CCL21 is abundantly expressed (Muller et al., 2001). Often when the spread of 
cancer cells to the sentinel lymph nodes has occurred, lymph node removal is the 
primacy choice for treatment. Therefore, CCR7 expression has been suggested as 
a diagnostic marker to predict the metastatic spread status (Chen et al., 2016, 
Cabioglu et al., 2005). For example, if CCR7 is not upregulated, surgery could be 
avoided and a treatment of chemotherapy or targeted- drugs can be prioritised.  
A number of studies have shown that blocking CCR7 using antibodies or knocking 
down CCR7 results in decreased invasion and migration of cancer cells in vitro 
(Xia et al., 2014, Sperveslage et al., 2012). Furthermore, knocking down CCR7 in 
vivo has been correlated with less lymph node metastases in animal models (Xia et 
al., 2014, Tutunea-Fatan et al., 2015, Mashino et al., 2002, Cunningham et al., 
2010).  
Therefore this project was initiated to investigate the expression of CCR7 receptor 
in different cancer cell lines, xenografts and clinical samples to determine its 
presence in cancer and to determine how it may affect cancer progression, how we 
may simulate clinical situations (e.g. hypoxia) and to evaluate the efficacy of 
developing small molecules CCR7 antagonists. 
Notably, CCR7 expression was detected in most of the cancer cell lines examined 
(chapter 2) and particularly in head and neck cancer cell lines. Furthermore, the 
head and neck cell lines (SCC-4, OSC-19, FaDu, Detroit 562 and A-253) were 
exposed to hypoxia (0.1% O2), under these conditions, upregulation of CCR7 in 
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OSC-19, FaDu, and Detroit 562 cells was observed. Furthermore, we also 
observed CCR7 upregulation in the hypoxic core of OSC-19 spheroids.  
We propose that the hypoxic upregulation of CCR7 can be potentially mediated by 
HIF-1α. Researches have analysed the CCR7 gene, and showed the presence of 
HREs binding sites of HIFs; therefore we assumed that binding of HIF-1α to HRE 
will induce the transcription of CCR7 (Li et al., 2009).  
In addition to cells and spheroids, we have also shown that CCR7 is highly 
expressed in xenograft and clinical tissues. The expression of CCR7 in head and 
neck xenografts showed a potential correlation with HIF-1α expression and cell 
differentiation. This correlation between hypoxia and differentiation is precedent, as 
it has been shown that hypoxia and hypoxia mimicking agents can cause cell 
differentiation in leukemia cells (Huang et al., 2003). Our clinical patient’s samples 
confirmed the previous observed correlation in xenografts between CCR7 and HIF-
1α. This correlation was increased accordingly with clinical stages and lymph node 
metastasis. In regard to the histological status of the patient samples the highest 
correlation between CCR7 and HIF-1α was observed in grade 1 in which cells are 
mostly differentiated. We hence postulate that developing drugs that target CCR7 
(antagonize the receptor), will be beneficial to target not only undifferentiated cells 
that could be damaged by chemotherapy and radio-therapy, but also, such strategy 
may have the advantage to target the less proliferating differentiated cells that 
remain unaffected by conventional chemotherapy. This is particularly important 
when considering tumour recurrence, after conventional therapy, because these 
well differentiated cells will still have proliferating cells at the rim that are 
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responsible for tumour re-growth and metastasis (Bhattacharya et al., 2004). 
Furthermore, it has been shown that differentiated cells can undergo 
dedifferentiation to cancer stem cells which are responsible for tumour 
heterogeneity and tumour recurrence after treatment (Friedmann-Morvinski and 
Verma, 2014). 
Our results showed that CCL21 induces cell migration and invasion in wound 
healing migration, transwell invasion and spheroid invasion assays under 
normoxia. Although we demonstrated upregulation of CCR7 expression in OSC-19 
under hypoxia, our migration (scratch assay) results indicate that migration is 
reduced in comparison to the same experiments carried out under normoxia. To 
clarify if such effects are govern by CCR7, we performed knockdown studies 
(chapter 3) and shown that CCR7 presence enhances the migration of OSC-19 
under hypoxia when compared with knockdown CCR7 cells. Our preliminary 
results suggest that the reduction in migration under hypoxic conditions could be 
mediated through other factors, such as the downregulation of ROS under hypoxia.  
We studied ROS levels and showed a decrease not only when cells were cultured 
in the hypoxia chamber, but also when subjected to CoCl2. This decrease in ROS 
paralleled the reduced migratory ability of OSC-19 cells. 
Studies on the ROS effect in regard to cell migration and cell kill in cancer are 
controversial (Zablocka and Janusz, 2008). Our data indicates that induction of 
ROS increases cell migration and CCR7 expression. Whether this increased 
migration is CCR7-dependent has not yet been demonstrated. We believe that 
ROS concentrations should be carefully evaluated during therapeutic treatments, 
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since survival mechanisms and metastasis can inadvertently be induced. The 
current practice in treatment is to elevate the ROS level to increase the cell kill. 
However, as ROS can also increase the cell survival, future studies should 
consider neutralizing ROS molecules, instead of increasing concentrations as 
another therapeutic option.  
Recently, our understanding of the significance and differences in CCR7 activation 
by its two ligands (CCL19 and CCL21) has increased. It has been suggested that 
CCR7 could have ligand biased signalling pathways leading to different functional 
effects (Steen et al., 2014). It is believed that CCL21 is mainly involved in migration 
in vivo, while CCL19 could support this role by providing survival signals 
(Comerford et al., 2013). We have observed that CCL19 has a limited role in 
migration (chapter 2) compared to CCL21, however it still enhances the invasion of 
OSC-19 cells in transwell and spheroid invasion assays (chapter 4).  
Another important aspect of CCR7 activation by CCL21/CCL19 is the effect on 
survival, proliferation and apoptosis. We have demonstrated that CCL21 and 
CCL19 treatment does not resulted in increased proliferation in two head and neck 
(OSC-19 and FaDu) cell lines and other prostate cell lines ( PC-3, DU-145, data 
not shown but currently under investigation in our group). Furthermore, CCL21 did 
not decrease the apoptotic cell death in OSC-19 cells. 
This could be explained by different autocrine/paracrine loops activation of CCR7 
(Wendt et al., 2008) or endogenous/ exogenous activation of CCR7 as seen in 
melanoma (Shields et al., 2010) breast (Wendt et al., 2008) cell lines (see 
discussion in chapter 2 and 3). Furthermore, secretion of CCL21 as detected in 
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OSC-19 cell line supernatant after mechanical stress and head and neck tumour 
xenografts might suggest the presence of autocrine activation of CCR7 to support 
tumour proliferation and growth after stress. 
It also appears that the different signalling pathways that are triggered by CCR7 
activation could differ from cell to cell type and/or whether CCL19 or CCL21 is the 
activating ligand (see discussion chapter 1). This biased signalling suggestion 
could be associated to the theory of “functional selectivity”. Different ligands can 
prompt different receptor conformations resulting in the activation of specific 
signalling pathways and certain agonists can induce one or more multifaceted 
conformations that are able to activate multiple G proteins, while others induce only 
a conformation able to activate a specific subtype of G proteins. This again is an 
area that requires further investigation, in particular, to understand the interaction 
between signalling pathways and CCR7 activation.  
Furthermore, Mei-Lin Su et al, have reported that the sialylation of CCR7 affects its 
activation by CCL19 (Su et al., 2014). This study showed that CCL19 can activate 
CCR7 as long as the receptor is sialylated. This recent study, warrants 
investigating the sialylation of CCR7 in different cancer types and what roles do 
CCL19 and CCL21 play differentially to support the lymph metastasis. However, 
CCL19 studies are sparse and therefore, its effects in cancer biology should be 
evaluated more carefully. It has also been shown that CCL19 is involved in 
endocytosis and desensitization of the CCR7 receptor (Kohout et al., 2004), while 
CCL21 has negligible effect on this.  
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The possibility of inhibiting CCR7 functional activity was also evaluated in order to 
study its potential as a pharmacological target. The knockdown of CCR7 has 
shown that CCR7 is important in cell migration and confirmed that the increase of 
migration seen in chapter 2 is connected to the binding of CCL21 to CCR7. 
To follow on from the knockdown studies, our medicinal chemistry team is focused 
on the development of CCR7 small molecule antagonists, to determine if small 
molecules CCR7 antagonists could affect cell migration and invasion. Synthesising 
and developing small molecules to antagonise CCR7 can provide more economical 
and safer option than antibody and microRNA therapies to prevent metastasis and 
improve efficacy and patient benefit. Nonetheless, if compounds are going to be 
generated, developing a good model for evaluating the lymph node metastasis 
status in vivo is paramount, to enable the successful selection and eventually 
transition to clinical trials (Horuk, 2009); in this context, the following points are key: 
(1) to determine the most beneficial time of administrating these compounds in vivo 
to explicit the most of its benefits to have a good efficacy and (2) to determine 
appropriate study end-points are warranted. 
Furthermore, Horuk et al, have suggested that a potential failure of chemokine 
inhibitors in clinical trials could result from the redundancy of the chemokine 
network (Horuk, 2009). Taking this into consideration, one could also consider the 
development of dual antagonist that for example can target CCR7 and another 
chemokine receptor involved in cancer, for example CXCR4. 
Dual antagonism is usually not an easy alternative, and could give rise to 
undesired side effect profiles. However, effective examples of dual antagonisms 
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already exist in diseases other than cancer such as, schizophrenia and AIDS (Roth 
et al., 2004, Wermuth, 2004) Furthermore, reparixin, a dual inhibitor of CXCR1 and 
CXCR2 has been shown to be effective in reducing inflammation in cerebral 
ischemia (Villa et al., 2007, Horuk, 2009). 
Our in house antagonists, namely ICT13069 has been shown to stop cell migration 
and invasion in 2D and 3D assays. Currently, further work is continuing within the 
medicinal chemistry team to understand the SAR and to develop more potent drug-
like compound such as follow up lead ICT13312. CCR7 antagonism is still a novel 
therapeutic target with a promising potential therapeutics in cancer and indeed 
other areas (e.g. inflammation) and to date, no CCR7 small molecule antagonists 
have been reported in the literature.  
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5.2 Conclusion: 
In summary, the results presented in this thesis show the importance of the 
CCR7/CCL21 axis in cancer cell migration and invasion, we have also 
demonstrated that this axis can be modulated by small molecule antagonists. Of 
note, ICT13069 resulted in significant inhibition of cell migration and invasion. As 
such effects are triggered by CCL21, our investigations suggest that ICT13069 
effects are caused by blocking CCR7, but further investigations remain. Our results 
also showed that CCR7 expression in cancer can be upregulated by, serum 
deprivation, hypoxia and increased ROS levels, conditions that resemble those 
present in tumours growing in clinical settings. We proposed that the induction of 
CCR7 expression under hypoxia is potentially regulated through HIF-1α, as we 
also observed it by CoCl2 treatment, head and neck xenografts and clinical 
samples. Furthermore, a model for in vitro testing of compounds in OSC-19 cells, 
demonstrated that compounds could be predictive of the in vivo conditions.  
We are still gathering exciting information to support the role of CCR7 in cancer, to 
understand the chemokine biased signalling in the context of cancer metastasis 
and progression.  
The eventual development of CCR7 antagonist directed therapies may yet offer 
new hope for addressing cancer metastasis and patient survival. Taken together, 
these findings support the use and development of CCR7 antagonists for the 
potential treatment of lymph node metastasis to increase patient survival.  
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 The novel findings of this work include:- 
 
- Expression of CCR7 under hypoxia is upregulated in head and neck cell 
lines and OSC-19 spheroids and its expression is potentially regulated 
by HIF-1α as shown by CoCl2 treatment, xenografts and clinical 
samples. 
 
- This is the first time to demonstrate a correlation between CCR7 
expression and histological grade 1 in in head and neck clinical tissues. 
 
- This is the first time to show a relationship between ROS and CCR7 in 
cancer as has been observed in OSC-19 cells, in which ROS has 
induced the expression of CCR7. 
 
- This is the first to show that CCL21 and CCL19 can increase the 
invasion of cancer cells in a 3D spheroid model “OSC-19”. 
 
- This is the first time to show that CCL21 induced CCR7 activation can be 
modulated by small molecules antagonist in vitro. 
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5.3 Future work 
Therefore the future work should include: 
- Investigation of its correlation between CCR7 and differentiation markers to 
see whether increased CCR7 expression in hypoxic region influences cell 
differentiation. 
 
- Regulation of CCR7 by hypoxia expression was a key aspect in this study. 
For example, the effect of hypoxia on alteration of CCR7 expression was 
evaluated along with its consequences of cell migration and proliferation and 
therefore to confirm that this upregulation of CCR7 was through HIF-1α, 
knockdown studies of HIF-1α under hypoxia should be perform to confirm its 
effect on CCR7 expression. 
 
- Furthermore, future investigations should focus on the mechanism by which 
CCR7 expression is altered by ROS and serum deprivation. 
 
- Future investigations should study if different intracellular signalling 
pathways are activated by CCL21 or CCL19 since we have observed 
differential effect of their activation of CCR7 in OSC-19 cell migration. For 
instance, a recent study has shown that CCL19 is associated with increase 
proliferation, invasion and inhibiting anoikis through ERK and Akt pathways 
in breast cancer (Su et al., 2014). Of note, this study showed that CCL21, 
which is proved by us and many published work to have more significant 
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importance on the downstream effects upon CCR7 activation, did not 
increase the expression level of either ERK or Akt. 
 
- To understand if there is a different role of CCL21 induced activation by 
paracrine and autocrine loops, knock in studies of CCL21 should be 
considered to evaluate the effect of autocrine activation of CCR7 in head 
and neck cell lines. 
 
- As both CCL19 and CCL21 are the ligands of CCR7 that resulted in 
increasing cell invasion in 2D and 3D models, further investigations should 
be performed to determine whether ICT13069 would block the invasion 
induced with CCL19 or whether that ICT13069 works through CCL21/CCR7 
axis only. Although OSC-19 cell line is a satisfactory model for testing 
compounds, however hence it is a metastatic cell line, further 
characterization of other primary and metastatic head and neck cancer cell 
lines is important to determine whether the effect seen in OSC-19 cell line is 
cell line specific. In addition, studying primary-derived patient cells as well 
as organoids is important to understand the CCR7 driven metastatic related 
events in better models. 
 
- Since the chemokine system is a redundant and promiscuous one, studying 
the effect of CCR7 upregulation or blocking on the expression of other 
chemokine receptors is warranted. 
  
   
 
 323 
 
 
- Our Study demonstrated the importance of 3D spheroid as a model more 
closely resembled in vivo tumours in drug screening. Accordingly, co-
culturing of spheroids with stromal cells would be important to further bring 
the gap closer between in vitro and in vivo and to be a better indicator of in 
vivo drug efficacy. 
 
- To test the most potent drug-like compound in tumour xenografts such as 
OSC-19 to determine if the effects seen in vitro can be translated to an in 
vivo setting. In this context, the pharmacokinetic profile of ICT13069 and 
related molecules is being studied within the team. Furthermore, testing the 
antagonists against other chemokine receptor is important to determine their 
selectivity. 
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Appendix: 
Appendix I: Media used for each cell line. 
Five types of media (Sigma) were used for growing cell: 
o RPMI: Roswell Park Memorial Institute 
o DMEM: Dulbecco's Modified Eagle Medium 
o DMEM- F12: Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
o McCoy's 5A 
o MEME: Minimum Essential Medium Eagle 
Glutamine and sodium pyruvate were not added to media if incomplete media was 
originally supplemented.  
 
  
 
Cell line Media incomplete  Additives to complete media  
 
PC-3 
 
RPMI FBS, glutamine, sodium pyruvate 
DU-145 
 
RPMI FBS, glutamine, sodium pyruvate 
U-87 MG 
 
RPMI FBS, glutamine, sodium pyruvate 
PANC-1 
 
DMEM FBS, glutamine, sodium pyruvate 
DLD-1 
 
RPMI FBS, glutamine, sodium pyruvate 
SW480 
 
RPMI FBS, glutamine, sodium pyruvate 
MCF-7 
 
RPMI FBS, glutamine, sodium pyruvate 
MDA-231 
 
RPMI FBS, glutamine, sodium pyruvate 
COLO 205 
 
RPMI FBS, glutamine, sodium pyruvate 
OSC-19 
 
RPMI FBS, glutamine, sodium pyruvate 
FaDu MEME FBS, glutamine, sodium pyruvate, 
non-essential amino acids  
Detroit-256 MEME FBS, glutamine, sodium pyruvate, 
non-essential amino acid 
A-253 McCoy’s 5A 
 
FBS, glutamine, sodium pyruvate 
SCC-4 DMEM-F12 FBS, hydrocortisone,, sodium 
pyruvate 
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Appendix II: Preparation of MTT stock solution. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5  
mg/ml) was prepared by dissolving MTT powder (sigma) in distilled water, which 
was then passed through 0.2 μm sterile syringe filter (corning incorporated). The 
solution was covered with aluminum paper to protect it from light and kept at 4ºC 
until used for a period of 4 weeks. 
 
Appendix III: Preparation of Methylcellulose. 
The preparation of methylcellulose solution is very important for obtaining well-
defined rounded spheroids. Methylcellulose is used to enhance cell matrix 
assembly. Otherwise, several small spheroids or unrounded cell aggregates will be 
formed in each drop. Methylcellulose (6 g) was autoclaved in a 500ml flask 
containing a magnetic stirrer. The autoclaved methylcellulose is then mixed in 
preheated 250 ml 60°C medium for 30 min. Then, another 250 ml medium was 
added and stirred for another 30 min at R.T. The methylcellulose solution was left 
for 1-2 h at 4°C to ensure complete solution. The 500 ml of methylcellulose solution 
was then centrifuged (5000 g, 2 h, R.T.). The clear highly viscous supernatant was 
then taken and kept at 4°C.  
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Appendix IV: Morphology of 2D cultured, spheroid forming ability of head 
and neck cell lines and growth curves. 
 
 
 
 
 
 
 
  
C
e
ll
 l
in
e
 
 
Monolayer Spheroid formation 
O
S
C
-1
9
 
 
 
S
C
C
-4
 
 
 
F
a
D
u
 
  
D
e
tr
o
it
 2
5
6
 
  
A
-2
5
3
 
  
  
   
 
 344 
 
 
  
  
   
 
 345 
 
Appendix V: Haematoxylin and Eosin Staining. 
Sections were de-paraffinised with xylene (2 × 5 min) and 50% xylene/ethanol (1 × 
5 min) rehydrated using 100% ethanol (1 × 5 min) 90% ethanol (1 × 2 min) and 
70% ethanol (1 × 2 min). Later, sections were stained with Harris’ haematoxylin 
(Sigma) for 10 min and then washed with running water for 5 min. The excess stain 
was removed from the section by acid alcohol (0.5% HCl in 70% ethanol) by 
immersing in 5s. This will help to differentiate the cytoplasm from nucleus. Next, 
Slides were washed with running water for 5 min and immersing in Scott’s Tap 
Water for 2 min to colour development Sections were counterstained in Eosin for 1 
min before a final wash in running tap water. Finally, the sections were dehydrated 
using 100%, 90% and 70% ethanol each for (1 x 1 min, 1 x 3 min), 50% 
xylene/ethanol (1 × 3 min), xylene (1 × 3 min, 1 × 5 min) and mounted using 
diphenylxylene.   
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U-87 MG 
 
 
 
 
DU-145 PC-3 
  
MDA-MB- 231 MCF-7 
  
FaDu OSC-19 
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DLD-1 HT-29 
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Appendix VI: Agarose preparation and 96 well plate coating 
1.5 g of agarose (Sigma) was added to 100 ml of PBS, stirred on a hot plate under 
sterile conditions to avoid clumping. The solution was brought to its boiling point to 
ensure that the agarose is completely dissolved. Then was allowed to cool to 50-
55°C, where it was still in its liquid state. Next 50 μl of this solution were added to 
96 flat bottom 96 well plates. Agarose was solidified and cooled down to R.T in 20 
min to create a concave surface. Plates were kept at 4°C until the spheroid seeding 
day. Plates were taken out and incubated for 5 min in humidified atmosphere with 
5% CO2 in air at 37°C before adding the cell suspension. 
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Appendix VII: Characteristics of microarrays clinical sample 
position sex age organ pathology grade stage tnm type 
A1 F 61 
Oral 
cavity 
Squamous cell carcinoma of 
palate 1 I T1N0M0 Malignant 
A2 M 61 Lip 
Squamous cell carcinoma of lower 
lip 1 I T1N0M0 Malignant 
A3 M 77 Lip 
Squamous cell carcinoma of lower 
lip 1 I T1N0M0 Malignant 
A4 F 75 
Oral 
cavity 
Squamous cell carcinoma of 
upper jaw 1 I T1N0M0 Malignant 
A5 M 67 
Oral 
cavity 
Squamous cell carcinoma of right 
palate 1 II T2N0M0 Malignant 
A6 M 50 Tongue 
Squamous cell carcinoma of root 
of tongue 1 III T3N1M0 Malignant 
A7 M 66 Pharynx 
Squamous cell carcinoma of 
pharynx 1 IVA T3N2M0 Malignant 
A8 M 49 Gingiva 
Squamous cell carcinoma of right 
gingiva 1 IVA T4N0M0 Malignant 
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A9 M 55 Pharynx 
Squamous cell carcinoma of 
epiglottis 1 IVA T4N0M0 Malignant 
A10 M 57 Pharynx 
Squamous cell carcinoma of 
oropharynx 1 IV T4N0M0 Malignant 
B1 M 74 Nose 
Squamous cell carcinoma of root 
of nose 2 II T2N0M0 Malignant 
B2 M 90 Cheek 
Squamous cell carcinoma of 
cheek - II T2N0M0 Malignant 
B3 M 72 Larynx 
Squamous cell carcinoma of 
larynx 1 II T2N0M0 Malignant 
B4 F 61 
Oral 
cavity 
Squamous cell carcinoma of right 
mandible 1 II T2N0M0 Malignant 
B5 M 50 Larynx 
Squamous cell carcinoma of 
larynx 1 III T2N1M0 Malignant 
B6 M 67 Larynx 
Squamous cell carcinoma of 
larynx 2 III T3N1M0 Malignant 
B7 M 58 Larynx 
Squamous cell carcinoma of 
larynx 2 III T3N1M1 Malignant 
B8 M 52 Nose 
Squamous cell carcinoma of 
nasopharynx 2 I T1N0M0 Malignant 
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B9 M 60 Tongue 
Squamous cell carcinoma of 
tongue 2 II T2N0M0 Malignant 
B10 M 60 Tongue 
Squamous cell carcinoma of 
tongue 2 II T2N0M0 Malignant 
C1 M 67 Larynx 
Squamous cell carcinoma of 
throat 3 II T2N0M0 Malignant 
C2 M 48 Cheek 
Squamous cell carcinoma of 
cheek 1 II T2N0M0 Malignant 
C3 M 70 
Oral 
cavity 
Squamous cell carcinoma of right 
mandible 2 II T2N0M0 Malignant 
C4 M 43 
Oral 
cavity 
Squamous cell carcinoma of right 
mandible 2 II T2N0M0 Malignant 
C5 M 56 Pharynx 
Squamous cell carcinoma of 
pharynx 2 II T2N0M0 Malignant 
C6 M 45 Cheek 
Squamous cell carcinoma of right 
cheek - II T2N0M0 Malignant 
C7 M 47 Larynx 
Squamous cell carcinoma of 
larynx 2 II T2N0M0 Malignant 
C8 M 61 Pharynx 
Squamous cell carcinoma of 
epiglottis - II T2N0M0 Malignant 
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C9 M 50 Larynx 
Squamous cell carcinoma of 
larynx 2 II T2N0M0 Malignant 
C10 F 38 Lip 
Squamous cell carcinoma of lower 
lip 2 II T2N0M0 Malignant 
D1 M 47 Larynx 
Squamous cell carcinoma of 
larynx 3 III T2N1M0 Malignant 
D2 F 50 Pharynx 
Squamous cell carcinoma of 
hypopharynx 2 III T2N1M0 Malignant 
D3 M 71 Pharynx 
Squamous cell carcinoma of 
hypopharynx 2 III T2N1M0 Malignant 
D4 M 44 Pharynx 
Squamous cell carcinoma of 
hypopharynx 2 III T2N1M0 Malignant 
D5 M 61 Pharynx 
Squamous cell carcinoma of 
epiglottis 2 III T2N1M0 Malignant 
D6 M 54 
Oral 
cavity 
Squamous cell carcinoma of left 
upper jaw 2 III T3N0M0 Malignant 
D7 M 61 Pharynx 
Squamous cell carcinoma of 
hypopharynx 3 III T3N0M0 Malignant 
D8 M 58 Larynx 
Squamous cell carcinoma of 
larynx 3 III T3N0M0 Malignant 
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D9 M 63 Pharynx 
Squamous cell carcinoma of 
epiglottis 2 III T3N1M0 Malignant 
D10 M 71 Pharynx 
Squamous cell carcinoma of 
epiglottis 3 III T3N1M0 Malignant 
E1 M 51 Pharynx 
Squamous cell carcinoma of left 
pharynx 2 III T3N1M0 Malignant 
E2 M 55 Larynx 
Squamous cell carcinoma of 
larynx 2 III T3N1M0 Malignant 
E3 M 75 
Oral 
cavity 
Squamous cell carcinoma of 
maxillary sinus 2 IV T4N0M0 Malignant 
E4 M 56 Pharynx 
Squamous cell carcinoma of 
epiglottis 1 IVA T4N0M0 Malignant 
E5 M 57 Larynx 
Squamous cell carcinoma of 
larynx - IVA T4N0M0 Malignant 
E6 M 49 Larynx 
Squamous cell carcinoma of 
larynx 3 IVA T4N1M0 Malignant 
E7 F 69 Cheek 
Squamous cell carcinoma of right 
cheek 2 I T2N0M0 Malignant 
E8 M 29 Larynx 
Squamous cell carcinoma of 
larynx - II T2N0M0 Malignant 
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E9 F 56 Lip 
Squamous cell carcinoma of oral 
lip 2 II T2N0M0 Malignant 
E10 M 50 
Oral 
cavity 
Squamous cell carcinoma of 
maxillary sinus 2 II T2N0M0 Malignant 
F1 M 50 Tongue 
Squamous cell carcinoma of 
tongue 3 II T2N0M0 Malignant 
F2 M 64 Larynx 
Squamous cell carcinoma of 
larynx 3 II T2N0M0 Malignant 
F3 M 49 Larynx 
Squamous cell carcinoma of 
larynx 3 III T2N1M0 Malignant 
F4 F 42 Nose 
Squamous cell carcinoma of nasal 
sinus 3 III T3N0M0 Malignant 
F5 M 50 Larynx 
Squamous cell carcinoma of 
larynx 3 III T3N1M0 Malignant 
F6 M 58 Larynx 
Squamous cell carcinoma of 
larynx 3 IV T2N2N0 Malignant 
F7 M 75 Nose 
Squamous cell carcinoma of nasal 
sinus 3 IV T4N0M0 Malignant 
F8 M 48 Pharynx 
Squamous cell carcinoma of 
hypopharynx 3 IV T4N0M0 Malignant 
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F9 M 74 Pharynx 
Squamous cell carcinoma of 
hypopharynx - IV T4N0M0 Malignant 
F10 M 65 Larynx 
Squamous cell carcinoma of 
larynx 3 IV T3N2M0 Malignant 
G1 F 32 
Oral 
cavity 
Carcinoma sarcomatodes of 
maxillary sinus - II T2N0M0 Malignant 
G2 F 40 
Lymph 
node 
Metastatic mucoepidermoid 
carcinoma - - - Metastasis 
G3 M 67 
Lymph 
node 
Metastatic mucoepidermoid 
carcinoma - - - Metastasis 
G4 M 45 
Lymph 
node 
Metastatic mucoepidermoid 
carcinoma - - - Metastasis 
G5 M 47 
Lymph 
node 
Metastatic squamous cell 
carcinoma 1 - - Metastasis 
G6 M 48 
Lymph 
node 
Metastatic squamous cell 
carcinoma 2 - - Metastasis 
G7 M 53 
Lymph 
node 
Metastatic squamous cell 
carcinoma 3 - - Metastasis 
G8 F 45 
Lymph 
node 
Metastatic squamous cell 
carcinoma 2 - - Metastasis 
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G9 F 52 
Lymph 
node Metastatic acinic cell carcinoma - - - Metastasis 
G10 M 38 Tongue Adjacent normal tongue tissue - - - NAT 
H1 M 28 Tongue Tongue tissue - - - Normal 
H2 F 27 Tongue Tongue tissue - - - Normal 
H3 M 48 Tongue Tongue tissue - - - Normal 
H4 F 42 Tongue Adjacent normal tongue tissue - - - NAT 
H5 F 15 Tongue Tongue tissue - - - Normal 
H6 F 19 Tongue Tongue tissue - - - Normal 
H7 M 35 Tongue Tongue tissue - - - Normal 
H8 F 18 Tongue Tongue tissue - - - Normal 
H9 F 19 Tongue Tongue tissue - - - Normal 
H10 M 28 Tongue Tongue tissue - - - Normal 
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Appendix VIII: western blot solutions  
-RIPA lysis buffer stock solution  
150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS 
(GE Healthcare), 50 mM Tris, pH 8.0.  
-RIPA lysis buffer working solution  
940 μl RIPA buffer, 50 μl protease inhibitor (1x cOmplete mini EDTA free, S8830) , 
10 μl 1x phosphatase inhibitor (P5726)  
-4x sample loading buffer (Lammeli buffer)  
300 mM Tris-HCl pH 6.8, 35% glycerol (GE Healthcare), 12% SDS, 0.02% 
bromophenol blue, 6% mercaptoethanol, made up to 20 ml with deionised water.  
-1.5M Tris-HCL (pH 8.8): 
36.6g Tris, 200ml of distilled H2O, Adjust pH with HCL. 
-10% (w/v) ammonium persulfate (APS): 
100g of APS, 1ml of distilled H2O. 
-10% (w/v) SDS (10ml): 
1g SDS, 10ml of distilled H2O. 
-Preparation of resolving and stacking gel: 
 
 10% Resolving gel for 20 ml 
H2O 7.9 ml 
30% acrylamide 
mix  
6.7 ml  
1.5 M Tris-HCl 
(pH 8.8)  
5.0 ml  
10% SDS (GE 
Healthcare)  
0.2 ml  
10% ammonium 
persulfate  
0.2 ml  
TEMED  0.008 ml  
12% Resolving gel for 20 ml 
H2O 6.6 ml 
30% acrylamide 
mix  
8.0 ml  
1.5 M Tris-HCl 
(pH 8.8)  
5.0 ml  
10% SDS (GE 
Healthcare)  
0.2 ml  
10% ammonium 
persulfate  
0.2 ml  
TEMED  0.008ml  
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-10x Running buffer 
15 g Tris base, 72 g Glycine and 5 g SDS (GE Healthcare) in 500 ml deionised 
water.  
-10x Transfer buffer  
30 g Tris base and 144 g Glycine in 1 L deionised water.  
-1X Running buffer  
100 mL running buffer stock 10x and 900 ml distillate H2O 
-1x Transfer buffer  
100 ml 10x Transfer buffer, 200 ml methanol, 10 ml 10% SDS (GE Healthcare) and 
690 ml deionised water.  
-PBS Tween 20 (PBST)  
1 ml of Tween 20 in 1 L PBS (pH 7.4)  
-5% blocking solution  
5 g milk (less than 0.1% fat) in 100 ml of 0.1% PBST.  
-Developing solution  
50 ml multigrade developer (ILFORD) in 500 ml distilled H2O.  
-Fixation solution  
50 ml rapid fixer (ILFORD) in 500 ml distilled H2O. 
 
 
5% Stacking gel for 10 ml 
H2O 6.8 ml 
30% acrylamide 
mix  
1.7 ml  
1.5 M Tris-HCl 
(pH 8.8)  
1.25 ml  
10% SDS (GE 
Healthcare)  
0.1 ml  
10% ammonium 
persulfate  
0.1ml  
TEMED  0.01 ml  
